{"_default": {}, "Somatic Variant": {"1": {"gene": "ABL1", "chromosome": "9", "start_position": "133747580", "end_position": "133747580", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.944C>T", "protein_change": "p.T315I", "variant_annotation": "Missense", "exon": "5", "rsid": NaN, "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Imatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "T315I mutant ABL1 in p210 BCR-ABL cells resulted in retained high levels of phosphotyrosine at increasing concentrations of inhibitor STI-571, whereas wildtype appropriately received inhibition.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Gorre, Mercedes E., et al. \"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.\" Science 293.5531 (2001): 876-880.", "url": "https://doi.org/10.1126/science.1062538", "doi": "10.1126/science.1062538", "pmid": "11423618", "nct": NaN, "last_updated": "6/13/19", "feature_display": "ABL1 p.T315I (Missense)"}, "2": {"gene": "ABL1", "chromosome": "9", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Missense", "exon": "", "rsid": NaN, "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Dasatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": "27760149", "nct": NaN, "last_updated": "11/3/17", "feature_display": "ABL1 (Missense)"}, "3": {"gene": "ABL1", "chromosome": "9", "start_position": "133747582", "end_position": "133747582", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.943A>G", "protein_change": "p.T315A", "variant_annotation": "Missense", "exon": "6", "rsid": "rs1057519772", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Dasatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": "27760149", "nct": NaN, "last_updated": "6/13/19", "feature_display": "ABL1 p.T315A (Missense)"}, "4": {"gene": "ABL1", "chromosome": "9", "start_position": "133747580", "end_position": "133747580", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.944C>T", "protein_change": "p.T315I", "variant_annotation": "Missense", "exon": "5", "rsid": NaN, "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Dasatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": "27760149", "nct": NaN, "last_updated": "6/13/19", "feature_display": "ABL1 p.T315I (Missense)"}, "5": {"gene": "ABL1", "chromosome": "9", "start_position": "133748290", "end_position": "133748290", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.951C>G", "protein_change": "p.F317L", "variant_annotation": "Missense", "exon": "6", "rsid": NaN, "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Dasatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": "27760149", "nct": NaN, "last_updated": "11/3/17", "feature_display": "ABL1 p.F317L (Missense)"}, "6": {"gene": "ABL1", "chromosome": "9", "start_position": "133748288", "end_position": "133748288", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.949T>G", "protein_change": "p.F317V", "variant_annotation": "Missense", "exon": "6", "rsid": "rs1057519773", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Dasatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": "27760149", "nct": NaN, "last_updated": "6/13/19", "feature_display": "ABL1 p.F317V (Missense)"}, "7": {"gene": "ABL1", "chromosome": "9", "start_position": "133748288", "end_position": "133748288", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.949T>A", "protein_change": "p.F317I", "variant_annotation": "Missense", "exon": "6", "rsid": "rs1057519773", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Dasatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": "27760149", "nct": NaN, "last_updated": "6/13/19", "feature_display": "ABL1 p.F317I (Missense)"}, "8": {"gene": "ABL1", "chromosome": "9", "start_position": "133747586", "end_position": "133747586", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.950T>G", "protein_change": "p.F317C", "variant_annotation": "Missense", "exon": "5", "rsid": NaN, "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Dasatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [T315I, V299L, T315A, F317L/V/I/C] are known to be less sensitive to dasatinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": "27760149", "nct": NaN, "last_updated": "6/13/19", "feature_display": "ABL1 p.F317C (Missense)"}, "9": {"gene": "ABL1", "chromosome": "9", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Imatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": "27760149", "nct": NaN, "last_updated": "11/3/17", "feature_display": "ABL1"}, "10": {"gene": "ABL1", "chromosome": "9", "start_position": "133738306", "end_position": "133738306", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.763G>A", "protein_change": "p.E255K", "variant_annotation": "Missense", "exon": "4", "rsid": "rs387906517", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Nilotinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": "27760149", "nct": NaN, "last_updated": "6/13/19", "feature_display": "ABL1 p.E255K (Missense)"}, "11": {"gene": "ABL1", "chromosome": "9", "start_position": "133738307", "end_position": "133738307", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.764A>T", "protein_change": "p.E255V", "variant_annotation": "Missense", "exon": "4", "rsid": "rs387906516", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Nilotinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": "27760149", "nct": NaN, "last_updated": "6/13/19", "feature_display": "ABL1 p.E255V (Missense)"}, "12": {"gene": "ABL1", "chromosome": "9", "start_position": "133738357", "end_position": "133738357", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.757T>C", "protein_change": "p.Y253H", "variant_annotation": "Missense", "exon": "4", "rsid": "rs121913461", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Nilotinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": "27760149", "nct": NaN, "last_updated": "6/13/19", "feature_display": "ABL1 p.Y253H (Missense)"}, "13": {"gene": "ABL1", "chromosome": "9", "start_position": "133748414", "end_position": "133748414", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1075T>G", "protein_change": "p.F359V", "variant_annotation": "Missense", "exon": "6", "rsid": "rs121913452", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Nilotinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": "27760149", "nct": NaN, "last_updated": "6/13/19", "feature_display": "ABL1 p.F359V (Missense)"}, "14": {"gene": "ABL1", "chromosome": "9", "start_position": "133748358", "end_position": "133748358", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1076T>G", "protein_change": "p.F359C", "variant_annotation": "Missense", "exon": "6", "rsid": NaN, "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Nilotinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": "27760149", "nct": NaN, "last_updated": "6/13/19", "feature_display": "ABL1 p.F359C (Missense)"}, "15": {"gene": "ABL1", "chromosome": "9", "start_position": "133748414", "end_position": "133748414", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.1075T>A", "protein_change": "p.F359I", "variant_annotation": "Missense", "exon": "6", "rsid": "rs121913452", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Nilotinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML. ABL [E255K/V, Y253H, F359V/C/I] are known to be less sensitive to Nilotinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": "27760149", "nct": NaN, "last_updated": "6/13/19", "feature_display": "ABL1 p.F359I (Missense)"}, "16": {"gene": "ABL1", "chromosome": "9", "start_position": "133738357", "end_position": "133738357", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.757T>C", "protein_change": "p.Y253H", "variant_annotation": "Missense", "exon": "4", "rsid": "rs121913461", "disease": "Chronic Myeloid Leukemia", "context": "Advanced", "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Dasatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.Y253H (Missense)"}, "17": {"gene": "ABL1", "chromosome": "9", "start_position": "133738306", "end_position": "133738306", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.763G>A", "protein_change": "p.E255K", "variant_annotation": "Missense", "exon": "4", "rsid": "rs387906517", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Dasatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.E255K (Missense)"}, "18": {"gene": "ABL1", "chromosome": "9", "start_position": "133738307", "end_position": "133738307", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.764A>T", "protein_change": "p.E255V", "variant_annotation": "Missense", "exon": "4", "rsid": "rs387906516", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Dasatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.E255V (Missense)"}, "19": {"gene": "ABL1", "chromosome": "9", "start_position": "133748414", "end_position": "133748414", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1075T>G", "protein_change": "p.F359V", "variant_annotation": "Missense", "exon": "6", "rsid": "rs121913452", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Dasatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.F359V (Missense)"}, "20": {"gene": "ABL1", "chromosome": "9", "start_position": "133748358", "end_position": "133748358", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1076T>G", "protein_change": "p.F359C", "variant_annotation": "Missense", "exon": "6", "rsid": NaN, "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Dasatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.F359C (Missense)"}, "21": {"gene": "ABL1", "chromosome": "9", "start_position": "133748414", "end_position": "133748414", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.1075T>A", "protein_change": "p.F359I", "variant_annotation": "Missense", "exon": "6", "rsid": "rs121913452", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Dasatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.F359I (Missense)"}, "22": {"gene": "ABL1", "chromosome": "9", "start_position": "133748290", "end_position": "133748290", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.951C>G", "protein_change": "p.F317L", "variant_annotation": "Missense", "exon": "6", "rsid": NaN, "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Nilotinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.F317L (Missense)"}, "23": {"gene": "ABL1", "chromosome": "9", "start_position": "133748288", "end_position": "133748288", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.949T>G", "protein_change": "p.F317V", "variant_annotation": "Missense", "exon": "6", "rsid": "rs1057519773", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Nilotinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.F317V (Missense)"}, "24": {"gene": "ABL1", "chromosome": "9", "start_position": "133748288", "end_position": "133748288", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.949T>A", "protein_change": "p.F317I", "variant_annotation": "Missense", "exon": "6", "rsid": "rs1057519773", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Nilotinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.F317I (Missense)"}, "25": {"gene": "ABL1", "chromosome": "9", "start_position": "133747586", "end_position": "133747586", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.950T>G", "protein_change": "p.F317C", "variant_annotation": "Missense", "exon": "5", "rsid": NaN, "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Nilotinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.F317C (Missense)"}, "26": {"gene": "ABL1", "chromosome": "9", "start_position": "133747582", "end_position": "133747582", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.943A>G", "protein_change": "p.T315A", "variant_annotation": "Missense", "exon": "6", "rsid": "rs1057519772", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Nilotinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.T315A (Missense)"}, "27": {"gene": "ABL1", "chromosome": "9", "start_position": "133747531", "end_position": "133747531", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.895G>T", "protein_change": "p.V299L", "variant_annotation": "Missense", "exon": "5", "rsid": NaN, "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Nilotinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.V299L (Missense)"}, "28": {"gene": "ABL1", "chromosome": "9", "start_position": "133738306", "end_position": "133738306", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.763G>A", "protein_change": "p.E255K", "variant_annotation": "Missense", "exon": "4", "rsid": "rs387906517", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Bosutinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.E255K (Missense)"}, "29": {"gene": "ABL1", "chromosome": "9", "start_position": "133738307", "end_position": "133738307", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.764A>T", "protein_change": "p.E255V", "variant_annotation": "Missense", "exon": "4", "rsid": "rs387906516", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Bosutinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.E255V (Missense)"}, "30": {"gene": "ABL1", "chromosome": "9", "start_position": "133748290", "end_position": "133748290", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.951C>G", "protein_change": "p.F317L", "variant_annotation": "Missense", "exon": "6", "rsid": NaN, "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Bosutinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.F317L (Missense)"}, "31": {"gene": "ABL1", "chromosome": "9", "start_position": "133748288", "end_position": "133748288", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.949T>G", "protein_change": "p.F317V", "variant_annotation": "Missense", "exon": "6", "rsid": "rs1057519773", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Bosutinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.F317V (Missense)"}, "32": {"gene": "ABL1", "chromosome": "9", "start_position": "133748288", "end_position": "133748288", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.949T>A", "protein_change": "p.F317I", "variant_annotation": "Missense", "exon": "6", "rsid": "rs1057519773", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Bosutinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.F317I (Missense)"}, "33": {"gene": "ABL1", "chromosome": "9", "start_position": "133747586", "end_position": "133747586", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.950T>G", "protein_change": "p.F317C", "variant_annotation": "Missense", "exon": "5", "rsid": NaN, "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Bosutinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.F317C (Missense)"}, "34": {"gene": "ABL1", "chromosome": "9", "start_position": "133748414", "end_position": "133748414", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1075T>G", "protein_change": "p.F359V", "variant_annotation": "Missense", "exon": "6", "rsid": "rs121913452", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Bosutinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.F359V (Missense)"}, "35": {"gene": "ABL1", "chromosome": "9", "start_position": "133748358", "end_position": "133748358", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1076T>G", "protein_change": "p.F359C", "variant_annotation": "Missense", "exon": "6", "rsid": NaN, "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Bosutinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.F359C (Missense)"}, "36": {"gene": "ABL1", "chromosome": "9", "start_position": "133747582", "end_position": "133747582", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.943A>G", "protein_change": "p.T315A", "variant_annotation": "Missense", "exon": "6", "rsid": "rs1057519772", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Bosutinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.T315A (Missense)"}, "37": {"gene": "ABL1", "chromosome": "9", "start_position": "133738357", "end_position": "133738357", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.757T>C", "protein_change": "p.Y253H", "variant_annotation": "Missense", "exon": "4", "rsid": "rs121913461", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Bosutinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.Y253H (Missense)"}, "38": {"gene": "ABL1", "chromosome": "9", "start_position": "133748283", "end_position": "133748283", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.944C>T", "protein_change": "p.T315I", "variant_annotation": "Missense", "exon": "6", "rsid": NaN, "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Ponatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.T315I (Missense)"}, "39": {"gene": "ABL1", "chromosome": "9", "start_position": "133748283", "end_position": "133748283", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.944C>T", "protein_change": "p.T315I", "variant_annotation": "Missense", "exon": "6", "rsid": NaN, "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Omacetaxine", "therapy_strategy": "Chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.T315I (Missense)"}, "40": {"gene": "ABL1", "chromosome": "9", "start_position": "133748414", "end_position": "133748414", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.1075T>A", "protein_change": "p.F359I", "variant_annotation": "Missense", "exon": "6", "rsid": "rs121913452", "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Dasatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/9/19", "feature_display": "ABL1 p.F359I (Missense)"}, "41": {"gene": "AKT1", "chromosome": "14", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Missense", "exon": "", "rsid": NaN, "disease": NaN, "context": NaN, "oncotree_term": NaN, "oncotree_code": NaN, "therapy_name": "MK-2206", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.", "url": "https://doi.org/10.1158/1535-7163.MCT-15-0230", "doi": "10.1158/1535-7163.MCT-15-0230", "pmid": "26351323", "nct": NaN, "last_updated": "3/16/17", "feature_display": "AKT1 (Missense)"}, "42": {"gene": "AKT1", "chromosome": "14", "start_position": "105246551", "end_position": "105246551", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.49G>A", "protein_change": "p.E17K", "variant_annotation": "Missense", "exon": "2", "rsid": "rs34409589", "disease": NaN, "context": NaN, "oncotree_term": NaN, "oncotree_code": NaN, "therapy_name": "MK-2206", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.", "url": "https://doi.org/10.1158/1535-7163.MCT-15-0230", "doi": "10.1158/1535-7163.MCT-15-0230", "pmid": "26351323", "nct": NaN, "last_updated": "6/13/19", "feature_display": "AKT1 p.E17K (Missense)"}, "43": {"gene": "AKT2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Missense", "exon": "", "rsid": NaN, "disease": NaN, "context": NaN, "oncotree_term": NaN, "oncotree_code": NaN, "therapy_name": "MK-2206", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.", "url": "https://doi.org/10.1158/1535-7163.MCT-15-0230", "doi": "10.1158/1535-7163.MCT-15-0230", "pmid": "26351323", "nct": NaN, "last_updated": "3/16/17", "feature_display": "AKT2 (Missense)"}, "44": {"gene": "AKT3", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Missense", "exon": "", "rsid": NaN, "disease": NaN, "context": NaN, "oncotree_term": NaN, "oncotree_code": NaN, "therapy_name": "MK-2206", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.", "url": "https://doi.org/10.1158/1535-7163.MCT-15-0230", "doi": "10.1158/1535-7163.MCT-15-0230", "pmid": "26351323", "nct": NaN, "last_updated": "3/16/17", "feature_display": "AKT3 (Missense)"}, "45": {"gene": "ALK", "chromosome": "2", "start_position": "29443613", "end_position": "29443613", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.3604G>A", "protein_change": "p.G1202R", "variant_annotation": "Missense", "exon": "23", "rsid": "rs1057519783", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Ceritinib", "therapy_strategy": "ALK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.", "url": "https://doi.org/10.1158/2159-8290.CD-13-0846", "doi": "10.1158/2159-8290.CD-13-0846", "pmid": "24675041", "nct": NaN, "last_updated": "6/13/19", "feature_display": "ALK p.G1202R (Missense)"}, "46": {"gene": "ALK", "chromosome": "2", "start_position": "29443696", "end_position": "29443696", "reference_allele": "A", "alternate_allele": "C", "cdna_change": "c.3521T>G", "protein_change": "p.F1174C", "variant_annotation": "Missense", "exon": "23", "rsid": "rs1057519697", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Ceritinib", "therapy_strategy": "ALK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.", "url": "https://doi.org/10.1158/2159-8290.CD-13-0846", "doi": "10.1158/2159-8290.CD-13-0846", "pmid": "24675041", "nct": NaN, "last_updated": "6/13/19", "feature_display": "ALK p.F1174C (Missense)"}, "47": {"gene": "ALK", "chromosome": "2", "start_position": "29443631", "end_position": "29443631", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.3586C>A", "protein_change": "p.L1196M", "variant_annotation": "Missense", "exon": "23", "rsid": "rs1057519784", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Ceritinib", "therapy_strategy": "ALK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.", "url": "https://doi.org/10.1158/2159-8290.CD-13-0846", "doi": "10.1158/2159-8290.CD-13-0846", "pmid": "24675041", "nct": NaN, "last_updated": "6/13/19", "feature_display": "ALK p.L1196M (Missense)"}, "48": {"gene": "ALK", "chromosome": "2", "start_position": "29432682", "end_position": "29432682", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.3806G>C", "protein_change": "p.G1269A", "variant_annotation": "Missense", "exon": "25", "rsid": "rs1057519781", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Ceritinib", "therapy_strategy": "ALK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.", "url": "https://doi.org/10.1158/2159-8290.CD-13-0846", "doi": "10.1158/2159-8290.CD-13-0846", "pmid": "24675041", "nct": NaN, "last_updated": "6/13/19", "feature_display": "ALK p.G1269A (Missense)"}, "49": {"gene": "ALK", "chromosome": "2", "start_position": "29443600", "end_position": "29443600", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.3617C>A", "protein_change": "p.S1206Y", "variant_annotation": "Missense", "exon": "23", "rsid": "rs1057519782", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Ceritinib", "therapy_strategy": "ALK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.", "url": "https://doi.org/10.1158/2159-8290.CD-13-0846", "doi": "10.1158/2159-8290.CD-13-0846", "pmid": "24675041", "nct": NaN, "last_updated": "6/13/19", "feature_display": "ALK p.S1206Y (Missense)"}, "50": {"gene": "AR", "chromosome": "X", "start_position": "66943552", "end_position": "66943552", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.2632A>G", "protein_change": "p.T878A", "variant_annotation": "Missense", "exon": "8", "rsid": "rs137852578", "disease": "Prostate Cancer", "context": "Castration Resistant Prostate Cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Abiraterone", "therapy_strategy": "Antiandrogen", "therapy_type": "Hormone therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.", "url": "https://doi.org/10.1158/1078-0432.CCR-14-1220", "doi": "10.1158/1078-0432.CCR-14-1220", "pmid": "25320358", "nct": NaN, "last_updated": "6/13/19", "feature_display": "AR p.T878A (Missense)"}, "51": {"gene": "AR", "chromosome": "X", "start_position": "66931463", "end_position": "66931463", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.2105T>A", "protein_change": "p.L702H", "variant_annotation": "Missense", "exon": "4", "rsid": NaN, "disease": "Prostate Cancer", "context": "Castration Resistant Prostate Cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Abiraterone", "therapy_strategy": "Antiandrogen", "therapy_type": "Hormone therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.", "url": "https://doi.org/10.1158/1078-0432.CCR-14-1220", "doi": "10.1158/1078-0432.CCR-14-1220", "pmid": "25320358", "nct": NaN, "last_updated": "6/13/19", "feature_display": "AR p.L702H (Missense)"}, "52": {"gene": "ARAF", "chromosome": "X", "start_position": "47426121", "end_position": "47426121", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.641C>G", "protein_change": "p.S214C", "variant_annotation": "Missense", "exon": "7", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Advanced", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Sorafenib", "therapy_strategy": "RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.", "url": "https://doi.org/10.1172/JCI72763", "doi": "10.1172/JCI72763", "pmid": "24569458", "nct": NaN, "last_updated": "6/13/19", "feature_display": "ARAF p.S214C (Missense)"}, "53": {"gene": "ARID1A", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Metastatic", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Durvalumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.", "url": "https://doi.org/10.1038/s41591-018-0012-z", "doi": "10.1038/s41591-018-0012-z", "pmid": "29736026", "nct": NaN, "last_updated": "2/4/19", "feature_display": "ARID1A (Nonsense)"}, "54": {"gene": "ARID1A", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Metastatic", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Durvalumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.", "url": "https://doi.org/10.1038/s41591-018-0012-z", "doi": "10.1038/s41591-018-0012-z", "pmid": "29736026", "nct": NaN, "last_updated": "2/4/19", "feature_display": "ARID1A (Frameshift)"}, "55": {"gene": "ARID1A", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Pancreatic Cancer", "context": NaN, "oncotree_term": "Pancreatic Adenocarcinoma", "oncotree_code": "PAAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.", "url": "https://doi.org/10.1038/ncomms7744", "doi": "10.1038/ncomms7744", "pmid": "25855536", "nct": NaN, "last_updated": "11/3/17", "feature_display": "ARID1A"}, "56": {"gene": "ASXL1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Most frequent in Chronic Myelomonocytic Leukemia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "ASXL1 (Nonsense)"}, "57": {"gene": "ASXL1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Most frequent in Chronic Myelomonocytic Leukemia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "ASXL1 (Frameshift)"}, "58": {"gene": "ATM", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Any solid tumor", "context": "Advanced or metastatic", "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "BAY 1895344", "therapy_strategy": "ATR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.", "preferred_assertion": NaN, "source_type": "Abstract", "citation": "De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.", "url": "https://10.1200/JCO.2019.37.15_suppl.3007", "doi": "10.1200/JCO.2019.37.15_suppl.3007", "pmid": NaN, "nct": "NCT03188965", "last_updated": "11/4/19", "feature_display": "ATM (Frameshift)"}, "59": {"gene": "ATM", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Splice Site", "exon": "", "rsid": NaN, "disease": "Any solid tumor", "context": "Advanced or metastatic", "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "BAY 1895344", "therapy_strategy": "ATR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.", "preferred_assertion": NaN, "source_type": "Abstract", "citation": "De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.", "url": "https://10.1200/JCO.2019.37.15_suppl.3007", "doi": "10.1200/JCO.2019.37.15_suppl.3007", "pmid": NaN, "nct": "NCT03188965", "last_updated": "11/4/19", "feature_display": "ATM (Splice Site)"}, "60": {"gene": "ATM", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Any solid tumor", "context": "Advanced or metastatic", "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "BAY 1895344", "therapy_strategy": "ATR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.", "preferred_assertion": NaN, "source_type": "Abstract", "citation": "De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.", "url": "https://10.1200/JCO.2019.37.15_suppl.3007", "doi": "10.1200/JCO.2019.37.15_suppl.3007", "pmid": NaN, "nct": "NCT03188965", "last_updated": "11/4/19", "feature_display": "ATM (Nonsense)"}, "61": {"gene": "ATM", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Any solid tumor", "context": NaN, "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Radiation therapy", "therapy_strategy": "Radiation", "therapy_type": "Radiation therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "In a retrospective review of 8 patients with somatic truncating ATM mutations receiving palliative radiation therapy, excellent responses were seen with a median local control period of 4.62 years.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Ma J, Setton J, Morris L, et al. Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM Oncotarget. 2016; 8(6).", "url": "https://doi.org/10.18632/oncotarget.14400", "doi": "10.18632/oncotarget.14400", "pmid": "28055970", "nct": NaN, "last_updated": "8/8/19", "feature_display": "ATM (Frameshift)"}, "62": {"gene": "ATM", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Splice Site", "exon": "", "rsid": NaN, "disease": "Any solid tumor", "context": NaN, "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Radiation therapy", "therapy_strategy": "Radiation", "therapy_type": "Radiation therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "In a retrospective review of 8 patients with somatic truncating ATM mutations receiving palliative radiation therapy, excellent responses were seen with a median local control period of 4.62 years.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Ma J, Setton J, Morris L, et al. Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM Oncotarget. 2016; 8(6).", "url": "https://doi.org/10.18632/oncotarget.14400", "doi": "10.18632/oncotarget.14400", "pmid": "28055970", "nct": NaN, "last_updated": "8/8/19", "feature_display": "ATM (Splice Site)"}, "63": {"gene": "ATM", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Any solid tumor", "context": NaN, "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Radiation therapy", "therapy_strategy": "Radiation", "therapy_type": "Radiation therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "In a retrospective review of 8 patients with somatic truncating ATM mutations receiving palliative radiation therapy, excellent responses were seen with a median local control period of 4.62 years.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Ma J, Setton J, Morris L, et al. Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM Oncotarget. 2016; 8(6).", "url": "https://doi.org/10.18632/oncotarget.14400", "doi": "10.18632/oncotarget.14400", "pmid": "28055970", "nct": NaN, "last_updated": "8/8/19", "feature_display": "ATM (Nonsense)"}, "64": {"gene": "ATM", "chromosome": "11", "start_position": "108150313", "end_position": "108150313", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "c.3380C>A", "protein_change": "p.A1127D", "variant_annotation": "Missense", "exon": "23", "rsid": "rs1555090340", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.", "url": "https://doi.org/10.1016/j.tranon.2017.01.007", "doi": "10.1016/j.tranon.2017.01.007", "pmid": "28182994", "nct": NaN, "last_updated": "8/15/19", "feature_display": "ATM p.A1127D (Missense)"}, "65": {"gene": "ATM", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Prostate Cancer", "context": "Metastatic castration resistant prostate cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/22/20", "feature_display": "ATM"}, "66": {"gene": "BARD1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BARD1"}, "67": {"gene": "BARD1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BARD1"}, "68": {"gene": "BARD1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BARD1"}, "69": {"gene": "BARD1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BARD1"}, "70": {"gene": "BARD1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BARD1"}, "71": {"gene": "BARD1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BARD1"}, "72": {"gene": "BARD1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Prostate Cancer", "context": "Metastatic castration resistant prostate cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/22/20", "feature_display": "BARD1"}, "73": {"gene": "BCOR", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "More frequent in Chronic Myelomonocytic Leukemia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "BCOR (Nonsense)"}, "74": {"gene": "BCOR", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "More frequent in Chronic Myelomonocytic Leukemia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "BCOR (Frameshift)"}, "75": {"gene": "BCOR", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Splice Site", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "More frequent in Chronic Myelomonocytic Leukemia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "BCOR (Splice Site)"}, "76": {"gene": "BCOR", "chromosome": "X", "start_position": "39921444", "end_position": "39921444", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.4376A>G", "protein_change": "p.N1425S", "variant_annotation": "Missense", "exon": "10", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "More frequent in Chronic Myelomonocytic Leukemia.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "BCOR p.N1425S (Missense)"}, "77": {"gene": "BCR", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Imatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405", "url": "https://doi.org/10.1182/blood-2010-12-326405", "doi": "10.1182/blood-2010-12-326405", "pmid": "27760149", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BCR"}, "78": {"gene": "BLM", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.", "url": "https://doi.org/10.1038/srep14060", "doi": "10.1038/srep14060", "pmid": "26358404", "nct": NaN, "last_updated": "4/30/19", "feature_display": "BLM"}, "79": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Melanoma", "context": "Unresctable or metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Dabrafenib", "therapy_strategy": "B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRAF p.V600E (Missense)"}, "80": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Melanoma", "context": "Unresctable or metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Dabrafenib + Trametinib", "therapy_strategy": "B-RAF inhibition + MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.", "preferred_assertion": "1", "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRAF p.V600E (Missense)"}, "81": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453137", "reference_allele": "AC", "alternate_allele": "TT", "cdna_change": "c.1798_1799GT>AA", "protein_change": "p.V600K", "variant_annotation": "Missense", "exon": "15", "rsid": "rs121913227", "disease": "Melanoma", "context": "Unresctable or metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Dabrafenib + Trametinib", "therapy_strategy": "B-RAF inhibition + MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.", "preferred_assertion": "1", "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRAF p.V600K (Missense)"}, "82": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Dabrafenib + Trametinib", "therapy_strategy": "B-RAF inhibition + MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the adjuvant treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.", "preferred_assertion": "1", "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRAF p.V600E (Missense)"}, "83": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453137", "reference_allele": "AC", "alternate_allele": "TT", "cdna_change": "c.1798_1799GT>AA", "protein_change": "p.V600K", "variant_annotation": "Missense", "exon": "15", "rsid": "rs121913227", "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Dabrafenib + Trametinib", "therapy_strategy": "B-RAF inhibition + MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the adjuvant treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.", "preferred_assertion": "1", "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRAF p.V600K (Missense)"}, "84": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Dabrafenib + Trametinib", "therapy_strategy": "B-RAF inhibition + MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E, as detected by an FDA-approved test.", "preferred_assertion": "1", "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRAF p.V600E (Missense)"}, "85": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Melanoma", "context": "Unresctable or metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Trametinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to trametinib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf. Revised June 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRAF p.V600E (Missense)"}, "86": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453137", "reference_allele": "AC", "alternate_allele": "TT", "cdna_change": "c.1798_1799GT>AA", "protein_change": "p.V600K", "variant_annotation": "Missense", "exon": "15", "rsid": "rs121913227", "disease": "Melanoma", "context": "Unresctable or metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Trametinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to trametinib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf. Revised June 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRAF p.V600K (Missense)"}, "87": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453137", "reference_allele": "AC", "alternate_allele": "TT", "cdna_change": "c.1798_1799GT>AA", "protein_change": "p.V600K", "variant_annotation": "Missense", "exon": "15", "rsid": "rs121913227", "disease": "Melanoma", "context": "Unresctable or metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Encorafenib", "therapy_strategy": "B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600K mutation, as detected by an FDA-approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRAF p.V600K (Missense)"}, "88": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Melanoma", "context": "Unresctable or metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Encorafenib", "therapy_strategy": "B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRAF p.V600E (Missense)"}, "89": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Colorectal Cancer", "context": "Metastatic, after prior therapy", "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Cetuximab + Encorafenib", "therapy_strategy": "EGFR inhibition + B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "BRAF p.V600E (Missense)"}, "90": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Melanoma", "context": "Unresctable or metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Vemurafenib", "therapy_strategy": "B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to vemurafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Genentech, Inc. Zelboraf (vemurafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf. Revised May 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRAF p.V600E (Missense)"}, "91": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Colorectal Cancer", "context": "Metastatic", "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Panitumumab", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "92": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Colorectal Cancer", "context": "Metastatic", "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "93": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Vemurafenib", "therapy_strategy": "B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Melanoma NCCN Evidence Blocks (Version 3.2016). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf", "url": "https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "94": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Dabrafenib", "therapy_strategy": "B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Melanoma NCCN Evidence Blocks (Version 3.2016). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf", "url": "https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "95": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Cobimetinib + Vemurafenib", "therapy_strategy": "MEK inhibition + B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Melanoma NCCN Evidence Blocks (Version 3.2016). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf", "url": "https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "96": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Dabrafenib + Trametinib", "therapy_strategy": "B-RAF inhibition + MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "preferred_assertion": "1", "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Melanoma NCCN Evidence Blocks (Version 3.2016). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf", "url": "https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "97": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Dabrafenib + Trametinib", "therapy_strategy": "B-RAF inhibition + MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "U.S. Food and Drug Administration granted regular approvals to dabrafenib and trametinib, administered in combination for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.", "preferred_assertion": "1", "source_type": "Guideline", "citation": "Center for Drug Evaluation and Research. Approved Drugs - FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation. U S Food and Drug Administration Home Page. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm564331.htm.", "url": "https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm564331.htm", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "98": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Ipilimumab + Vemurafenib", "therapy_strategy": "CTLA-4 inhibition + B-RAF inhibition", "therapy_type": "Combination therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "The combination of ipilimumab and vemurafenib in a sequencing strategy showed limited efficacy in a phase II study.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Amin A, Lawson DH, Salama AK, et al. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. J Immunother Cancer. 2016;4:44.", "url": "https://doi.org/10.1186/s40425-016-0148-7", "doi": "10.1186/s40425-016-0148-7", "pmid": "27532019", "nct": "NCT01673854", "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "99": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Ipilimumab + Vemurafenib", "therapy_strategy": "CTLA-4 inhibition + B-RAF inhibition", "therapy_type": "Combination therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "The combination of ipilimumab and vemurafenib in a sequencing strategy showed limited efficacy in a phase II study.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Amin A, Lawson DH, Salama AK, et al. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. J Immunother Cancer. 2016;4:44.", "url": "https://doi.org/10.1186/s40425-016-0148-7", "doi": "10.1186/s40425-016-0148-7", "pmid": "27532019", "nct": "NCT01673854", "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "100": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Bevacizumab", "therapy_strategy": "VEGF/VEGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Administration of bevacizumab in a dabrafenib-resistant cell line counteracted the tumor growth stimulating effect of administering dabrafenib post-resistance.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Caporali S, Alvino E, Lacal PM, et al. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. Int J Oncol. 2016;49(3):1164-74.", "url": "https://doi.org/10.3892/ijo.2016.3594", "doi": "10.3892/ijo.2016.3594", "pmid": "27572939", "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "101": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Omipalisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Administration of GSK2126458A, a PI3K/AKT/mTOR pathway inhibitor, in a dabrafenib-resistant cell line counteracted the tumor growth stimulating effect of administering dabrafenib post-resistance.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Caporali S, Alvino E, Lacal PM, et al. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. Int J Oncol. 2016;49(3):1164-74.", "url": "https://doi.org/10.3892/ijo.2016.3594", "doi": "10.3892/ijo.2016.3594", "pmid": "27572939", "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "102": {"gene": "BRAF", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Selumetinib + Vemurafenib", "therapy_strategy": "MEK inhibition + B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Treating mutant BRAF melanoma cell with both Selumetinib and PLX4720, a predecessor to Vemurafenib, prevented emergence of resistant clones.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.", "url": "https://doi.org/10.1073/pnas.0905833106", "doi": "10.1073/pnas.0905833106", "pmid": "19915144", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BRAF"}, "103": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Bleomycin", "therapy_strategy": "Intercalated chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Three human melanoma cell lines displayed sensitivity to bleomycin, particularly when co-administered with human interferon-beta gene or herpes simplex virus thymidine kinase/ganciclovir suicide gene lipofection.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Fondello C, Agnetti L, Villaverde MS, Simian M, Glikin GC, Finocchiaro LM. The combination of bleomycin with suicide or interferon-beta gene transfer is able to efficiently eliminate human melanoma tumor initiating cells. Biomed Pharmacother. 2016;83:290-301.", "url": "https://doi.org/10.1016/j.biopha.2016.06.038", "doi": "10.1016/j.biopha.2016.06.038", "pmid": "27399807", "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "104": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Mito-CP", "therapy_strategy": "Metabolism interference", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Mitochondria-targeted metabolism-interferring agent mito-CP (mitochondria-targeted carboxy-proxyl) demonstrated a tumor-suppressing effect in BRAF V600E-mutated melanoma mouse models, including models that had developed resistance to vemurafenib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Hong SK, Starenki D, Wu PK, Park JI. Suppression of B-Raf(V600E) melanoma cell survival by targeting mitochondria using triphenyl-phosphonium-conjugated nitroxide or ubiquinone. Cancer Biol Ther. 2016;", "url": "https://doi.org/10.1080/15384047.2016.1250987", "doi": "10.1080/15384047.2016.1250987", "pmid": "27786591", "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "105": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Langerhans Cell Histiocytosis", "context": NaN, "oncotree_term": "Langerhans Cell Histiocytosis", "oncotree_code": "LCH", "therapy_name": "Vemurafenib", "therapy_strategy": "B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373(8):726-36.", "url": "https://doi.org/10.1056/NEJMoa1502309", "doi": "10.1056/NEJMoa1502309", "pmid": "26287849", "nct": "NCT01524978", "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "106": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Erdheim-Chester Disease", "context": NaN, "oncotree_term": "Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease", "oncotree_code": "ECD", "therapy_name": "Vemurafenib", "therapy_strategy": "B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373(8):726-36.", "url": "https://doi.org/10.1056/NEJMoa1502309", "doi": "10.1056/NEJMoa1502309", "pmid": "26287849", "nct": "NCT01524978", "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "107": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Vemurafenib", "therapy_strategy": "B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "Activating BRAF mutations are associated with an increased sensitivity to BRAF inhibitors. Co-administration with a MEK inhibitor may potentiate the effects of BRAF inhibitors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373(8):726-36.", "url": "https://doi.org/10.1056/NEJMoa1502309", "doi": "10.1056/NEJMoa1502309", "pmid": "26287849", "nct": "NCT01524978", "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "108": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Trametinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Study of a patient-derived orthotopic xenograft (PDOX) model suggests some vemurafenib-resistant BRAF-V600E-mutated melanomas may be sensitive to trametinib (but not cobimetinib) treatment.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Kawaguchi K, Murakami T, Chmielowski B, et al. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. Oncotarget. 2016;", "url": "https://doi.org/10.18632/oncotarget.12328", "doi": "10.18632/oncotarget.12328", "pmid": "27690220", "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "109": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Rectal neuroendrocrine tumor", "context": "Poorly differentiatied high-grade", "oncotree_term": "High-Grade Neuroendocrine Carcinoma of the Colon and Rectum", "oncotree_code": "HGNEC", "therapy_name": "Dabrafenib + Trametinib", "therapy_strategy": "B-RAF inhibition + MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Two patients with metastatic colorectal neuroendocrine tumors refractory to treatment exhibited a durable response to combined BRAF-MEK inhibition. One patient with BRAF V600E observed ongoing response lasting over 7 months when treated with dabrafenib and trametinib in combination.", "preferred_assertion": "1", "source_type": "Journal", "citation": "Klempner SJ, Gershenhorn B, Tran P, et al. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. Cancer Discov. 2016;6(6):594-600.", "url": "https://doi.org/10.1158/2159-8290.CD-15-1192", "doi": "10.1158/2159-8290.CD-15-1192", "pmid": "27048246", "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "110": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Rectal neuroendrocrine tumor", "context": "Locally advanced high-grade", "oncotree_term": "High-Grade Neuroendocrine Carcinoma of the Colon and Rectum", "oncotree_code": "HGNEC", "therapy_name": "Trametinib + Vemurafenib", "therapy_strategy": "MEK inhibition + B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Two patients with metastatic colorectal neuroendocrine tumors refractory to treatment exhibited a durable response to combined BRAF-MEK inhibition. One patient with BRAF V600E observed ongoing response lasting 9 months when treated with vemurafenib and trametinib in combination.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Klempner SJ, Gershenhorn B, Tran P, et al. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. Cancer Discov. 2016;6(6):594-600.", "url": "https://doi.org/10.1158/2159-8290.CD-15-1192", "doi": "10.1158/2159-8290.CD-15-1192", "pmid": "27048246", "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "111": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Interferon-alpha + Ixazomib", "therapy_strategy": "Interferon-alpha + Proteasome inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Preclinical evidence suggests the combination of proteasome inhibitor ixazomib with interferon-alpha may negatively impact tumor cell viability in melanoma, particularly in patients with BRAF V600E mutations.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Suarez-kelly LP, Kemper GM, Duggan MC, et al. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma. Oncotarget. 2016;", "url": "https://doi.org/10.18632/oncotarget.12791", "doi": "10.18632/oncotarget.12791", "pmid": "27783987", "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "112": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "GANT61", "therapy_strategy": "GLI1/GLI2 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Loss of tumor cell viability was observed in nine cell lines after administration of GANT61, a GLI1/GLI2 inhibitor (targeting the Hedgehog/GLI pathway). Co-administration of GANT61 with obatoclax, a BCL2 family inhibitor, increased treatment effectiveness.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Vickova K, Reda J, Krayem M, Ghanem G, Vachtenheim J. GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax. Int J Oncol. 2016;49(3):953-60.", "url": "https://doi.org/10.3892/ijo.2016.3596", "doi": "10.3892/ijo.2016.3596", "pmid": "27572939", "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "113": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "GANT61 + Obatoclax", "therapy_strategy": "GLI1/GLI2 inhibition + Bcl-2 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Loss of tumor cell viability was observed in nine cell lines after administration of GANT61, a GLI1/GLI2 inhibitor (targeting the Hedgehog/GLI pathway). Co-administration of GANT61 with obatoclax, a BCL2 family inhibitor, increased treatment effectiveness.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Vickova K, Reda J, Krayem M, Ghanem G, Vachtenheim J. GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax. Int J Oncol. 2016;49(3):953-60.", "url": "https://doi.org/10.3892/ijo.2016.3596", "doi": "10.3892/ijo.2016.3596", "pmid": "27572939", "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "114": {"gene": "BRAF", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Dabrafenib", "therapy_strategy": "B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Targeted agents, such as dabrafenib, that inhibit effector kinases of the mitogen-activated protein kinase (MAPK) signaling cascade, including BRAF, have improved progression-free survival and overall survival when used as a monotherapy in BRAF-mutant melanoma.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wagle, Nikhil, et al. \"MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.\" Cancer discovery 4.1 (2014): 61-68.", "url": "https://doi.org/10.1158/2159-8290.CD-13-0631", "doi": "10.1158/2159-8290.CD-13-0631", "pmid": "24265154", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BRAF"}, "115": {"gene": "BRAF", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Vemurafenib", "therapy_strategy": "B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Targeted agents, such as vemurafenib, that inhibit effector kinases of the mitogen-activated protein kinase (MAPK) signaling cascade, including BRAF, have improved progression-free survival and overall survival when used as a monotherapy in BRAF-mutant melanoma.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wagle, Nikhil, et al. \"MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.\" Cancer discovery 4.1 (2014): 61-68.", "url": "https://doi.org/10.1158/2159-8290.CD-13-0631", "doi": "10.1158/2159-8290.CD-13-0631", "pmid": "24265154", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BRAF"}, "116": {"gene": "BRAF", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Dabrafenib + Trametinib", "therapy_strategy": "B-RAF inhibition + MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Combination therapy of dabrafenib and tremetinib improved progression-free survival, objective response, and duration of response relative to dabrafenib monotherapy in a phase I/II trial.", "preferred_assertion": "1", "source_type": "Journal", "citation": "Wagle, Nikhil, et al. \"MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.\" Cancer discovery 4.1 (2014): 61-68.", "url": "https://doi.org/10.1158/2159-8290.CD-13-0631", "doi": "10.1158/2159-8290.CD-13-0631", "pmid": "24265154", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BRAF"}, "117": {"gene": "BRAF", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Trametinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Targeted agents, such as tremetinib, that inhibit effector kinases of the mitogen-activated protein kinase (MAPK) signaling cascade, including MEK1 and MEK2, have improved progression-free survival and overall survival when used as a monotherapy in BRAF-mutant melanoma.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wagle, Nikhil, et al. \"MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.\" Cancer discovery 4.1 (2014): 61-68.", "url": "https://doi.org/10.1158/2159-8290.CD-13-0631", "doi": "10.1158/2159-8290.CD-13-0631", "pmid": "24265154", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BRAF"}, "118": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Pancreatic Cancer", "context": NaN, "oncotree_term": "Pancreatic Adenocarcinoma", "oncotree_code": "PAAD", "therapy_name": "Vemurafenib", "therapy_strategy": "B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "BRAF V600E mutations were associated with sensitivity to the BRAF inhibitor PLX-4032 in a study of 109 microdissected pancreatic ductal adenocarcinoma patients.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.", "url": "https://doi.org/10.1038/ncomms7744", "doi": "10.1038/ncomms7744", "pmid": "25855536", "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "119": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Glioma", "context": NaN, "oncotree_term": "Glioma", "oncotree_code": "GNOS", "therapy_name": "Neratinib + Vemurafenib", "therapy_strategy": "ER signaling inhibition + B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Vemurafenib monotherapy is efficacious in preclinical models of pediatric gliomas harboring BRAF V600E mutations, but resistance quickly develops. EGFR inhibition appears to rescue the effects of vemurafenib in these models.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Yao TW, Zhang J, Prados M, Weiss WA, James CD, Nicolaides T. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Oncotarget. 2015;6(26):21993-2005.", "url": "https://doi.org/10.18632/oncotarget.4014", "doi": "10.18632/oncotarget.4014", "pmid": "26023796", "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "120": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Colorectal Cancer", "context": "Metastatic", "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Cetuximab", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "121": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Colorectal Cancer", "context": "Metastatic", "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "BRAF p.V600E (Missense)"}, "122": {"gene": "BRAF", "chromosome": "7", "start_position": "140453136", "end_position": "140453136", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1799T>A", "protein_change": "p.V600E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs113488022", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Cetuximab + Vemurafenib", "therapy_strategy": "EGFR inhibition + B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "Vemurafenib alone had insufficient activity in BRAF V600E mutant colorectal cancer patients. Of patients who received vemurafenib and cetuximab, one response was observed; however, approximately half of the patients had tumor regression that did not meet the standard criteria of partial response. ", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015;373(8):726-36.", "url": "https://doi.org/10.1056/NEJMoa1502309", "doi": "10.1056/NEJMoa1502309", "pmid": "26287849", "nct": "NCT01524978", "last_updated": "10/4/19", "feature_display": "BRAF p.V600E (Missense)"}, "123": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Epithelial ovarian cancer", "context": "Advanced", "oncotree_term": "Ovarian Epithelial Tumor", "oncotree_code": "OVT", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT01844986", "last_updated": "11/12/20", "feature_display": "BRCA1"}, "124": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Fallopian tube cancer", "context": NaN, "oncotree_term": "High-Grade Serous Fallopian Tube Cancer", "oncotree_code": "HGSFT", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT01844986", "last_updated": "11/12/20", "feature_display": "BRCA1"}, "125": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Peritoneal cancer", "context": "Primary", "oncotree_term": "Peritoneal Serous Carcinoma", "oncotree_code": "PSEC", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT01844986", "last_updated": "11/12/20", "feature_display": "BRCA1"}, "126": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Oncogenic Mutations", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Previously treated with 2 or more chemotherapies", "oncotree_term": "Ovarian Epithelial Tumor", "oncotree_code": "OVT", "therapy_name": "Rucaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Rucaparib is indicated as monotherapy for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutation (germline and/or somatic) as detected by a US FDA-approved test (available at http://www.fda.gov/CompanionDiagnostics) in patients who have been previously treated with 2 or more chemotherapies", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Clovis Oncology, Inc. Rucaparib (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s008lbl.pdf. Revised October 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s008lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRCA1 (Oncogenic Mutations)"}, "127": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Oncogenic Mutations", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": NaN, "oncotree_term": "Fallopian Tube", "oncotree_code": "HGSFT", "therapy_name": "Rucaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Rucaparib is indicated as monotherapy for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutation (germline and/or somatic) as detected by a US FDA-approved test (available at http://www.fda.gov/CompanionDiagnostics) in patients who have been previously treated with 2 or more chemotherapies", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Clovis Oncology, Inc. Rucaparib (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s008lbl.pdf. Revised October 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s008lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRCA1 (Oncogenic Mutations)"}, "128": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Oncogenic Mutations", "exon": "", "rsid": NaN, "disease": "Peritoneal cancer", "context": "Previously treated with 2 or more chemotherapies", "oncotree_term": "Peritoneal Serous Carcinoma", "oncotree_code": "PSEC", "therapy_name": "Rucaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Rucaparib is indicated as monotherapy for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutation (germline and/or somatic) as detected by a US FDA-approved test (available at http://www.fda.gov/CompanionDiagnostics) in patients who have been previously treated with 2 or more chemotherapies", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Clovis Oncology, Inc. Rucaparib (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s008lbl.pdf. Revised October 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s008lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRCA1 (Oncogenic Mutations)"}, "129": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": NaN, "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Mutations in BRCA1 or BRCA2 may predict sensitivity to PARP inhibition in ovarian cancer", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512-9.", "url": "https://doi.org/10.1200/JCO.2009.26.9589", "doi": "10.1200/JCO.2009.26.9589", "pmid": "20406929", "nct": NaN, "last_updated": "3/20/19", "feature_display": "BRCA1"}, "130": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": NaN, "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.", "url": "https://doi.org/10.1200/JCO.2016.71.3677", "doi": "10.1200/JCO.2016.71.3677", "pmid": "28221868", "nct": NaN, "last_updated": "3/20/19", "feature_display": "BRCA1"}, "131": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Pancreatic Cancer", "context": NaN, "oncotree_term": "Pancreatic Adenocarcinoma", "oncotree_code": "PAAD", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "When present alongside genomic instability, defined by a large number of structural variation events, the inactivation of DNA maintenance genes (BRCA1, BRCA2, PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients. ", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495-501.", "url": "https://doi.org/10.1038/nature14169", "doi": "10.1038/nature14169", "pmid": "25719666", "nct": NaN, "last_updated": "3/7/19", "feature_display": "BRCA1"}, "132": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Advanced, treated with three or more prior lines of chemotherapy", "oncotree_term": "Ovarian Epithelial Tumor", "oncotree_code": "OVT", "therapy_name": "Niraparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "BRCA1"}, "133": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Fallopian tube cancer", "context": "Treated with three or more prior lines of chemotherapy", "oncotree_term": "High-Grade Serous Fallopian Tube Cancer", "oncotree_code": "HGSFT", "therapy_name": "Niraparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "BRCA1"}, "134": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Peritoneal cancer", "context": "Primary, treated with three or more prior lines of chemotherapy", "oncotree_term": "Peritoneal Serous Carcinoma", "oncotree_code": "PSEC", "therapy_name": "Niraparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "BRCA1"}, "135": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Prostate Cancer", "context": "Metastatic castration resistant prostate cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/22/20", "feature_display": "BRCA1"}, "136": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Epithelial ovarian cancer", "context": "HRD-positive advanced", "oncotree_term": "Ovarian Epithelial Tumor", "oncotree_code": "OVT", "therapy_name": "Bevacizumab + Olaparib", "therapy_strategy": "VEGF/VEGFR inhibition + PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12th, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRCA1"}, "137": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Fallopian tube cancer", "context": "HRD-positive advanced", "oncotree_term": "High-Grade Serous Fallopian Tube Cancer", "oncotree_code": "HGSFT", "therapy_name": "Bevacizumab + Olaparib", "therapy_strategy": "VEGF/VEGFR inhibition + PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12th, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRCA1"}, "138": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Peritoneal cancer", "context": "HRD-positive advanced", "oncotree_term": "Peritoneal Serous Carcinoma", "oncotree_code": "PSEC", "therapy_name": "Bevacizumab + Olaparib", "therapy_strategy": "VEGF/VEGFR inhibition + PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12th, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRCA1"}, "139": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Advanced, treated with three or more prior lines of chemotherapy", "oncotree_term": "Ovarian Epithelial Tumor", "oncotree_code": "OVT", "therapy_name": "Niraparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "BRCA2"}, "140": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Fallopian tube cancer", "context": "Treated with three or more prior lines of chemotherapy", "oncotree_term": "High-Grade Serous Fallopian Tube Cancer", "oncotree_code": "HGSFT", "therapy_name": "Niraparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "BRCA2"}, "141": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Peritoneal cancer", "context": "Primary, treated with three or more prior lines of chemotherapy", "oncotree_term": "Peritoneal Serous Carcinoma", "oncotree_code": "PSEC", "therapy_name": "Niraparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "BRCA2"}, "142": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Epithelial ovarian cancer", "context": "Advanced", "oncotree_term": "Ovarian Epithelial Tumor", "oncotree_code": "OVT", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT01844986", "last_updated": "11/12/20", "feature_display": "BRCA2"}, "143": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Fallopian tube cancer", "context": NaN, "oncotree_term": "High-Grade Serous Fallopian Tube Cancer", "oncotree_code": "HGSFT", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT01844986", "last_updated": "11/12/20", "feature_display": "BRCA2"}, "144": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Peritoneal cancer", "context": "Primary", "oncotree_term": "Peritoneal Serous Carcinoma", "oncotree_code": "PSEC", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT01844986", "last_updated": "11/12/20", "feature_display": "BRCA2"}, "145": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Oncogenic Mutations", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Previously treated with 2 or more chemotherapies", "oncotree_term": "Ovarian Epithelial Tumor", "oncotree_code": "OVT", "therapy_name": "Rucaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Rucaparib is indicated as monotherapy for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutation (germline and/or somatic) as detected by a US FDA-approved test (available at http://www.fda.gov/CompanionDiagnostics) in patients who have been previously treated with 2 or more chemotherapies", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Clovis Oncology, Inc. Rucaparib (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s008lbl.pdf. Revised October 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s008lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRCA2 (Oncogenic Mutations)"}, "146": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Oncogenic Mutations", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Previously treated with 2 or more chemotherapies", "oncotree_term": "Fallopian Tube", "oncotree_code": "HGSFT", "therapy_name": "Rucaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Rucaparib is indicated as monotherapy for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutation (germline and/or somatic) as detected by a US FDA-approved test (available at http://www.fda.gov/CompanionDiagnostics) in patients who have been previously treated with 2 or more chemotherapies", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Clovis Oncology, Inc. Rucaparib (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s008lbl.pdf. Revised October 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s008lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRCA2 (Oncogenic Mutations)"}, "147": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Oncogenic Mutations", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Previously treated with 2 or more chemotherapies", "oncotree_term": "Peritoneal Serous Carcinoma", "oncotree_code": "PSEC", "therapy_name": "Rucaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Rucaparib is indicated as monotherapy for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer with deleterious BRCA mutation (germline and/or somatic) as detected by a US FDA-approved test (available at http://www.fda.gov/CompanionDiagnostics) in patients who have been previously treated with 2 or more chemotherapies", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Clovis Oncology, Inc. Rucaparib (rucaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s008lbl.pdf. Revised October 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209115s008lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRCA2 (Oncogenic Mutations)"}, "148": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": NaN, "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Mutations in BRCA1 or BRCA2 may predict sensitivity to PARP inhibition in ovarian cancer", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512-9.", "url": "https://doi.org/10.1200/JCO.2009.26.9589", "doi": "10.1200/JCO.2009.26.9589", "pmid": "20406929", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BRCA2"}, "149": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": NaN, "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.", "url": "https://doi.org/10.1200/JCO.2016.71.3677", "doi": "10.1200/JCO.2016.71.3677", "pmid": "28221868", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BRCA2"}, "150": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Prostate Cancer", "context": NaN, "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "Patients with chemotherapy-refractory prostate cancer have higher response rates to PARP inhibitor therapy in the presence of DNA repair mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Mateo J, Carreira S, Sandhu S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373(18):1697-708.", "url": "https://doi.org/10.1056/NEJMoa1506859", "doi": "10.1056/NEJMoa1506859", "pmid": "26510020", "nct": "NCT01682772", "last_updated": "11/3/17", "feature_display": "BRCA2"}, "151": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Pancreatic Cancer", "context": NaN, "oncotree_term": "Pancreatic Adenocarcinoma", "oncotree_code": "PAAD", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "When present alongside genomic instability, defined by a large number of structural variation events, the inactivation of DNA maintenance genes (BRCA1, BRCA2, PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients. ", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495-501.", "url": "https://doi.org/10.1038/nature14169", "doi": "10.1038/nature14169", "pmid": "25719666", "nct": NaN, "last_updated": "3/7/19", "feature_display": "BRCA2"}, "152": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Nivolumab + Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.", "url": "https://doi.org/10.1016/j.cell.2016.02.065", "doi": "10.1016/j.cell.2016.02.065", "pmid": "26997480", "nct": NaN, "last_updated": "4/16/19", "feature_display": "BRCA2 (Nonsense)"}, "153": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Prostate Cancer", "context": "Metastatic castration resistant prostate cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/22/20", "feature_display": "BRCA2"}, "154": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Epithelial ovarian cancer", "context": "HRD-positive advanced", "oncotree_term": "Ovarian Epithelial Tumor", "oncotree_code": "OVT", "therapy_name": "Bevacizumab + Olaparib", "therapy_strategy": "VEGF/VEGFR inhibition + PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12th, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRCA2"}, "155": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Fallopian tube cancer", "context": "HRD-positive advanced", "oncotree_term": "High-Grade Serous Fallopian Tube Cancer", "oncotree_code": "HGSFT", "therapy_name": "Bevacizumab + Olaparib", "therapy_strategy": "VEGF/VEGFR inhibition + PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12th, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRCA2"}, "156": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Peritoneal cancer", "context": "HRD-positive advanced", "oncotree_term": "Peritoneal Serous Carcinoma", "oncotree_code": "PSEC", "therapy_name": "Bevacizumab + Olaparib", "therapy_strategy": "VEGF/VEGFR inhibition + PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12th, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRCA2"}, "157": {"gene": "BRIP1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BRIP1"}, "158": {"gene": "BRIP1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BRIP1"}, "159": {"gene": "BRIP1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BRIP1"}, "160": {"gene": "BRIP1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BRIP1"}, "161": {"gene": "BRIP1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "High-Grade Serous Fallopian Tube Cancer", "oncotree_code": "HGSFT", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BRIP1"}, "162": {"gene": "BRIP1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "High-Grade Serous Fallopian Tube Cancer", "oncotree_code": "HGSFT", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BRIP1"}, "163": {"gene": "BRIP1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Prostate Cancer", "context": "Metastatic castration resistant prostate cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/22/20", "feature_display": "BRIP1"}, "164": {"gene": "CDK12", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Prostate Cancer", "context": "Metastatic castration resistant prostate cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/22/20", "feature_display": "CDK12"}, "165": {"gene": "CHEK1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK1"}, "166": {"gene": "CHEK1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK1"}, "167": {"gene": "CHEK1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK1"}, "168": {"gene": "CHEK1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK1"}, "169": {"gene": "CHEK1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK1"}, "170": {"gene": "CHEK1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK1"}, "171": {"gene": "CHEK1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Prostate Cancer", "context": "Metastatic castration resistant prostate cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/22/20", "feature_display": "CHEK1"}, "172": {"gene": "CHEK2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK2"}, "173": {"gene": "CHEK2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK2"}, "174": {"gene": "CHEK2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK2"}, "175": {"gene": "CHEK2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK2"}, "176": {"gene": "CHEK2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK2"}, "177": {"gene": "CHEK2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK2"}, "178": {"gene": "CHEK2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Prostate Cancer", "context": "Metastatic castration resistant prostate cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/22/20", "feature_display": "CHEK2"}, "179": {"gene": "CTNNB1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Medulloblastoma", "context": NaN, "oncotree_term": "Medulloblastoma", "oncotree_code": "MBL", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Clinical evidence", "description": "Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.", "url": "https://doi.org/10.1200/JCO.2009.27.4324", "doi": "10.1200/JCO.2009.27.4324", "pmid": "20823417", "nct": NaN, "last_updated": "9/12/19", "feature_display": "CTNNB1"}, "180": {"gene": "DNMT3A", "chromosome": "2", "start_position": "25457242", "end_position": "25457242", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2645G>A", "protein_change": "p.R882H", "variant_annotation": "Missense", "exon": "23", "rsid": "rs147001633", "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Associated with a poor prognosis in patients without mutations in SF3B1.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "DNMT3A p.R882H (Missense)"}, "181": {"gene": "DNMT3A", "chromosome": "2", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Associated with a poor prognosis in patients without mutations in SF3B1.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "DNMT3A (Nonsense)"}, "182": {"gene": "DNMT3A", "chromosome": "2", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Associated with a poor prognosis in patients without mutations in SF3B1.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "DNMT3A (Frameshift)"}, "183": {"gene": "DNMT3A", "chromosome": "2", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Splice Site", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Associated with a poor prognosis in patients without mutations in SF3B1.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "DNMT3A (Splice Site)"}, "184": {"gene": "EGFR", "chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "variant_annotation": "Missense", "exon": "20", "rsid": "rs121434569", "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Osimertinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "EGFR p.T790M (Missense)"}, "185": {"gene": "EGFR", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Erlotinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Mutant EGFR may suggest sensitivity to Erlotinib as a first or subsequent line of therapy. See NCCN guidelines for more details in the case of resistance to Erlotinib in the presence of mutant EGFR.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "EGFR"}, "186": {"gene": "EGFR", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Gefitinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Mutant EGFR may suggest sensitivity to Gefitinib as a first or subsequent line of therapy. See NCCN guidelines for more details in the case of resistance to Gefitinib in the presence of mutant EGFR.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "EGFR"}, "187": {"gene": "EGFR", "chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "variant_annotation": "Missense", "exon": "20", "rsid": "rs121434569", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Gefitinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "EGFR p.T790M (Missense)"}, "188": {"gene": "EGFR", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Afatinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Mutant EGFR may suggest sensitivity to Afatinib as a first or subsequent line of therapy. See NCCN guidelines for more details in the case of resistance to Afatinib in the presence of mutant EGFR.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "EGFR"}, "189": {"gene": "EGFR", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Gefitinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "There is significant association between EGFR mutants and sensitivity to EGFR TKIs.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "EGFR"}, "190": {"gene": "EGFR", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Insertion", "exon": "20", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Gefitinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "EGFR exon 20 insertions may predict resistance to TKIs.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "EGFR Exon 20 (Insertion)"}, "191": {"gene": "EGFR", "chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "variant_annotation": "Missense", "exon": "20", "rsid": "rs121434569", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Durvalumab + Osimertinib", "therapy_strategy": "PD-1/PD-L1 inhibition + EGFR inhibition", "therapy_type": "Combination therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "Durvalumab (a PD-L1 inhibitor), is being evaluated in combination with Osimertinib (an EGFR-TKI) in patients with sensitizing EGFR mutations or T790M.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Ahn MJ, Yang J, Yu H, et al. 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial. J Thorac Oncol. 2016;11(4 Suppl):S115.", "url": "https://doi.org/10.1016/S1556-0864(16)30246-5", "doi": "10.1016/S1556-0864(16)30246-5", "pmid": "27599705", "nct": "NCT02143466", "last_updated": "6/13/19", "feature_display": "EGFR p.T790M (Missense)"}, "192": {"gene": "EGFR", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Durvalumab + Gefitinib", "therapy_strategy": "PD-1/PD-L1 inhibition + EGFR inhibition", "therapy_type": "Combination therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "Durvalumab, a PD-L1 inhibitor, has shown clinical activity when given alongside gefitinib in patients with sensitizing EGFR mutations.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Gibbons D, Chow L, Kim D, et al. 57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naive patients (pts) with EGFR mutant NSCLC Journal of Thoracic Oncology. 2016; 11(4):S79-.", "url": "https://doi.org/10.1016/S1556-0864(16)30171-X", "doi": "10.1016/S1556-0864(16)30171-X", "pmid": NaN, "nct": "NCT02088112", "last_updated": "1/29/19", "feature_display": "EGFR"}, "193": {"gene": "EGFR", "chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "variant_annotation": "Missense", "exon": "20", "rsid": "rs121434569", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Olmutinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "HM61713 showed clinical activity in patients with an EGFR T790M mutation in a Phase I trial.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Park K, Lee J, Han J, et al. 1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose Journal of Thoracic Oncology. 2016; 11(4):S113-.", "url": "https://doi.org/10.1016/S1556-0864(16)30243-X", "doi": "10.1016/S1556-0864(16)30243-X", "pmid": NaN, "nct": "NCT01588145", "last_updated": "6/13/19", "feature_display": "EGFR p.T790M (Missense)"}, "194": {"gene": "EGFR", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Cabozantinib", "therapy_strategy": "RET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "Cabozantinib (a dual MET-VEGF inhibitor) is being evaluated in patents with EGFR mutations.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Ke EE, Wu YL. EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. Trends Pharmacol Sci. 2016;37(11):887-903.", "url": "https://doi.org/10.1016/j.tips.2016.09.003", "doi": "10.1016/j.tips.2016.09.003", "pmid": "27717507", "nct": "NCT01708954", "last_updated": "1/29/19", "feature_display": "EGFR"}, "195": {"gene": "EGFR", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Capmatinib", "therapy_strategy": "MET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "Capmatinib (a cMET inhibitor) is being evaluated in patients with EGFR mutations.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Ke EE, Wu YL. EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. Trends Pharmacol Sci. 2016;37(11):887-903.", "url": "https://doi.org/10.1016/j.tips.2016.09.003", "doi": "10.1016/j.tips.2016.09.003", "pmid": "27717507", "nct": "NCT01610336", "last_updated": "1/29/19", "feature_display": "EGFR"}, "196": {"gene": "EGFR", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "AZD3759", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "AZD3759, a CNS-penetrant EGFR-TKI, is being evaluated in patients with activating EGFR mutations.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Ke EE, Wu YL. EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. Trends Pharmacol Sci. 2016;37(11):887-903.", "url": "https://doi.org/10.1016/j.tips.2016.09.003", "doi": "10.1016/j.tips.2016.09.003", "pmid": "27717507", "nct": "NCT02228369", "last_updated": "1/29/19", "feature_display": "EGFR"}, "197": {"gene": "EGFR", "chromosome": "7", "start_position": "55259515", "end_position": "55259515", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.2573T>G", "protein_change": "p.L858R", "variant_annotation": "Missense", "exon": "21", "rsid": "rs121434568", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Dacomitinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "Dacomitinib is being evaluated in comparison with gefitinib for the treatment of locally advanced or metastatic non-small cell lung cancer.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Ke EE, Wu YL. EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. Trends Pharmacol Sci. 2016;37(11):887-903.", "url": "https://doi.org/10.1016/j.tips.2016.09.003", "doi": "10.1016/j.tips.2016.09.003", "pmid": "27717507", "nct": "NCT01774721", "last_updated": "6/13/19", "feature_display": "EGFR p.L858R (Missense)"}, "198": {"gene": "EGFR", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Icotinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "Mutant EGFR may suggest sensitivity to Icotinib as a first or subsequent line of therapy.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Ke EE, Wu YL. EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. Trends Pharmacol Sci. 2016;37(11):887-903.", "url": "https://doi.org/10.1016/j.tips.2016.09.003", "doi": "10.1016/j.tips.2016.09.003", "pmid": "27717507", "nct": "NCT01719536", "last_updated": "1/29/19", "feature_display": "EGFR"}, "199": {"gene": "EGFR", "chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "variant_annotation": "Missense", "exon": "20", "rsid": "rs121434569", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Osimertinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "Osimertinib is being evaluated in patients who have progressed following treatment with an EGFR TKI.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Ke EE, Wu YL. EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?. Trends Pharmacol Sci. 2016;37(11):887-903.", "url": "https://doi.org/10.1016/j.tips.2016.09.003", "doi": "10.1016/j.tips.2016.09.003", "pmid": "27717507", "nct": "NCT02094261", "last_updated": "6/13/19", "feature_display": "EGFR p.T790M (Missense)"}, "200": {"gene": "EGFR", "chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "variant_annotation": "Missense", "exon": "20", "rsid": "rs121434569", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Rociletinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "Rociletinib was found to be effective in some patients in a 130-patient trial.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;372(18):1700-9.", "url": "https://doi.org/10.1056/NEJMoa1413654", "doi": "10.1056/NEJMoa1413654", "pmid": "25923550", "nct": "NCT01526928", "last_updated": "6/13/19", "feature_display": "EGFR p.T790M (Missense)"}, "201": {"gene": "EGFR", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Gefitinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Amplification and mutation of EGFR was associated with better clinical outcomes in a trial of 66 non-small cell lung cancer patients who had experienced relapse after surgery.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23(28):6829-37.", "url": "https://doi.org/10.1200/JCO.2005.01.0793", "doi": "10.1200/JCO.2005.01.0793", "pmid": "15998907", "nct": NaN, "last_updated": "11/3/17", "feature_display": "EGFR"}, "202": {"gene": "EGFR", "chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "variant_annotation": "Missense", "exon": "20", "rsid": "rs121434569", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Osimertinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Osimertinib is FDA-Approved for metastatic non-small cell lung cancer patients with EGFR T790M mutations.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.", "url": "https://doi.org/10.1186/s13045-016-0268-z", "doi": "10.1186/s13045-016-0268-z", "pmid": "27071706", "nct": NaN, "last_updated": "6/13/19", "feature_display": "EGFR p.T790M (Missense)"}, "203": {"gene": "EGFR", "chromosome": "7", "start_position": "55259515", "end_position": "55259515", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.2573T>G", "protein_change": "p.L858R", "variant_annotation": "Missense", "exon": "21", "rsid": "rs121434568", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "EGF816", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "EGF816 demonstrated clinical activity in a Phase 1 trial of patients with L858R and T790M mutations.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.", "url": "https://doi.org/10.1186/s13045-016-0268-z", "doi": "10.1186/s13045-016-0268-z", "pmid": "27071706", "nct": NaN, "last_updated": "6/13/19", "feature_display": "EGFR p.L858R (Missense)"}, "204": {"gene": "EGFR", "chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "variant_annotation": "Missense", "exon": "20", "rsid": "rs121434569", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "EGF816", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "EGF816 demonstrated clinical activity in a Phase 1 trial of patients with L858R and T790M mutations.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.", "url": "https://doi.org/10.1186/s13045-016-0268-z", "doi": "10.1186/s13045-016-0268-z", "pmid": "27071706", "nct": NaN, "last_updated": "6/13/19", "feature_display": "EGFR p.T790M (Missense)"}, "205": {"gene": "EGFR", "chromosome": "7", "start_position": "55259515", "end_position": "55259515", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.2573T>G", "protein_change": "p.L858R", "variant_annotation": "Missense", "exon": "21", "rsid": "rs121434568", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "PF-06747775", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "PF-06747775, a small molecule inhibitor of EGFR T790M, is being evaluated in advanced NSCLC patients with EGFR mutations (del 19 and L858R with or without T790M).", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.", "url": "https://doi.org/10.1186/s13045-016-0268-z", "doi": "10.1186/s13045-016-0268-z", "pmid": "27071706", "nct": NaN, "last_updated": "6/13/19", "feature_display": "EGFR p.L858R (Missense)"}, "206": {"gene": "EGFR", "chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "variant_annotation": "Missense", "exon": "20", "rsid": "rs121434569", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "PF-06747775", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "PF-06747775, a small molecule inhibitor of EGFR T790M, is being evaluated in advanced NSCLC patients with EGFR mutations (del 19 and L858R with or without T790M).", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:34.", "url": "https://doi.org/10.1186/s13045-016-0268-z", "doi": "10.1186/s13045-016-0268-z", "pmid": "27071706", "nct": NaN, "last_updated": "6/13/19", "feature_display": "EGFR p.T790M (Missense)"}, "207": {"gene": "EGFR", "chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "variant_annotation": "Missense", "exon": "20", "rsid": "rs121434569", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Erlotinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "TKI therapy for patients with T790M has limited benefit.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M, Riely GJ. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing Annals of Oncology. 2014; 25(2):423-428.", "url": "https://doi.org/10.1093/annonc/mdt573", "doi": "10.1093/annonc/mdt573", "pmid": "24478319", "nct": NaN, "last_updated": "6/13/19", "feature_display": "EGFR p.T790M (Missense)"}, "208": {"gene": "EGFR", "chromosome": "7", "start_position": "55249071", "end_position": "55249071", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2369C>T", "protein_change": "p.T790M", "variant_annotation": "Missense", "exon": "20", "rsid": "rs121434569", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Afatinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "TKI therapy for patients with T790M has limited benefit.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Yu HA, Arcila ME, Hellmann MD, Kris MG, Ladanyi M, Riely GJ. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing Annals of Oncology. 2014; 25(2):423-428.", "url": "https://doi.org/10.1093/annonc/mdt573", "doi": "10.1093/annonc/mdt573", "pmid": "24478319", "nct": NaN, "last_updated": "6/13/19", "feature_display": "EGFR p.T790M (Missense)"}, "209": {"gene": "EGFR", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Afatinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "EGFR"}, "210": {"gene": "EGFR", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Afatinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "EGFR (Nonsense)"}, "211": {"gene": "EGFR", "chromosome": "7", "start_position": "55259515", "end_position": "55259515", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.2573T>G", "protein_change": "p.L858R", "variant_annotation": "Missense", "exon": "21", "rsid": "rs121434568", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Afatinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "EGFR p.L858R (Missense)"}, "212": {"gene": "EGFR", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Intracranial metastases", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Gamma knife", "therapy_strategy": "Radiation", "therapy_type": "Radiation therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "In a retrospective study of patients with NSCLC, tumors with EGFR mutations or EML4-ALK locations had improved in-field local control of brain metastases treated with gamma knife.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Johung, Kimberly L. A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non-Small Cell Lung Cancer. Clin Cancer Res. 2013 Oct 1;19(19):5523-32. ", "url": "https://clincancerres.aacrjournals.org/content/19/19/5523.long", "doi": "10.1158/1078-0432.CCR-13-0836", "pmid": "23897899", "nct": NaN, "last_updated": "8/9/19", "feature_display": "EGFR"}, "213": {"gene": "EGFR", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "19", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Advanced", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Osimertinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "In a phase 3 trial, EGFR mutant positive advanced NSCLC (n=556) patients observed significantly longer PFS when treated with osimertinib instead of standard EGFR-TKIs.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Soria J, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated -Mutated Advanced Non-Small-Cell Lung Cancer N Engl J Med. 2018; 378(2):113-125.", "url": "https://doi.org/10.1056/NEJMoa1713137", "doi": "10.1056/NEJMoa1713137", "pmid": "29151359", "nct": NaN, "last_updated": "8/15/19", "feature_display": "EGFR Exon 19 (Nonsense)"}, "214": {"gene": "EGFR", "chromosome": "7", "start_position": "55259515", "end_position": "55259515", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.2573T>G", "protein_change": "p.L858R", "variant_annotation": "Missense", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Advanced", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Osimertinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "In a phase 3 trial, EGFR mutant positive advanced NSCLC (n=556) patients observed significantly longer PFS when treated with osimertinib instead of standard EGFR-TKIs.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Soria J, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated -Mutated Advanced Non-Small-Cell Lung Cancer N Engl J Med. 2018; 378(2):113-125.", "url": "https://doi.org/10.1056/NEJMoa1713137", "doi": "10.1056/NEJMoa1713137", "pmid": "29151359", "nct": NaN, "last_updated": "8/15/19", "feature_display": "EGFR p.L858R (Missense)"}, "215": {"gene": "EGFR", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Deletion", "exon": "19", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Osimertinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for osimertinib for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions, as detected by an FDA-approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf. Revised December 2020. Accessed February 2nd, 2021.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "2/2/21", "feature_display": "EGFR Exon 19 (Deletion)"}, "216": {"gene": "EGFR", "chromosome": "7", "start_position": "55259515", "end_position": "55259515", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.2573T>G", "protein_change": "p.L858R", "variant_annotation": "Missense", "exon": "21", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Osimertinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for osimertinib for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 21 L858R mutations, as detected by an FDA-approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf. Revised December 2020. Accessed February 2nd, 2021.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s021lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "2/2/21", "feature_display": "EGFR p.L858R (Missense)"}, "217": {"gene": "ERBB2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Missense", "exon": "", "rsid": NaN, "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Neratinib", "therapy_strategy": "ER signaling inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Missesnse mutations may predict sensitivity to HER2 inhibitors", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.", "url": "https://doi.org/10.1038/nature25475", "doi": "10.1038/nature25475", "pmid": "29420467", "nct": NaN, "last_updated": "9/10/18", "feature_display": "ERBB2 (Missense)"}, "218": {"gene": "ERBB2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Ado-Trastuzumab Emtansine", "therapy_strategy": "ER signaling inhibition", "therapy_type": "Hormone therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Ado-trasuzumab emtansine is an available targeted agent with activity against ERBB2 variants in metastatic, NSCLC.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/12/19", "feature_display": "ERBB2"}, "219": {"gene": "ERBB3", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Missense", "exon": "", "rsid": NaN, "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Neratinib", "therapy_strategy": "ER signaling inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Missesnse mutations may predict sensitivity to HER2 inhibitors", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.", "url": "https://doi.org/10.1038/nature25475", "doi": "10.1038/nature25475", "pmid": "29420467", "nct": NaN, "last_updated": "9/10/18", "feature_display": "ERBB3 (Missense)"}, "220": {"gene": "ERCC2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Missense", "exon": "", "rsid": NaN, "disease": "Bladder Cancer", "context": "Muscle-Invasive", "oncotree_term": "Bladder Urothelial Carcinoma", "oncotree_code": "BLCA", "therapy_name": "Cisplatin", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.", "url": "https://doi.org/10.1001/jamaoncol.2016.1056", "doi": "10.1001/jamaoncol.2016.1056", "pmid": "27310333", "nct": NaN, "last_updated": "11/3/17", "feature_display": "ERCC2 (Missense)"}, "221": {"gene": "ERCC2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Missense", "exon": "", "rsid": NaN, "disease": "Bladder Cancer", "context": "Muscle-Invasive", "oncotree_term": "Bladder Urothelial Carcinoma", "oncotree_code": "BLCA", "therapy_name": "Cisplatin", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Van Allen, Eliezer M., et al. \"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.\" Cancer discovery 4.10 (2014): 1140-1153.", "url": "https://doi.org/10.1158/2159-8290.CD-14-0623", "doi": "10.1158/2159-8290.CD-14-0623", "pmid": "25096233", "nct": NaN, "last_updated": "11/3/17", "feature_display": "ERCC2 (Missense)"}, "222": {"gene": "ERRFI1", "chromosome": "1", "start_position": "8073509", "end_position": "8073509", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "c.1150G>T", "protein_change": "p.E384*", "variant_annotation": "Nonsense", "exon": "4", "rsid": NaN, "disease": "Cholangiocarcinoma", "context": NaN, "oncotree_term": "Cholangiocarcinoma", "oncotree_code": "CHOL", "therapy_name": "Erlotinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.", "url": "https://doi.org/10.1371/journal.pgen.1004135", "doi": "10.1371/journal.pgen.1004135", "pmid": "24550739", "nct": NaN, "last_updated": "6/13/19", "feature_display": "ERRFI1 p.E384* (Nonsense)"}, "223": {"gene": "ESR1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Letrozole + Tamoxifen", "therapy_strategy": "Aromatase inhibition + ER signaling inhibition", "therapy_type": "Combination therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.", "url": "https://doi.org/10.1038/ng.2823", "doi": "10.1038/ng.2823", "pmid": "24185510", "nct": NaN, "last_updated": "11/3/17", "feature_display": "ESR1"}, "224": {"gene": "ETV6", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "May be familial in rare cases.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "ETV6 (Nonsense)"}, "225": {"gene": "ETV6", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "May be familial in rare cases.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "ETV6 (Frameshift)"}, "226": {"gene": "EZH2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Most frequent in Chronic Myelomonocytic Leukemia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "EZH2 (Nonsense)"}, "227": {"gene": "EZH2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Most frequent in Chronic Myelomonocytic Leukemia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "EZH2 (Frameshift)"}, "228": {"gene": "EZH2", "chromosome": "7", "start_position": "148508726", "end_position": "148508726", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.1938C>A", "protein_change": "p.Y646*", "variant_annotation": "Nonsense", "exon": "16", "rsid": NaN, "disease": "Follicular Lymphoma", "context": "Relapsed or refractory", "oncotree_term": "Follicular Lymphoma", "oncotree_code": "FL", "therapy_name": "Tazemetostat", "therapy_strategy": "EZH2 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/10/20", "feature_display": "EZH2 p.Y646* (Nonsense)"}, "229": {"gene": "EZH2", "chromosome": "7", "start_position": "148508727", "end_position": "148508727", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.1937A>T", "protein_change": "p.Y646F", "variant_annotation": "Missense", "exon": "16", "rsid": NaN, "disease": "Follicular Lymphoma", "context": "Relapsed or refractory", "oncotree_term": "Follicular Lymphoma", "oncotree_code": "FL", "therapy_name": "Tazemetostat", "therapy_strategy": "EZH2 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/10/20", "feature_display": "EZH2 p.Y646F (Missense)"}, "230": {"gene": "EZH2", "chromosome": "7", "start_position": "148508728", "end_position": "148508728", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.1936T>A", "protein_change": "p.Y646N", "variant_annotation": "Missense", "exon": "16", "rsid": NaN, "disease": "Follicular Lymphoma", "context": "Relapsed or refractory", "oncotree_term": "Follicular Lymphoma", "oncotree_code": "FL", "therapy_name": "Tazemetostat", "therapy_strategy": "EZH2 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/10/20", "feature_display": "EZH2 p.Y646N (Missense)"}, "231": {"gene": "EZH2", "chromosome": "7", "start_position": "148506467", "end_position": "148506467", "reference_allele": "G", "alternate_allele": "C", "cdna_change": "c.2045C>G", "protein_change": "p.A682G", "variant_annotation": "Missense", "exon": "18", "rsid": NaN, "disease": "Follicular Lymphoma", "context": "Relapsed or refractory", "oncotree_term": "Follicular Lymphoma", "oncotree_code": "FL", "therapy_name": "Tazemetostat", "therapy_strategy": "EZH2 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/10/20", "feature_display": "EZH2 p.A682G (Missense)"}, "232": {"gene": "EZH2", "chromosome": "7", "start_position": "148506437", "end_position": "148506437", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.2075C>T", "protein_change": "p.A692V", "variant_annotation": "Missense", "exon": "18", "rsid": NaN, "disease": "Follicular Lymphoma", "context": "Relapsed or refractory", "oncotree_term": "Follicular Lymphoma", "oncotree_code": "FL", "therapy_name": "Tazemetostat", "therapy_strategy": "EZH2 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/10/20", "feature_display": "EZH2 p.A692V (Missense)"}, "233": {"gene": "FANCL", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Prostate Cancer", "context": "Metastatic castration resistant prostate cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/22/20", "feature_display": "FANCL"}, "234": {"gene": "FBXW7", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Missense", "exon": "", "rsid": NaN, "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Breast Invasive Ductal Carcinoma", "oncotree_code": "IDC", "therapy_name": "Sirolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.", "url": "https://doi.org/10.1126/science.1162981", "doi": "10.1126/science.1162981", "pmid": "18787170", "nct": NaN, "last_updated": "11/3/17", "feature_display": "FBXW7 (Missense)"}, "235": {"gene": "FGFR3", "chromosome": "4", "start_position": "1803564", "end_position": "1803564", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.742C>T", "protein_change": "p.R248C", "variant_annotation": "Missense", "exon": "6", "rsid": "rs121913482", "disease": "Urothelial carcinoma", "context": "Locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy.", "oncotree_term": "Bladder Urothelial Carcinoma", "oncotree_code": "BLCA", "therapy_name": "Erdafitinib", "therapy_strategy": "FGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "FGFR3 p.R248C (Missense)"}, "236": {"gene": "FGFR3", "chromosome": "4", "start_position": "1803568", "end_position": "1803568", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.746C>G", "protein_change": "p.S249C", "variant_annotation": "Missense", "exon": "6", "rsid": "rs121913483", "disease": "Urothelial carcinoma", "context": "Locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy.", "oncotree_term": "Bladder Urothelial Carcinoma", "oncotree_code": "BLCA", "therapy_name": "Erdafitinib", "therapy_strategy": "FGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "FGFR3 p.S249C (Missense)"}, "237": {"gene": "FGFR3", "chromosome": "4", "start_position": "1806089", "end_position": "1806089", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.1180G>T", "protein_change": "p.G370C", "variant_annotation": "Missense", "exon": "8", "rsid": "rs121913479", "disease": "Urothelial carcinoma", "context": "Locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy.", "oncotree_term": "Bladder Urothelial Carcinoma", "oncotree_code": "BLCA", "therapy_name": "Erdafitinib", "therapy_strategy": "FGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "FGFR3 p.G370C (Missense)"}, "238": {"gene": "FGFR3", "chromosome": "4", "start_position": "1806099", "end_position": "1806099", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.1118A>G", "protein_change": "p.Y373C", "variant_annotation": "Missense", "exon": "8", "rsid": "rs121913485", "disease": "Urothelial carcinoma", "context": "Locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy.", "oncotree_term": "Bladder Urothelial Carcinoma", "oncotree_code": "BLCA", "therapy_name": "Erdafitinib", "therapy_strategy": "FGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "FGFR3 p.Y373C (Missense)"}, "239": {"gene": "FLCN", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Bladder Cancer", "context": "Metastatic", "oncotree_term": "Bladder Urothelial Carcinoma", "oncotree_code": "BLCA", "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.", "url": "https://doi.org/10.1126/science.1226344", "doi": "10.1126/science.1226344", "pmid": "22923433", "nct": NaN, "last_updated": "11/3/17", "feature_display": "FLCN (Nonsense)"}, "240": {"gene": "FLCN", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Bladder Cancer", "context": "Metastatic", "oncotree_term": "Bladder Urothelial Carcinoma", "oncotree_code": "BLCA", "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.", "url": "https://doi.org/10.1126/science.1226344", "doi": "10.1126/science.1226344", "pmid": "22923433", "nct": NaN, "last_updated": "11/3/17", "feature_display": "FLCN (Nonsense)"}, "241": {"gene": "FLCN", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Anaplastic Thyroid Cancer", "context": NaN, "oncotree_term": "Anaplastic Thyroid Cancer", "oncotree_code": "THAP", "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wagle N, Grabiner BC, Van allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371(15):1426-33.", "url": "https://doi.org/10.1056/NEJMoa1403352", "doi": "10.1056/NEJMoa1403352", "pmid": "25295501", "nct": NaN, "last_updated": "11/3/17", "feature_display": "FLCN (Nonsense)"}, "242": {"gene": "FLCN", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Anaplastic Thyroid Cancer", "context": NaN, "oncotree_term": "Anaplastic Thyroid Cancer", "oncotree_code": "THAP", "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wagle N, Grabiner BC, Van allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371(15):1426-33.", "url": "https://doi.org/10.1056/NEJMoa1403352", "doi": "10.1056/NEJMoa1403352", "pmid": "25295501", "nct": NaN, "last_updated": "11/3/17", "feature_display": "FLCN (Frameshift)"}, "243": {"gene": "FLCN", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Bladder Cancer", "context": "Metastatic", "oncotree_term": "Bladder Urothelial Carcinoma", "oncotree_code": "BLCA", "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wagle N, Grabiner BC, Van allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371(15):1426-33.", "url": "https://doi.org/10.1056/NEJMoa1403352", "doi": "10.1056/NEJMoa1403352", "pmid": "25295501", "nct": NaN, "last_updated": "11/3/17", "feature_display": "FLCN (Frameshift)"}, "244": {"gene": "FLCN", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Bladder Cancer", "context": "Metastatic", "oncotree_term": "Bladder Urothelial Carcinoma", "oncotree_code": "BLCA", "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wagle N, Grabiner BC, Van allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371(15):1426-33.", "url": "https://doi.org/10.1056/NEJMoa1403352", "doi": "10.1056/NEJMoa1403352", "pmid": "25295501", "nct": NaN, "last_updated": "11/3/17", "feature_display": "FLCN (Frameshift)"}, "245": {"gene": "FLT3", "chromosome": "13", "start_position": "28601361", "end_position": "28601361", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.2071T>C", "protein_change": "p.F691L", "variant_annotation": "Missense", "exon": "17", "rsid": "rs759272576", "disease": "Acute Myeloid Leukemia", "context": NaN, "oncotree_term": "Acute Myeloid Leukemia", "oncotree_code": "AML", "therapy_name": "Quizartinib", "therapy_strategy": "targets FLT3", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.", "url": "https://doi.org/10.1038/leu.2013.14", "doi": "10.1038/leu.2013.14", "pmid": "23392356", "nct": NaN, "last_updated": "6/13/19", "feature_display": "FLT3 p.F691L (Missense)"}, "246": {"gene": "FLT3", "chromosome": "13", "start_position": "28602381", "end_position": "28602381", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1987A>C", "protein_change": "p.K663Q", "variant_annotation": "Missense", "exon": "16", "rsid": "rs1057520026", "disease": "Acute Myeloid Leukemia", "context": NaN, "oncotree_term": "Acute Myeloid Leukemia", "oncotree_code": "AML", "therapy_name": "Sunitinib", "therapy_strategy": "targets FLT3", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.", "url": "https://doi.org/10.1038/sj.leu.2404374", "doi": "10.1038/sj.leu.2404374", "pmid": "16990784", "nct": NaN, "last_updated": "6/13/19", "feature_display": "FLT3 p.K663Q (Missense)"}, "247": {"gene": "GATA3", "chromosome": "10", "start_position": "8106058", "end_position": "8106058", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.881T>A", "protein_change": "p.M294K", "variant_annotation": "Missense", "exon": "4", "rsid": NaN, "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Letrozole", "therapy_strategy": "Aromatase inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.", "url": "https://doi.org/10.1038/nature11143", "doi": "10.1038/nature11143", "pmid": "22722193", "nct": NaN, "last_updated": "6/13/19", "feature_display": "GATA3 p.M294K (Missense)"}, "248": {"gene": "IDH1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Acute Myeloid Leukemia", "context": "Relapsed or refractory", "oncotree_term": "Acute Myeloid Leukemia", "oncotree_code": "AML", "therapy_name": "Ivosidenib", "therapy_strategy": "IDH1 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT02074839", "last_updated": "11/12/20", "feature_display": "IDH1"}, "249": {"gene": "IDH1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Glioma", "context": NaN, "oncotree_term": "Glioma", "oncotree_code": "GNOS", "therapy_name": "Alkylating chemotherapy", "therapy_strategy": "Alkylating chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "IDH1"}, "250": {"gene": "IDH1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Glioma", "context": NaN, "oncotree_term": "Glioma", "oncotree_code": "GNOS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": "Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "IDH1"}, "251": {"gene": "IDH2", "chromosome": "15", "start_position": "90631934", "end_position": "90631934", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.419G>A", "protein_change": "p.R140Q", "variant_annotation": "Missense", "exon": "4", "rsid": "rs121913502", "disease": "Acute Myeloid Leukemia", "context": "Relapsed or refractory", "oncotree_term": "Acute Myeloid Leukemia", "oncotree_code": "AML", "therapy_name": "Enasidenib", "therapy_strategy": "IDH2 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT01915498", "last_updated": "11/12/20", "feature_display": "IDH2 p.R140Q (Missense)"}, "252": {"gene": "IDH2", "chromosome": "15", "start_position": "90631837", "end_position": "90631837", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "c.516G>T", "protein_change": "p.R172S", "variant_annotation": "Missense", "exon": "4", "rsid": NaN, "disease": "Acute Myeloid Leukemia", "context": "Relapsed or refractory", "oncotree_term": "Acute Myeloid Leukemia", "oncotree_code": "AML", "therapy_name": "Enasidenib", "therapy_strategy": "IDH2 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT01915498", "last_updated": "11/12/20", "feature_display": "IDH2 p.R172S (Missense)"}, "253": {"gene": "IDH2", "chromosome": "15", "start_position": "90631837", "end_position": "90631837", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.515G>A", "protein_change": "p.R172K", "variant_annotation": "Missense", "exon": "4", "rsid": NaN, "disease": "Acute Myeloid Leukemia", "context": "Relapsed or refractory", "oncotree_term": "Acute Myeloid Leukemia", "oncotree_code": "AML", "therapy_name": "Enasidenib", "therapy_strategy": "IDH2 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT01915498", "last_updated": "11/12/20", "feature_display": "IDH2 p.R172K (Missense)"}, "254": {"gene": "IDH2", "chromosome": "15", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Glioma", "context": NaN, "oncotree_term": "Glioma", "oncotree_code": "GNOS", "therapy_name": "Alkylating chemotherapy", "therapy_strategy": "Alkylating chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Mutation of IDH2 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "IDH2"}, "255": {"gene": "IDH2", "chromosome": "15", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Glioma", "context": NaN, "oncotree_term": "Glioma", "oncotree_code": "GNOS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": "Mutation of IDH2 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "IDH2"}, "256": {"gene": "IDH2", "chromosome": "15", "start_position": "90631934", "end_position": "90631934", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.419G>A", "protein_change": "p.R140Q", "variant_annotation": "Missense", "exon": "4", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "More frequent in Acute Myeloid Leukemia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "IDH2 p.R140Q (Missense)"}, "257": {"gene": "IDH2", "chromosome": "15", "start_position": "90631837", "end_position": "90631837", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "c.516G>T", "protein_change": "p.R172S", "variant_annotation": "Missense", "exon": "4", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "More frequent in Acute Myeloid Leukemia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "IDH2 p.R172S (Missense)"}, "258": {"gene": "IDH2", "chromosome": "15", "start_position": "90631837", "end_position": "90631837", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.515G>A", "protein_change": "p.R172K", "variant_annotation": "Missense", "exon": "4", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "More frequent in Acute Myeloid Leukemia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "IDH2 p.R172K (Missense)"}, "259": {"gene": "JAK1", "chromosome": "1", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "B-Cell Acute Lymphoblastic Leukemia", "context": NaN, "oncotree_term": "B-Cell Acute Lymphoid Leukemia", "oncotree_code": "BALL", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.", "url": "https://doi.org/10.1186/s13045-017-0431-1", "doi": "10.1186/s13045-017-0431-1", "pmid": "28245838", "nct": NaN, "last_updated": "4/30/19", "feature_display": "JAK1"}, "260": {"gene": "JAK1", "chromosome": "1", "start_position": "65312353", "end_position": "65312353", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "c.1966G>T", "protein_change": "p.V656F", "variant_annotation": "Missense", "exon": "14", "rsid": NaN, "disease": "Acute Lymphoblastic Leukemia", "context": NaN, "oncotree_term": "Acute Lymphoid Leukemia", "oncotree_code": "ALL", "therapy_name": "PU-H71", "therapy_strategy": "HSP90 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.", "url": "https://doi.org/10.1182/blood-2015-03-635821", "doi": "10.1182/blood-2015-03-635821", "pmid": "26443624", "nct": NaN, "last_updated": "6/13/19", "feature_display": "JAK1 p.V656F (Missense)"}, "261": {"gene": "JAK1", "chromosome": "1", "start_position": "65312418", "end_position": "65312418", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.1901C>A", "protein_change": "p.A634D", "variant_annotation": "Missense", "exon": "14", "rsid": "rs869312953", "disease": "Acute Lymphoblastic Leukemia", "context": NaN, "oncotree_term": "Acute Lymphoid Leukemia", "oncotree_code": "ALL", "therapy_name": "PU-H71", "therapy_strategy": "HSP90 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "MOHITO JAK1 A634D transplated mice were highly sensitive to growth inhibition by PU-H71.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.", "url": "https://doi.org/10.1182/blood-2015-03-635821", "doi": "10.1182/blood-2015-03-635821", "pmid": "26443624", "nct": NaN, "last_updated": "6/13/19", "feature_display": "JAK1 p.A634D (Missense)"}, "262": {"gene": "JAK2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "B-Cell Acute Lymphoblastic Leukemia", "context": NaN, "oncotree_term": "B-Cell Acute Lymphoid Leukemia", "oncotree_code": "BALL", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.", "url": "https://doi.org/10.1186/s13045-017-0431-1", "doi": "10.1186/s13045-017-0431-1", "pmid": "28245838", "nct": NaN, "last_updated": "4/30/19", "feature_display": "JAK2"}, "263": {"gene": "JAK2", "chromosome": "9", "start_position": "5073770", "end_position": "5073770", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.1849G>T", "protein_change": "p.V617F", "variant_annotation": "Missense", "exon": "14", "rsid": NaN, "disease": "Myeloproliferative Disorders", "context": NaN, "oncotree_term": "Myeloproliferative Neoplasm", "oncotree_code": "MPN", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.", "url": "https://doi.org/10.1056/NEJMoa051113", "doi": "10.1056/NEJMoa051113", "pmid": "15858187", "nct": NaN, "last_updated": "6/13/19", "feature_display": "JAK2 p.V617F (Missense)"}, "264": {"gene": "JAK3", "chromosome": "19", "start_position": "17948010", "end_position": "17948010", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.1714G>A", "protein_change": "p.A572T", "variant_annotation": "Missense", "exon": "13", "rsid": NaN, "disease": "T-Cell Acute Lymphoblastic Leukemia", "context": NaN, "oncotree_term": "T-Cell Acute Lymphoid Leukemia", "oncotree_code": "TALL", "therapy_name": "Ruxolitinib", "therapy_strategy": "JAK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.", "url": "https://doi.org/10.1182/blood-2014-04-566687", "doi": "10.1182/blood-2014-04-566687", "pmid": "25193870", "nct": NaN, "last_updated": "6/13/19", "feature_display": "JAK3 p.A572T (Missense)"}, "265": {"gene": "JAK3", "chromosome": "19", "start_position": "17949108", "end_position": "17949108", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.1533G>A", "protein_change": "p.M511I", "variant_annotation": "Missense", "exon": "11", "rsid": NaN, "disease": "T-Cell Acute Lymphoblastic Leukemia", "context": NaN, "oncotree_term": "T-Cell Acute Lymphoid Leukemia", "oncotree_code": "TALL", "therapy_name": "Ruxolitinib", "therapy_strategy": "JAK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.", "url": "https://doi.org/10.1182/blood-2014-04-566687", "doi": "10.1182/blood-2014-04-566687", "pmid": "25193870", "nct": NaN, "last_updated": "6/13/19", "feature_display": "JAK3 p.M511I (Missense)"}, "266": {"gene": "JAK3", "chromosome": "19", "start_position": "17943438", "end_position": "17943438", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.2570T>A", "protein_change": "p.L857Q", "variant_annotation": "Missense", "exon": "19", "rsid": NaN, "disease": "T-Cell Acute Lymphoblastic Leukemia", "context": NaN, "oncotree_term": "T-Cell Acute Lymphoid Leukemia", "oncotree_code": "TALL", "therapy_name": "Ruxolitinib", "therapy_strategy": "JAK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.", "url": "https://doi.org/10.1182/blood-2014-04-566687", "doi": "10.1182/blood-2014-04-566687", "pmid": "25193870", "nct": NaN, "last_updated": "6/13/19", "feature_display": "JAK3 p.L857Q (Missense)"}, "267": {"gene": "JAK3", "chromosome": "19", "start_position": "17948010", "end_position": "17948010", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.1714G>A", "protein_change": "p.A572T", "variant_annotation": "Missense", "exon": "13", "rsid": NaN, "disease": "T-Cell Acute Lymphoblastic Leukemia", "context": NaN, "oncotree_term": "T-Cell Acute Lymphoid Leukemia", "oncotree_code": "TALL", "therapy_name": "Tofacitinib", "therapy_strategy": "JAK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Ba/F3 cell lines with mutant JAK3 were sensitive to Tofacitinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.", "url": "https://doi.org/10.1182/blood-2014-04-566687", "doi": "10.1182/blood-2014-04-566687", "pmid": "25193870", "nct": NaN, "last_updated": "6/13/19", "feature_display": "JAK3 p.A572T (Missense)"}, "268": {"gene": "JAK3", "chromosome": "19", "start_position": "17949108", "end_position": "17949108", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.1533G>A", "protein_change": "p.M511I", "variant_annotation": "Missense", "exon": "11", "rsid": NaN, "disease": "T-Cell Acute Lymphoblastic Leukemia", "context": NaN, "oncotree_term": "T-Cell Acute Lymphoid Leukemia", "oncotree_code": "TALL", "therapy_name": "Tofacitinib", "therapy_strategy": "JAK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Ba/F3 cell lines with mutant JAK3 were sensitive to Tofacitinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.", "url": "https://doi.org/10.1182/blood-2014-04-566687", "doi": "10.1182/blood-2014-04-566687", "pmid": "25193870", "nct": NaN, "last_updated": "6/13/19", "feature_display": "JAK3 p.M511I (Missense)"}, "269": {"gene": "JAK3", "chromosome": "19", "start_position": "17943438", "end_position": "17943438", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.2570T>A", "protein_change": "p.L857Q", "variant_annotation": "Missense", "exon": "19", "rsid": NaN, "disease": "T-Cell Acute Lymphoblastic Leukemia", "context": NaN, "oncotree_term": "T-Cell Acute Lymphoid Leukemia", "oncotree_code": "TALL", "therapy_name": "Tofacitinib", "therapy_strategy": "JAK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Ba/F3 cell lines with mutant JAK3 were sensitive to Tofacitinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.", "url": "https://doi.org/10.1182/blood-2014-04-566687", "doi": "10.1182/blood-2014-04-566687", "pmid": "25193870", "nct": NaN, "last_updated": "6/13/19", "feature_display": "JAK3 p.L857Q (Missense)"}, "270": {"gene": "KIT", "chromosome": "4", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Gastrointestinal Stromal Tumor", "context": "Unresctable and/or metastatic", "oncotree_term": "Gastrointestinal Stromal Tumor", "oncotree_code": "GIST", "therapy_name": "Imatinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for imatinib for patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "KIT"}, "271": {"gene": "KIT", "chromosome": "4", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Oncogenic Mutations", "exon": "", "rsid": NaN, "disease": "Gastrointestinal Stromal Tumor", "context": NaN, "oncotree_term": "Gastrointestinal Stromal Tumor", "oncotree_code": "GIST", "therapy_name": "Imatinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "FDA-approved for (1) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) and (2) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "KIT (Oncogenic Mutations)"}, "272": {"gene": "KIT", "chromosome": "4", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Gastrointestinal Stromal Tumor", "context": "Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.", "oncotree_term": "Gastrointestinal Stromal Tumor", "oncotree_code": "GIST", "therapy_name": "Regorafenib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "KIT"}, "273": {"gene": "KIT", "chromosome": "4", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Oncogenic Mutations", "exon": "", "rsid": NaN, "disease": "Gastrointestinal Stromal Tumor", "context": "Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.", "oncotree_term": "Gastrointestinal Stromal Tumor", "oncotree_code": "GIST", "therapy_name": "Regorafenib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "KIT (Oncogenic Mutations)"}, "274": {"gene": "KIT", "chromosome": "4", "start_position": "55595519", "end_position": "55595519", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2009C>T", "protein_change": "p.T670I", "variant_annotation": "Missense", "exon": "14", "rsid": "rs121913516", "disease": "Gastrointestinal Stromal Tumor", "context": "Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.", "oncotree_term": "Gastrointestinal Stromal Tumor", "oncotree_code": "GIST", "therapy_name": "Regorafenib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "KIT p.T670I (Missense)"}, "275": {"gene": "KIT", "chromosome": "4", "start_position": "55594258", "end_position": "55594258", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.1961T>C", "protein_change": "p.V654A", "variant_annotation": "Missense", "exon": "13", "rsid": "rs121913523", "disease": "Gastrointestinal Stromal Tumor", "context": "Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.", "oncotree_term": "Gastrointestinal Stromal Tumor", "oncotree_code": "GIST", "therapy_name": "Regorafenib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "KIT p.V654A (Missense)"}, "276": {"gene": "KIT", "chromosome": "4", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Oncogenic Mutations", "exon": "", "rsid": NaN, "disease": "Gastrointestinal Stromal Tumor", "context": NaN, "oncotree_term": "Gastrointestinal Stromal Tumor", "oncotree_code": "GIST", "therapy_name": "Sunitinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to Sunitinib for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance of imatinib mesylate.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Pfizer, Inc. Sutent (sunitinib malate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf. Revised August 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "KIT (Oncogenic Mutations)"}, "277": {"gene": "KIT", "chromosome": "4", "start_position": "55595519", "end_position": "55595519", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2009C>T", "protein_change": "p.T670I", "variant_annotation": "Missense", "exon": "14", "rsid": "rs121913516", "disease": "Gastrointestinal Stromal Tumor", "context": NaN, "oncotree_term": "Gastrointestinal Stromal Tumor", "oncotree_code": "GIST", "therapy_name": "Sunitinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to Sunitinib for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance of imatinib mesylate.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Pfizer, Inc. Sutent (sunitinib malate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf. Revised August 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "KIT p.T670I (Missense)"}, "278": {"gene": "KIT", "chromosome": "4", "start_position": "55594258", "end_position": "55594258", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.1961T>C", "protein_change": "p.V654A", "variant_annotation": "Missense", "exon": "13", "rsid": "rs121913523", "disease": "Gastrointestinal Stromal Tumor", "context": NaN, "oncotree_term": "Gastrointestinal Stromal Tumor", "oncotree_code": "GIST", "therapy_name": "Sunitinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to Sunitinib for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance of imatinib mesylate.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Pfizer, Inc. Sutent (sunitinib malate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf. Revised August 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021938s037lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "KIT p.V654A (Missense)"}, "279": {"gene": "KIT", "chromosome": "4", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Head and Neck Squamous Cell Carcinoma", "context": "Mucosal Melanoma", "oncotree_term": "Head and Neck Squamous Cell Carcinoma", "oncotree_code": "HNSC", "therapy_name": "Imatinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf", "doi": NaN, "pmid": "20571149", "nct": NaN, "last_updated": "11/3/17", "feature_display": "KIT"}, "280": {"gene": "KIT", "chromosome": "4", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Head and Neck Squamous Cell Carcinoma", "context": "Mucosal Melanoma", "oncotree_term": "Head and Neck Squamous Cell Carcinoma", "oncotree_code": "HNSC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf", "doi": NaN, "pmid": "20571149", "nct": NaN, "last_updated": "11/3/17", "feature_display": "KIT"}, "281": {"gene": "KIT", "chromosome": "4", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "11", "rsid": NaN, "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Imatinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/12/19", "feature_display": "KIT Exon 11"}, "282": {"gene": "KIT", "chromosome": "4", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "13", "rsid": NaN, "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Imatinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/12/19", "feature_display": "KIT Exon 13"}, "283": {"gene": "KIT", "chromosome": "4", "start_position": "55593605", "end_position": "55593605", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.1671G>T", "protein_change": "p.W557C", "variant_annotation": "Missense", "exon": "11", "rsid": NaN, "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Imatinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/12/19", "feature_display": "KIT p.W557C (Missense)"}, "284": {"gene": "KIT", "chromosome": "4", "start_position": "55593603", "end_position": "55593603", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1669T>G", "protein_change": "p.W557G", "variant_annotation": "Missense", "exon": "11", "rsid": NaN, "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Imatinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/12/19", "feature_display": "KIT p.W557G (Missense)"}, "285": {"gene": "KIT", "chromosome": "4", "start_position": "55593603", "end_position": "55593603", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.1669T>C", "protein_change": "p.W557R", "variant_annotation": "Missense", "exon": "11", "rsid": NaN, "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Imatinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/12/19", "feature_display": "KIT p.W557R (Missense)"}, "286": {"gene": "KIT", "chromosome": "4", "start_position": "55593610", "end_position": "55593610", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.1676T>C", "protein_change": "p.V559A", "variant_annotation": "Missense", "exon": "11", "rsid": "rs121913517", "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Imatinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/12/19", "feature_display": "KIT p.V559A (Missense)"}, "287": {"gene": "KIT", "chromosome": "4", "start_position": "55593610", "end_position": "55593610", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1676T>G", "protein_change": "p.V559G", "variant_annotation": "Missense", "exon": "11", "rsid": "rs121913517", "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Imatinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/12/19", "feature_display": "KIT p.V559G (Missense)"}, "288": {"gene": "KIT", "chromosome": "4", "start_position": "55593661", "end_position": "55593661", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.1727T>C", "protein_change": "p.L576P", "variant_annotation": "Missense", "exon": "11", "rsid": "rs121913513", "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Imatinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/12/19", "feature_display": "KIT p.L576P (Missense)"}, "289": {"gene": "KIT", "chromosome": "4", "start_position": "55594221", "end_position": "55594221", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.1924A>G", "protein_change": "p.K642E", "variant_annotation": "Missense", "exon": "13", "rsid": NaN, "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Imatinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "KIT exon 11 and 13 variants (W557, V559, L576P, and K642E) appear to have high level of sensitivity to KIT inhibition.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/12/19", "feature_display": "KIT p.K642E (Missense)"}, "290": {"gene": "KIT", "chromosome": "4", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "17", "rsid": NaN, "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Imatinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "0", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "KIT exon 17 variants (D816H) appear to have minimal or no sensitivity to KIT inhibitors.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/12/19", "feature_display": "KIT Exon 17"}, "291": {"gene": "KIT", "chromosome": "4", "start_position": "55599320", "end_position": "55599320", "reference_allele": "G", "alternate_allele": "C", "cdna_change": "c.2446G>C", "protein_change": "p.D816H", "variant_annotation": "Missense", "exon": "17", "rsid": "rs121913506", "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Imatinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "0", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "KIT exon 17 variants (D816H) appear to have minimal or no sensitivity to KIT inhibitors.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/12/19", "feature_display": "KIT p.D816H (Missense)"}, "292": {"gene": "KIT", "chromosome": "4", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Imatinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Activating KIT mutations are associated with an increased sensitvity to imatinib.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Melanoma NCCN Evidence Blocks (Version 3.2016). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf", "url": "https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "KIT"}, "293": {"gene": "KIT", "chromosome": "4", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "11", "rsid": NaN, "disease": "Gastrointestinal Stromal Tumor", "context": NaN, "oncotree_term": "Gastrointestinal Stromal Tumor", "oncotree_code": "GIST", "therapy_name": "Imatinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Approximately 90% of patients have diseases that respond to imatinib when their tumors have a KIT exon 11 mutation.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/10/19", "feature_display": "KIT Exon 11"}, "294": {"gene": "KIT", "chromosome": "4", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "9", "rsid": NaN, "disease": "Gastrointestinal Stromal Tumor", "context": NaN, "oncotree_term": "Gastrointestinal Stromal Tumor", "oncotree_code": "GIST", "therapy_name": "Imatinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Approximately 50% of patients have diseases that respond to imatinib when their tumors have a KIT exon 9 mutation, and the likelihood of response improves with use of 800 mg dosage rather than the standard 400 mg.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/10/19", "feature_display": "KIT Exon 9"}, "295": {"gene": "KIT", "chromosome": "4", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Thymic carcinomas", "context": NaN, "oncotree_term": "Thymic Carcinoma", "oncotree_code": "THYC", "therapy_name": "Sunitinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Sunitinib is recommended for patients with c-KIT mutations.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Thymomas and Thymic Carcinomas NCCN Evidence Blocks (Version 1.2021). https://www.nccn.org/professionals/physician_gls/pdf/thymic_blocks.pdf. Accessed November 19th, 2020.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/thymic_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/16/20", "feature_display": "KIT"}, "296": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Palbociclib + Trametinib", "therapy_strategy": "CDK4/6 inhibition + MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "The combination of palbociclib and trametinib has shown antitumor and radiosensitizing activity in preclinical models of non-small cell lung cancer, and is currently in a phase III clinical trial for non-small cell lung cancer.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Tao Z, Le blanc JM, Wang C, et al. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo. Clin Cancer Res. 2016;22(1):122-33.", "url": "https://doi.org/10.1158/1078-0432.CCR-15-0589", "doi": "10.1158/1078-0432.CCR-15-0589", "pmid": "26728409", "nct": "NCT02154490", "last_updated": "9/14/18", "feature_display": "KRAS"}, "297": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": NaN, "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Buparlisib + Trametinib", "therapy_strategy": "PI3K/AKT/mTOR inhibition + MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "A phase 1b trial including 21 ovarian cancer patients demonstrated increased survival and an average PFS of 7 months when treated with a combination of buparlisib and trametinib (RP2D of buparlisib 60mg and trametinib 1.5mg daily).", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Bedard PL, Tabernero J, Janku F, et al. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res. 2015;21(4):730-8.", "url": "https://doi.org/10.1158/1078-0432.CCR-14-1814", "doi": "10.1158/1078-0432.CCR-14-1814", "pmid": "25500057", "nct": "NCT01155453", "last_updated": "1/29/19", "feature_display": "KRAS"}, "298": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "2", "rsid": NaN, "disease": "Colorectal Cancer", "context": "Primary or Metastatic", "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Cetuximab", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Patients with primary or metastatic colorectal cancer and known KRAS mutations (exon 2, 3, and 4) should not be treated with either cetuximab or panitumumab. NCCN Guidelines colorectal cancer COL-B 4 of 5. ", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "KRAS Exon 2"}, "299": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "2", "rsid": NaN, "disease": "Colorectal Cancer", "context": "Primary or Metastatic", "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Panitumumab", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Patients with primary or metastatic colorectal cancer and known KRAS mutations (exon 2, 3, and 4) should not be treated with either cetuximab or panitumumab. NCCN Guidelines colorectal cancer COL-B 4 of 5. ", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "KRAS Exon 2"}, "300": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "3", "rsid": NaN, "disease": "Colorectal Cancer", "context": "Primary or Metastatic", "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Cetuximab", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Patients with primary or metastatic colorectal cancer and known KRAS mutations (exon 2, 3, and 4) should not be treated with either cetuximab or panitumumab. NCCN Guidelines colorectal cancer COL-B 4 of 5. ", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "KRAS Exon 3"}, "301": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "3", "rsid": NaN, "disease": "Colorectal Cancer", "context": "Primary or Metastatic", "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Panitumumab", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Patients with primary or metastatic colorectal cancer and known KRAS mutations (exon 2, 3, and 4) should not be treated with either cetuximab or panitumumab. NCCN Guidelines colorectal cancer COL-B 4 of 5. ", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "KRAS Exon 3"}, "302": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "4", "rsid": NaN, "disease": "Colorectal Cancer", "context": "Primary or Metastatic", "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Cetuximab", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Patients with primary or metastatic colorectal cancer and known KRAS mutations (exon 2, 3, and 4) should not be treated with either cetuximab or panitumumab. NCCN Guidelines colorectal cancer COL-B 4 of 5. ", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "KRAS Exon 4"}, "303": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "4", "rsid": NaN, "disease": "Colorectal Cancer", "context": "Primary or Metastatic", "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Panitumumab", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Patients with primary or metastatic colorectal cancer and known KRAS mutations (exon 2, 3, and 4) should not be treated with either cetuximab or panitumumab. NCCN Guidelines colorectal cancer COL-B 4 of 5. ", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "KRAS Exon 4"}, "304": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "KRAS variants have been associated with decreased overall survival.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed June 13, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "KRAS"}, "305": {"gene": "KRAS", "chromosome": "12", "start_position": "25398285", "end_position": "25398285", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "c.35G>T", "protein_change": "p.G12C", "variant_annotation": "Missense", "exon": "2", "rsid": "rs121913530", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "AMG 510", "therapy_strategy": "targets KRAS G12C", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.", "preferred_assertion": NaN, "source_type": "Abstract", "citation": "J Clin Oncol 37, 2019 (suppl; abstr 3003)", "url": "https://abstracts.asco.org/239/AbstView_239_268371.html", "doi": NaN, "pmid": NaN, "nct": "NCT03600883", "last_updated": "8/14/19", "feature_display": "KRAS p.G12C (Missense)"}, "306": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Gefitinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "KRAS mutations are associated with intrinsic resistance to EGFR TKIs.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "KRAS"}, "307": {"gene": "KRAS", "chromosome": "12", "start_position": "25398284", "end_position": "25398284", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.35G>A", "protein_change": "p.G12D", "variant_annotation": "Missense", "exon": "2", "rsid": "rs121913529", "disease": "Pancreatic Cancer", "context": NaN, "oncotree_term": "Pancreatic Adenocarcinoma", "oncotree_code": "PAAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.", "url": "https://doi.org/10.1038/ctg.2016.18", "doi": "10.1038/ctg.2016.18", "pmid": "27010960", "nct": NaN, "last_updated": "6/13/19", "feature_display": "KRAS p.G12D (Missense)"}, "308": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "p.G12", "variant_annotation": "Missense", "exon": "2", "rsid": NaN, "disease": "Liver Metastases", "context": "Liver metastases from solid tumors", "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Proton-based SBRT", "therapy_strategy": "Radiation", "therapy_type": "Radiation therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).", "url": "https://doi.org/10.1093/jnci/djx031", "doi": "10.1093/jnci/djx031", "pmid": "28954285", "nct": NaN, "last_updated": "4/13/19", "feature_display": "KRAS p.G12 (Missense)"}, "309": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "p.G13", "variant_annotation": "Missense", "exon": "2", "rsid": NaN, "disease": "Liver Metastases", "context": "Liver metastases from solid tumors", "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Proton-based SBRT", "therapy_strategy": "Radiation", "therapy_type": "Radiation therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).", "url": "https://doi.org/10.1093/jnci/djx031", "doi": "10.1093/jnci/djx031", "pmid": "28954285", "nct": NaN, "last_updated": "4/13/19", "feature_display": "KRAS p.G13 (Missense)"}, "310": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "p.Q61", "variant_annotation": "Missense", "exon": "3", "rsid": NaN, "disease": "Liver Metastases", "context": "Liver metastases from solid tumors", "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Proton-based SBRT", "therapy_strategy": "Radiation", "therapy_type": "Radiation therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).", "url": "https://doi.org/10.1093/jnci/djx031", "doi": "10.1093/jnci/djx031", "pmid": "28954285", "nct": NaN, "last_updated": "4/13/19", "feature_display": "KRAS p.Q61 (Missense)"}, "311": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "FGFR1 inhibitor + Trametinib", "therapy_strategy": "FGFR1 inhibition + MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "The combination of trametinib (a MEK inhibitor) with inhibition of FGFR1 is shown to enhance lung cancer and pancreatic cancer tumor cell death in vitro and in vivo.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Manchado E, Weissmueller S, Morris JP, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016;534(7609):647-651.", "url": "https://doi.org/10.1038/nature18600", "doi": "10.1038/nature18600", "pmid": "27338794", "nct": NaN, "last_updated": "11/3/17", "feature_display": "KRAS"}, "312": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Pancreatic Cancer", "context": NaN, "oncotree_term": "Pancreatic Adenocarcinoma", "oncotree_code": "PAAD", "therapy_name": "FGFR1 inhibitor + Trametinib ", "therapy_strategy": "FGFR1 inhibition + MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "The combination of trametinib (a MEK inhibitor) with inhibition of FGFR1 is shown to enhance lung cancer and pancreatic cancer tumor cell death in vitro and in vivo.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Manchado E, Weissmueller S, Morris JP, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016;534(7609):647-651.", "url": "https://doi.org/10.1038/nature18600", "doi": "10.1038/nature18600", "pmid": "27338794", "nct": NaN, "last_updated": "11/3/17", "feature_display": "KRAS"}, "313": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "In a cohort of 34 non-small cell lung cancer patients treated with pembrolizumab, the presence of a KRAS mutation was associated with an increased chance of DCB.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-8.", "url": "https://doi.org/10.1126/science.aaa1348", "doi": "10.1126/science.aaa1348", "pmid": "25765070", "nct": NaN, "last_updated": "11/3/17", "feature_display": "KRAS"}, "314": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Pancreatic Cancer", "context": NaN, "oncotree_term": "Pancreatic Adenocarcinoma", "oncotree_code": "PAAD", "therapy_name": "Vemurafenib", "therapy_strategy": "B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "KRAS mutations were associated with resistance to the BRAF inhibitor PLX-4032 in a study of 109 microdissected pancreatic ductal adenocarcinoma patients.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.", "url": "https://doi.org/10.1038/ncomms7744", "doi": "10.1038/ncomms7744", "pmid": "25855536", "nct": NaN, "last_updated": "11/3/17", "feature_display": "KRAS"}, "315": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Lung Cancer", "context": NaN, "oncotree_term": "Leukemia", "oncotree_code": "LEUK", "therapy_name": "Momelotinib", "therapy_strategy": "JAK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Preclinical study suggests that TBK1/IKKepsilon promote tumor survival by activating CCL5 and IL-6 and identify concurrent inhibition of TBK1/IKKepsilon, Janus-activated kinase (JAK), and MEK signaling as an effective approach to inhibit the actions of oncogenic KRAS", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Zhu Z, Aref AR, Cohoon TJ, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 2014;4(4):452-65.", "url": "https://doi.org/10.1158/2159-8290.CD-13-0646", "doi": "10.1158/2159-8290.CD-13-0646", "pmid": "24444711", "nct": NaN, "last_updated": "11/3/17", "feature_display": "KRAS"}, "316": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Lung Cancer", "context": NaN, "oncotree_term": "Leukemia", "oncotree_code": "LEUK", "therapy_name": "Ruxolitinib", "therapy_strategy": "JAK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Preclinical study suggests that TBK1/IKKepsilon promote tumor survival by activating CCL5 and IL-6 and identify concurrent inhibition of TBK1/IKKepsilon, Janus-activated kinase (JAK), and MEK signaling as an effective approach to inhibit the actions of oncogenic KRAS", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Zhu Z, Aref AR, Cohoon TJ, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 2014;4(4):452-65.", "url": "https://doi.org/10.1158/2159-8290.CD-13-0646", "doi": "10.1158/2159-8290.CD-13-0646", "pmid": "24444711", "nct": NaN, "last_updated": "11/3/17", "feature_display": "KRAS"}, "317": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Rectal Adenocarcinoma", "context": NaN, "oncotree_term": "Rectal Adenocarcinoma", "oncotree_code": "READ", "therapy_name": "Neoadjuvant chemoradiation", "therapy_strategy": "Chemotherapy + Radiation", "therapy_type": "Combination therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;", "url": "https://doi.org/10.1158/1078-0432.CCR-19-0908", "doi": "10.1158/1078-0432.CCR-19-0908", "pmid": "31253631", "nct": NaN, "last_updated": "8/8/19", "feature_display": "KRAS"}, "318": {"gene": "KRAS", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Early stage", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "SBRT", "therapy_strategy": "Radiation", "therapy_type": "Radiation therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "In a retrosepctive series of early-stage NSCLC patients treated with SBRT, KRAS mutation was associated with decreased FFR and CSS. ", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Mak RH, Hermann G, Lewis JH, et al. Outcomes by Tumor Histology and KRAS Mutation Status After Lung Stereotactic Body Radiation Therapy for Early-Stage Non-Small-Cell Lung Cancer Clinical Lung Cancer. 2015; 16(1):24-32.", "url": "https://doi.org/10.1016/j.cllc.2014.09.005", "doi": "10.1016/j.cllc.2014.09.005", "pmid": "25450872", "nct": NaN, "last_updated": "8/8/19", "feature_display": "KRAS"}, "319": {"gene": "MAP2K1", "chromosome": "15", "start_position": "66729163", "end_position": "66729163", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.371C>T", "protein_change": "p.P124L", "variant_annotation": "Missense", "exon": "3", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Vemurafenib", "therapy_strategy": "B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Presence of this variant in vitro suggests resistance to PLX4720, a precursor to Vemurafenib, in metastatic melanoma.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.", "url": "https://doi.org/10.1073/pnas.0905833106", "doi": "10.1073/pnas.0905833106", "pmid": "19915144", "nct": NaN, "last_updated": "6/13/19", "feature_display": "MAP2K1 p.P124L (Missense)"}, "320": {"gene": "MAP2K1", "chromosome": "15", "start_position": "66727451", "end_position": "66727451", "reference_allele": "A", "alternate_allele": "C", "cdna_change": "c.167A>C", "protein_change": "p.Q56P", "variant_annotation": "Missense", "exon": "2", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Vemurafenib", "therapy_strategy": "B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Presence of this variant in vitro suggests resistance to PLX4720, a precursor to Vemurafenib, in metastatic melanoma.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.", "url": "https://doi.org/10.1073/pnas.0905833106", "doi": "10.1073/pnas.0905833106", "pmid": "19915144", "nct": NaN, "last_updated": "6/13/19", "feature_display": "MAP2K1 p.Q56P (Missense)"}, "321": {"gene": "MAP2K1", "chromosome": "15", "start_position": "66729163", "end_position": "66729163", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.371C>T", "protein_change": "p.P124L", "variant_annotation": "Missense", "exon": "3", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Presence of this variant may suggest resistance to Selumetinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.", "url": "https://doi.org/10.1073/pnas.0905833106", "doi": "10.1073/pnas.0905833106", "pmid": "19915144", "nct": NaN, "last_updated": "6/13/19", "feature_display": "MAP2K1 p.P124L (Missense)"}, "322": {"gene": "MAP2K1", "chromosome": "15", "start_position": "66727451", "end_position": "66727451", "reference_allele": "A", "alternate_allele": "C", "cdna_change": "c.167A>C", "protein_change": "p.Q56P", "variant_annotation": "Missense", "exon": "2", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.", "url": "https://doi.org/10.1158/0008-5472.CAN-08-0099", "doi": "10.1158/0008-5472.CAN-08-0099", "pmid": "18632602", "nct": NaN, "last_updated": "6/13/19", "feature_display": "MAP2K1 p.Q56P (Missense)"}, "323": {"gene": "MAP2K1", "chromosome": "15", "start_position": "66727451", "end_position": "66727451", "reference_allele": "A", "alternate_allele": "C", "cdna_change": "c.167A>C", "protein_change": "p.Q56P", "variant_annotation": "Missense", "exon": "2", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Vemurafenib", "therapy_strategy": "B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "MEK1 Q56P confers resistance to monotherapy with RAF or MEK inhibitors in vitro.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Trunzer, Kerstin, et al. \"Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.\" Journal of Clinical Oncology 31.14 (2013): 1767-1774.", "url": "https://doi.org/10.1200/JCO.2012.44.7888", "doi": "10.1200/JCO.2012.44.7888", "pmid": "23569304", "nct": NaN, "last_updated": "6/13/19", "feature_display": "MAP2K1 p.Q56P (Missense)"}, "324": {"gene": "MAP2K1", "chromosome": "15", "start_position": "66727451", "end_position": "66727451", "reference_allele": "A", "alternate_allele": "C", "cdna_change": "c.167A>C", "protein_change": "p.Q56P", "variant_annotation": "Missense", "exon": "2", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "MEK1 Q56P confers resistance to monotherapy with RAF or MEK inhibitors in vitro.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Trunzer, Kerstin, et al. \"Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.\" Journal of Clinical Oncology 31.14 (2013): 1767-1774.", "url": "https://doi.org/10.1200/JCO.2012.44.7888", "doi": "10.1200/JCO.2012.44.7888", "pmid": "23569304", "nct": NaN, "last_updated": "6/13/19", "feature_display": "MAP2K1 p.Q56P (Missense)"}, "325": {"gene": "MAP2K1", "chromosome": "15", "start_position": "66729153", "end_position": "66729153", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.361T>A", "protein_change": "p.C121S", "variant_annotation": "Missense", "exon": "3", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Vemurafenib", "therapy_strategy": "B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "MEK1 C121S confers resistance to monotherapy with RAF or MEK inhibitors in vitro.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-96.", "url": "https://doi.org/10.1200/JCO.2010.33.2312", "doi": "10.1200/JCO.2010.33.2312", "pmid": "21383288", "nct": NaN, "last_updated": "6/13/19", "feature_display": "MAP2K1 p.C121S (Missense)"}, "326": {"gene": "MAP2K1", "chromosome": "15", "start_position": "66729153", "end_position": "66729153", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.361T>A", "protein_change": "p.C121S", "variant_annotation": "Missense", "exon": "3", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "MEK1 C121S confers resistance to monotherapy with RAF or MEK inhibitors in vitro.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-96.", "url": "https://doi.org/10.1200/JCO.2010.33.2312", "doi": "10.1200/JCO.2010.33.2312", "pmid": "21383288", "nct": NaN, "last_updated": "6/13/19", "feature_display": "MAP2K1 p.C121S (Missense)"}, "327": {"gene": "MAP2K2", "chromosome": "19", "start_position": "4117541", "end_position": "4117541", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.179A>C", "protein_change": "p.Q60P", "variant_annotation": "Missense", "exon": "2", "rsid": "rs1057519808", "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Trametinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wagle, Nikhil, et al. \"MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.\" Cancer discovery 4.1 (2014): 61-68.", "url": "https://doi.org/10.1158/2159-8290.CD-13-0631", "doi": "10.1158/2159-8290.CD-13-0631", "pmid": "24265154", "nct": NaN, "last_updated": "6/13/19", "feature_display": "MAP2K2 p.Q60P (Missense)"}, "328": {"gene": "MAPK1", "chromosome": "22", "start_position": "22127164", "end_position": "22127164", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.964G>A", "protein_change": "p.E322K", "variant_annotation": "Missense", "exon": "7", "rsid": NaN, "disease": "Head and Neck Squamous Cell Carcinoma", "context": NaN, "oncotree_term": "Head and Neck Squamous Cell Carcinoma", "oncotree_code": "HNSC", "therapy_name": "Erlotinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.", "url": "https://doi.org/10.1001/jamaoncol.2015.34", "doi": "10.1001/jamaoncol.2015.34", "pmid": "26181029", "nct": NaN, "last_updated": "6/13/19", "feature_display": "MAPK1 p.E322K (Missense)"}, "329": {"gene": "MC1R", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "The presence of MC1R polymorphisms in a cohort of 53 metastatic melanoma patients treated with BRAF inhibitors was associated with a poorer prognosis (ORR: 59% vs. 95%; PFS shorter than 6 months: 72% vs. 33%).", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Guida M, Strippoli S, Ferretta A, et al. Detrimental effects of Melanocortin-1 receptor (MC1R) polymorphisms on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. Pigment Cell Melanoma Res. 2016;", "url": "https://doi.org/10.1111/pcmr.12516", "doi": "10.1111/pcmr.12516", "pmid": "27540956", "nct": NaN, "last_updated": "11/3/17", "feature_display": "MC1R"}, "330": {"gene": "MET", "chromosome": "7", "start_position": "116411990", "end_position": "116411990", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.3029C>T", "protein_change": "p.T1010I", "variant_annotation": "Missense", "exon": "14", "rsid": "rs56391007", "disease": "Head and Neck Squamous Cell Carcinoma", "context": "Metastatic", "oncotree_term": "Head and Neck Squamous Cell Carcinoma", "oncotree_code": "HNSC", "therapy_name": "SU11274", "therapy_strategy": "MET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Presence of this variant may suggest sensitivity to SU11274.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.", "url": "https://doi.org/10.1158/0008-5472.CAN-08-2881", "doi": "10.1158/0008-5472.CAN-08-2881", "pmid": "19318576", "nct": NaN, "last_updated": "6/13/19", "feature_display": "MET p.T1010I (Missense)"}, "331": {"gene": "MET", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Splice Site", "exon": "14", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Crizotinib", "therapy_strategy": "MET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Crizotinib is an available targeted agent with activity against MET exon 14 skipping variants in metastatic, NSCLC.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/12/19", "feature_display": "MET Exon 14 (Splice Site)"}, "332": {"gene": "MET", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Deletion", "exon": "14", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Crizotinib", "therapy_strategy": "MET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Crizotinib is an available targeted agent with activity against MET exon 14 skipping variants in metastatic, NSCLC.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/12/19", "feature_display": "MET Exon 14 (Deletion)"}, "333": {"gene": "MET", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "14", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Crizotinib", "therapy_strategy": "MET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Crizotinib is an available targeted agent with activity against MET exon 14 skipping variants in metastatic, NSCLC.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "MET Exon 14 (Nonsense)"}, "334": {"gene": "MET", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Splice Site", "exon": "14", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Capmatinib", "therapy_strategy": "MET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf. Revised May 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "MET Exon 14 (Splice Site)"}, "335": {"gene": "MET", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Deletion", "exon": "14", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Capmatinib", "therapy_strategy": "MET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf. Revised May 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "MET Exon 14 (Deletion)"}, "336": {"gene": "MET", "chromosome": "7", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "14", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Capmatinib", "therapy_strategy": "MET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf. Revised May 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "MET Exon 14 (Nonsense)"}, "337": {"gene": "MLH3", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.", "url": "https://doi.org/10.1056/NEJMoa1500596", "doi": "10.1056/NEJMoa1500596", "pmid": "26028255", "nct": "NCT01876511", "last_updated": "2/4/19", "feature_display": "MLH3"}, "338": {"gene": "MPL", "chromosome": "1", "start_position": "43815009", "end_position": "43815009", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.1544G>T", "protein_change": "p.W515L", "variant_annotation": "Missense", "exon": "10", "rsid": "rs121913615", "disease": "Myeloproliferative Disorders", "context": "Metastatic", "oncotree_term": "Myeloproliferative Neoplasm", "oncotree_code": "MPN", "therapy_name": "EXEL-8232", "therapy_strategy": "JAK2 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.", "url": "https://doi.org/10.1038/leu.2011.261", "doi": "10.1038/leu.2011.261", "pmid": "22005786", "nct": NaN, "last_updated": "6/13/19", "feature_display": "MPL p.W515L (Missense)"}, "339": {"gene": "MSH2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.", "url": "https://doi.org/10.1056/NEJMoa1500596", "doi": "10.1056/NEJMoa1500596", "pmid": "26028255", "nct": "NCT01876511", "last_updated": "2/4/19", "feature_display": "MSH2"}, "340": {"gene": "MSH6", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.", "url": "https://doi.org/10.1056/NEJMoa1500596", "doi": "10.1056/NEJMoa1500596", "pmid": "26028255", "nct": "NCT01876511", "last_updated": "2/4/19", "feature_display": "MSH6"}, "341": {"gene": "MTOR", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Renal clear cell carcinoma", "context": "Advanced", "oncotree_term": "Renal Clear Cell Carcinoma", "oncotree_code": "RCC", "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "0", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "In a study of 184 everolimus-treated patients with RCC from a phase 2 randomized trial,  PFS neither differed on univariate analysis nor on multivariate testing based on variant status in TSC1, TSC2, or MTOR.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Voss MH, Chen D, Reising A, et al. PTEN Expression, Not Mutation Status in, or, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial. Clin Cancer Res. 2019;25(2):506-514.", "url": "https://doi.org/10.1158/1078-0432.CCR-18-1833", "doi": "10.1158/1078-0432.CCR-18-1833", "pmid": "30327302", "nct": "NCT00903175 ", "last_updated": "8/12/19", "feature_display": "MTOR"}, "342": {"gene": "MYH", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Colorectal Cancer", "context": "Metastatic", "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.", "url": "https://doi.org/10.1056/NEJMoa1500596", "doi": "10.1056/NEJMoa1500596", "pmid": "26028255", "nct": "NCT01876511", "last_updated": "2/4/19", "feature_display": "MYH"}, "343": {"gene": "NFE2L2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Activating mutation", "exon": "", "rsid": NaN, "disease": "Squamous Cell Lung Cancer", "context": NaN, "oncotree_term": "Lung Squamous Cell Carcinoma", "oncotree_code": "LUSC", "therapy_name": "Radiation therapy", "therapy_strategy": "Radiation", "therapy_type": "Radiation therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.", "url": "https://doi.org/10.1158/0008-5472.can-13-1616", "doi": "10.1158/0008-5472.can-13-1616", "pmid": "23980093", "nct": NaN, "last_updated": "3/25/19", "feature_display": "NFE2L2 (Activating mutation)"}, "344": {"gene": "NRAS", "chromosome": "1", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Colorectal Cancer", "context": "Metastatic", "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Cetuximab", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "0", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Patients with primary or metastatic colorectal cancer and known NRAS mutations (exon 2, 3, and 4) should not be treated with either cetuximab or panitumumab. NCCN Guidelines colorectal cancer COL-B 4 of 5. ", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS"}, "345": {"gene": "NRAS", "chromosome": "1", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Colorectal Cancer", "context": "Metastatic", "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Panitumumab", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "0", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Patients with primary or metastatic colorectal cancer and known NRAS mutations (exon 2, 3, and 4) should not be treated with either cetuximab or panitumumab. NCCN Guidelines colorectal cancer COL-B 4 of 5. ", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS"}, "346": {"gene": "NRAS", "chromosome": "1", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Missense", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS (Missense)"}, "347": {"gene": "NRAS", "chromosome": "1", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Missense", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS (Missense)"}, "348": {"gene": "NRAS", "chromosome": "1", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Missense", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS (Missense)"}, "349": {"gene": "NRAS", "chromosome": "1", "start_position": "115258747", "end_position": "115258747", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.35G>C", "protein_change": "p.G12A", "variant_annotation": "Missense", "exon": "2", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": "18390968", "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS p.G12A (Missense)"}, "350": {"gene": "NRAS", "chromosome": "1", "start_position": "115258748", "end_position": "115258748", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "c.34G>T", "protein_change": "p.G12C", "variant_annotation": "Missense", "exon": "2", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": "18390968", "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS p.G12C (Missense)"}, "351": {"gene": "NRAS", "chromosome": "1", "start_position": "115258747", "end_position": "115258747", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.35G>A", "protein_change": "p.G12D", "variant_annotation": "Missense", "exon": "2", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": "18390968", "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS p.G12D (Missense)"}, "352": {"gene": "NRAS", "chromosome": "1", "start_position": "115258748", "end_position": "115258748", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "p.34G>C", "protein_change": "p.G12R", "variant_annotation": "Missense", "exon": "2", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": "18390968", "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS p.G12R (Missense)"}, "353": {"gene": "NRAS", "chromosome": "1", "start_position": "115258748", "end_position": "115258748", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "p.34G>A", "protein_change": "p.G12S", "variant_annotation": "Missense", "exon": "2", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": "18390968", "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS p.G12S (Missense)"}, "354": {"gene": "NRAS", "chromosome": "1", "start_position": "115258747", "end_position": "115258747", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "p.35G>T", "protein_change": "p.G12V", "variant_annotation": "Missense", "exon": "2", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": "18390968", "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS p.G12V (Missense)"}, "355": {"gene": "NRAS", "chromosome": "1", "start_position": "115258744", "end_position": "115258744", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.38G>C", "protein_change": "p.G13A", "variant_annotation": "Missense", "exon": "2", "rsid": "rs121434596", "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": "18390968", "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS p.G13A (Missense)"}, "356": {"gene": "NRAS", "chromosome": "1", "start_position": "115258744", "end_position": "115258744", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.38G>A", "protein_change": "p.G13D", "variant_annotation": "Missense", "exon": "2", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": "18390968", "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS p.G13D (Missense)"}, "357": {"gene": "NRAS", "chromosome": "1", "start_position": "115258745", "end_position": "115258745", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.37G>C", "protein_change": "p.G13R", "variant_annotation": "Missense", "exon": "2", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": "18390968", "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS p.G13R (Missense)"}, "358": {"gene": "NRAS", "chromosome": "1", "start_position": "115258744", "end_position": "115258744", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "c.38G>T", "protein_change": "p.G13V", "variant_annotation": "Missense", "exon": "2", "rsid": "rs121434596", "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": "18390968", "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS p.G13V (Missense)"}, "359": {"gene": "NRAS", "chromosome": "1", "start_position": "115256530", "end_position": "115256530", "reference_allele": "G", "alternate_allele": "C", "cdna_change": "c.181C>G", "protein_change": "p.Q61E", "variant_annotation": "Missense", "exon": "3", "rsid": "rs121913254", "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": "18390968", "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS p.Q61E (Missense)"}, "360": {"gene": "NRAS", "chromosome": "1", "start_position": "115256528", "end_position": "115256528", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.183A>T", "protein_change": "p.Q61H", "variant_annotation": "Missense", "exon": "3", "rsid": "rs121913255", "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": "18390968", "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS p.Q61H (Missense)"}, "361": {"gene": "NRAS", "chromosome": "1", "start_position": "115256529", "end_position": "115256529", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.182A>T", "protein_change": "p.Q61L", "variant_annotation": "Missense", "exon": "3", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": "18390968", "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS p.Q61L (Missense)"}, "362": {"gene": "NRAS", "chromosome": "1", "start_position": "115256529", "end_position": "115256529", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.182A>T", "protein_change": "p.Q61L", "variant_annotation": "Missense", "exon": "3", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": "18390968", "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS p.Q61L (Missense)"}, "363": {"gene": "NRAS", "chromosome": "1", "start_position": "115256529", "end_position": "115256529", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.182A>C", "protein_change": "p.Q61P", "variant_annotation": "Missense", "exon": "3", "rsid": "rs11554290", "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": "18390968", "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS p.Q61P (Missense)"}, "364": {"gene": "NRAS", "chromosome": "1", "start_position": "115256529", "end_position": "115256529", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.182A>G", "protein_change": "p.Q61R", "variant_annotation": "Missense", "exon": "3", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Presence of this variant may suggest sensitivity to Selumetinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.", "url": "https://doi.org/10.1200/JCO.2007.14.4956", "doi": "10.1200/JCO.2007.14.4956", "pmid": "18390968", "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS p.Q61R (Missense)"}, "365": {"gene": "NRAS", "chromosome": "1", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "A retrospective study of 677 metastatic melanoma patients found that patients with BRAF and NRAS mutations had a higher risk of CNS involvement at diagnosis of stage IV disease (24% of BRAF and 23% of NRAS compared to 12% WT). Non-uveal melanoma patients tested for mutations within a median 6 months of diagnosis (n=313) showed an association between BRAF and NRAS mutation and a shorter survival (median 8.2 months vs. 15.1 months).", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Jakob JA, Bassett RL, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer. 2012;118(16):4014-23.", "url": "https://doi.org/10.1002/cncr.26724", "doi": "10.1002/cncr.26724", "pmid": "22180178", "nct": NaN, "last_updated": "6/13/19", "feature_display": "NRAS"}, "366": {"gene": "PALB2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "PALB2"}, "367": {"gene": "PALB2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "PALB2"}, "368": {"gene": "PALB2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "PALB2"}, "369": {"gene": "PALB2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "PALB2"}, "370": {"gene": "PALB2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "PALB2"}, "371": {"gene": "PALB2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "PALB2"}, "372": {"gene": "PALB2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Pancreatic Cancer", "context": NaN, "oncotree_term": "Pancreatic Adenocarcinoma", "oncotree_code": "PAAD", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "When present alongside genomic instability, defined by a large number of structural variation events, the inactivation of DNA maintenance genes (BRCA1, BRCA2, PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients. ", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495-501.", "url": "https://doi.org/10.1038/nature14169", "doi": "10.1038/nature14169", "pmid": "25719666", "nct": NaN, "last_updated": "3/7/19", "feature_display": "PALB2"}, "373": {"gene": "PALB2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Prostate Cancer", "context": "Metastatic castration resistant prostate cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/22/20", "feature_display": "PALB2"}, "374": {"gene": "PBRM1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Renal clear cell carcinoma", "context": "Metastatic", "oncotree_term": "Renal Clear Cell Carcinoma", "oncotree_code": "CCRCC", "therapy_name": "Nivolumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.", "url": "https://doi.org/10.1126/science.aan5951", "doi": "10.1126/science.aan5951", "pmid": "29301960", "nct": NaN, "last_updated": "9/11/18", "feature_display": "PBRM1 (Nonsense)"}, "375": {"gene": "PDGFRA", "chromosome": "4", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Gastrointestinal Stromal Tumor", "context": NaN, "oncotree_term": "Gastrointestinal Stromal Tumor", "oncotree_code": "GIST", "therapy_name": "Imatinib", "therapy_strategy": "PDGF-R inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/10/19", "feature_display": "PDGFRA"}, "376": {"gene": "PDGFRA", "chromosome": "4", "start_position": "55152093", "end_position": "55152093", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.2525A>T", "protein_change": "p.D842V", "variant_annotation": "Missense", "exon": "18", "rsid": "rs121908585", "disease": "Gastrointestinal Stromal Tumor", "context": NaN, "oncotree_term": "Gastrointestinal Stromal Tumor", "oncotree_code": "GIST", "therapy_name": "Imatinib", "therapy_strategy": "PDGF-R inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/10/19", "feature_display": "PDGFRA p.D842V (Missense)"}, "377": {"gene": "PBRM1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Renal clear cell carcinoma", "context": "Metastatic", "oncotree_term": "Renal Clear Cell Carcinoma", "oncotree_code": "CCRCC", "therapy_name": "Nivolumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.", "url": "https://doi.org/10.1126/science.aan5951", "doi": "10.1126/science.aan5951", "pmid": "29301960", "nct": NaN, "last_updated": "9/11/18", "feature_display": "PBRM1 (Frameshift)"}, "378": {"gene": "PIK3CA", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Breast Cancer", "context": "Advanced or metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Alpelisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Alpelisib is a kinase inhibitor indictated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+, HER2-negative, PIK3CA mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endrocrine-based regime. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Piqray (alpelisib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf. Revised September 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "PIK3CA"}, "379": {"gene": "PIK3CA", "chromosome": "3", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Breast Invasive Ductal Carcinoma", "oncotree_code": "IDC", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "PIK3CA, but not AKT1 mutation, increased sensitivity to the PI3K inhibitor GDC-0941 and the allosteric AKT inhibitor MK-2206", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Beaver JA, Gustin JP, Yi KH, et al. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. Clin Cancer Res. 2013;19(19):5413-22.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-0884", "doi": "10.1158/1078-0432.CCR-13-0884", "pmid": "23888070", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA"}, "380": {"gene": "PIK3CA", "chromosome": "3", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Prostate Cancer", "context": NaN, "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical trial", "description": "Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.", "url": "https://doi.org/10.1200/JCO.2017.75.7310", "doi": "10.1200/JCO.2017.75.7310", "pmid": "29261439", "nct": "NCT01576172", "last_updated": "6/13/19", "feature_display": "PIK3CA"}, "381": {"gene": "PIK3CA", "chromosome": "3", "start_position": "178936091", "end_position": "178936091", "reference_allele": "G", "alternate_allele": "C", "cdna_change": "c.1633G>C", "protein_change": "p.E545Q", "variant_annotation": "Missense", "exon": "10", "rsid": "rs104886003", "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA p.E545Q (Missense)"}, "382": {"gene": "PIK3CA", "chromosome": "3", "start_position": "178927980", "end_position": "178927980", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.1258T>C", "protein_change": "p.C420R", "variant_annotation": "Missense", "exon": "8", "rsid": "rs121913272", "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA p.C420R (Missense)"}, "383": {"gene": "PIK3CA", "chromosome": "3", "start_position": "178936082", "end_position": "178936082", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.1624G>A", "protein_change": "p.E542K", "variant_annotation": "Missense", "exon": "10", "rsid": "rs121913273", "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA p.E542K (Missense)"}, "384": {"gene": "PIK3CA", "chromosome": "3", "start_position": "178936082", "end_position": "178936082", "reference_allele": "G", "alternate_allele": "C", "cdna_change": "c.1624G>C", "protein_change": "p.E542Q", "variant_annotation": "Missense", "exon": "10", "rsid": "rs121913273", "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA p.E542Q (Missense)"}, "385": {"gene": "PIK3CA", "chromosome": "3", "start_position": "178936092", "end_position": "178936092", "reference_allele": "A", "alternate_allele": "C", "cdna_change": "c.1634A>C", "protein_change": "p.E545A", "variant_annotation": "Missense", "exon": "10", "rsid": "rs121913274", "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA p.E545A (Missense)"}, "386": {"gene": "PIK3CA", "chromosome": "3", "start_position": "178936093", "end_position": "178936093", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.1635G>T", "protein_change": "p.E545D", "variant_annotation": "Missense", "exon": "10", "rsid": "rs121913275", "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA p.E545D (Missense)"}, "387": {"gene": "PIK3CA", "chromosome": "3", "start_position": "178936093", "end_position": "178936093", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.1635G>T", "protein_change": "p.E545D", "variant_annotation": "Missense", "exon": "10", "rsid": "rs121913275", "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA p.E545D (Missense)"}, "388": {"gene": "PIK3CA", "chromosome": "3", "start_position": "178936092", "end_position": "178936092", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.1634A>G", "protein_change": "p.E545G", "variant_annotation": "Missense", "exon": "10", "rsid": "rs121913274", "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA p.E545G (Missense)"}, "389": {"gene": "PIK3CA", "chromosome": "3", "start_position": "178936091", "end_position": "178936091", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.1633G>A", "protein_change": "p.E545K", "variant_annotation": "Missense", "exon": "10", "rsid": "rs104886003", "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA p.E545K (Missense)"}, "390": {"gene": "PIK3CA", "chromosome": "3", "start_position": "178952090", "end_position": "178952090", "reference_allele": "G", "alternate_allele": "C", "cdna_change": "c.3145G>C", "protein_change": "p.G1049R", "variant_annotation": "Missense", "exon": "21", "rsid": "rs121913277", "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA p.G1049R (Missense)"}, "391": {"gene": "PIK3CA", "chromosome": "3", "start_position": "178952090", "end_position": "178952090", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.3145G>A", "protein_change": "p.G1049S", "variant_annotation": "Missense", "exon": "21", "rsid": "rs121913277", "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA p.G1049S (Missense)"}, "392": {"gene": "PIK3CA", "chromosome": "3", "start_position": "178952085", "end_position": "178952085", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.3140A>T", "protein_change": "p.H1047L", "variant_annotation": "Missense", "exon": "21", "rsid": "rs121913279", "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA p.H1047L (Missense)"}, "393": {"gene": "PIK3CA", "chromosome": "3", "start_position": "178952085", "end_position": "178952085", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.3140A>G", "protein_change": "p.H1047R", "variant_annotation": "Missense", "exon": "21", "rsid": "rs121913279", "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA p.H1047R (Missense)"}, "394": {"gene": "PIK3CA", "chromosome": "3", "start_position": "178952084", "end_position": "178952084", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.3139C>T", "protein_change": "p.H1047Y", "variant_annotation": "Missense", "exon": "21", "rsid": "rs121913281", "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA p.H1047Y (Missense)"}, "395": {"gene": "PIK3CA", "chromosome": "3", "start_position": "178938860", "end_position": "178938860", "reference_allele": "A", "alternate_allele": "C", "cdna_change": "c.2102A>C", "protein_change": "p.H701P", "variant_annotation": "Missense", "exon": "14", "rsid": "rs121913282", "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA p.H701P (Missense)"}, "396": {"gene": "PIK3CA", "chromosome": "3", "start_position": "178952074", "end_position": "178952074", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.3129G>A", "protein_change": "p.M1043I", "variant_annotation": "Missense", "exon": "21", "rsid": "rs121913283", "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA p.M1043I (Missense)"}, "397": {"gene": "PIK3CA", "chromosome": "3", "start_position": "178952074", "end_position": "178952074", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.3129G>A", "protein_change": "p.M1043I", "variant_annotation": "Missense", "exon": "21", "rsid": "rs121913283", "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA p.M1043I (Missense)"}, "398": {"gene": "PIK3CA", "chromosome": "3", "start_position": "178936074", "end_position": "178936074", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.1616C>G", "protein_change": "p.P539R", "variant_annotation": "Missense", "exon": "10", "rsid": "rs121913285", "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA p.P539R (Missense)"}, "399": {"gene": "PIK3CA", "chromosome": "3", "start_position": "178936094", "end_position": "178936094", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "c.1636C>A", "protein_change": "p.Q546K", "variant_annotation": "Missense", "exon": "10", "rsid": "rs121913286", "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA p.Q546K (Missense)"}, "400": {"gene": "PIK3CA", "chromosome": "3", "start_position": "178952007", "end_position": "178952007", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.3062A>G", "protein_change": "p.Y1021C", "variant_annotation": "Missense", "exon": "21", "rsid": "rs121913288", "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.", "url": "https://doi.org/10.1158/1078-0432.CCR-09-2828", "doi": "10.1158/1078-0432.CCR-09-2828", "pmid": "20453058", "nct": NaN, "last_updated": "6/13/19", "feature_display": "PIK3CA p.Y1021C (Missense)"}, "401": {"gene": "PIK3CB", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": NaN, "context": "Metastatic", "oncotree_term": NaN, "oncotree_code": NaN, "therapy_name": "AZD8186", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "PIK3CB mutations may confer sensitivity to selective PI3K inhibition", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.", "url": "https://doi.org/10.1021/jm501629p", "doi": "10.1021/jm501629p", "pmid": "25514658", "nct": NaN, "last_updated": "3/16/17", "feature_display": "PIK3CB"}, "402": {"gene": "POLD1", "chromosome": "19", "start_position": "50905974", "end_position": "50905974", "reference_allele": "G", "alternate_allele": "C", "cdna_change": "c.946G>C", "protein_change": "p.D316H", "variant_annotation": "Missense", "exon": "8", "rsid": "rs746087148", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.", "url": "https://doi.org/10.1038/gim.2015.75", "doi": "10.1038/gim.2015.75", "pmid": "4823640", "nct": NaN, "last_updated": "6/13/19", "feature_display": "POLD1 p.D316H (Missense)"}, "403": {"gene": "POLD1", "chromosome": "19", "start_position": "50905975", "end_position": "50905975", "reference_allele": "A", "alternate_allele": "G", "cdna_change": "c.947A>G", "protein_change": "p.D316G", "variant_annotation": "Missense", "exon": "8", "rsid": "rs746087148", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.", "url": "https://doi.org/10.1038/gim.2015.75", "doi": "10.1038/gim.2015.75", "pmid": "4823640", "nct": NaN, "last_updated": "6/13/19", "feature_display": "POLD1 p.D316G (Missense)"}, "404": {"gene": "POLD1", "chromosome": "19", "start_position": "50906837", "end_position": "50906837", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.1225C>T", "protein_change": "p.R409W", "variant_annotation": "Missense", "exon": "10", "rsid": "rs778135510", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.", "url": "https://doi.org/10.1038/gim.2015.75", "doi": "10.1038/gim.2015.75", "pmid": "4823640", "nct": NaN, "last_updated": "6/13/19", "feature_display": "POLD1 p.R409W (Missense)"}, "405": {"gene": "POLD1", "chromosome": "19", "start_position": "50909701", "end_position": "50909701", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.1421T>C", "protein_change": "p.L474P", "variant_annotation": "Missense", "exon": "12", "rsid": "rs587777627", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.", "url": "https://doi.org/10.1038/gim.2015.75", "doi": "10.1038/gim.2015.75", "pmid": "4823640", "nct": NaN, "last_updated": "6/13/19", "feature_display": "POLD1 p.L474P (Missense)"}, "406": {"gene": "POLD1", "chromosome": "19", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Colorectal Cancer", "context": "Metastatic", "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.", "url": "https://doi.org/10.1056/NEJMoa1500596", "doi": "10.1056/NEJMoa1500596", "pmid": "26028255", "nct": "NCT01876511.", "last_updated": "2/4/19", "feature_display": "POLD1"}, "407": {"gene": "POLD1", "chromosome": "19", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": NaN, "context": NaN, "oncotree_term": NaN, "oncotree_code": NaN, "therapy_name": "Durvalumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Mutant tumors with somatic point mutations in POLE or POLD1 are being included along with MMR-deficient tumors in several ongoing ICB trials.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. DNA Damage and Repair Biomarkers of Immunotherapy Response Cancer Discov. 2017; 7(7):675-693.", "url": "https://doi.org/10.1158/2159-8290.CD-17-0226", "doi": "10.1158/2159-8290.CD-17-0226", "pmid": "28630051", "nct": NaN, "last_updated": "9/19/18", "feature_display": "POLD1"}, "408": {"gene": "POLD1", "chromosome": "19", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": NaN, "context": NaN, "oncotree_term": NaN, "oncotree_code": NaN, "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Mutant tumors with somatic point mutations in POLE or POLD1 are being included along with MMR-deficient tumors in several ongoing ICB trials.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. DNA Damage and Repair Biomarkers of Immunotherapy Response Cancer Discov. 2017; 7(7):675-693.", "url": "https://doi.org/10.1158/2159-8290.CD-17-0226", "doi": "10.1158/2159-8290.CD-17-0226", "pmid": "28630051", "nct": NaN, "last_updated": "9/19/18", "feature_display": "POLD1"}, "409": {"gene": "POLE", "chromosome": "12", "start_position": "133250250", "end_position": "133250250", "reference_allele": "G", "alternate_allele": "C", "cdna_change": "c.1270C>G", "protein_change": "p.L424V", "variant_annotation": "Missense", "exon": "13", "rsid": "rs483352909", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.", "url": "https://doi.org/10.1038/gim.2015.75", "doi": "10.1038/gim.2015.75", "pmid": "4823640", "nct": NaN, "last_updated": "6/13/19", "feature_display": "POLE p.L424V (Missense)"}, "410": {"gene": "POLE", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Colorectal Cancer", "context": "Metastatic", "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.", "url": "https://doi.org/10.1056/NEJMoa1500596", "doi": "10.1056/NEJMoa1500596", "pmid": "26028255", "nct": "NCT01876511.", "last_updated": "2/4/19", "feature_display": "POLE"}, "411": {"gene": "POLE", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": NaN, "context": NaN, "oncotree_term": NaN, "oncotree_code": NaN, "therapy_name": "Durvalumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Mutant tumors with somatic point mutations in POLE or POLD1 are being included along with MMR-deficient tumors in several ongoing ICB trials.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. DNA Damage and Repair Biomarkers of Immunotherapy Response Cancer Discov. 2017; 7(7):675-693.", "url": "https://doi.org/10.1158/2159-8290.CD-17-0226", "doi": "10.1158/2159-8290.CD-17-0226", "pmid": "28630051", "nct": NaN, "last_updated": "9/19/18", "feature_display": "POLE"}, "412": {"gene": "POLE", "chromosome": "12", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": NaN, "context": NaN, "oncotree_term": NaN, "oncotree_code": NaN, "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Mutant tumors with somatic point mutations in POLE or POLD1 are being included along with MMR-deficient tumors in several ongoing ICB trials.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. DNA Damage and Repair Biomarkers of Immunotherapy Response Cancer Discov. 2017; 7(7):675-693.", "url": "https://doi.org/10.1158/2159-8290.CD-17-0226", "doi": "10.1158/2159-8290.CD-17-0226", "pmid": "28630051", "nct": NaN, "last_updated": "9/19/18", "feature_display": "POLE"}, "413": {"gene": "PRPF8", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "PRPF8"}, "414": {"gene": "PTEN", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": NaN, "context": "Metastatic", "oncotree_term": NaN, "oncotree_code": NaN, "therapy_name": "AZD8186", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "PTEN loss of function may confer sensitivity to selective PI3K inhibition", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.", "url": "https://doi.org/10.1021/jm501629p", "doi": "10.1021/jm501629p", "pmid": "25514658", "nct": NaN, "last_updated": "3/16/17", "feature_display": "PTEN (Nonsense)"}, "415": {"gene": "PTEN", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": NaN, "context": "Metastatic", "oncotree_term": NaN, "oncotree_code": NaN, "therapy_name": "AZD8186", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "PTEN loss of function may confer sensitivity to selective PI3K inhibition", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.", "url": "https://doi.org/10.1021/jm501629p", "doi": "10.1021/jm501629p", "pmid": "25514658", "nct": NaN, "last_updated": "3/16/17", "feature_display": "PTEN (Frameshift)"}, "416": {"gene": "PTEN", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Splice Site", "exon": "", "rsid": NaN, "disease": NaN, "context": "Metastatic", "oncotree_term": NaN, "oncotree_code": NaN, "therapy_name": "AZD8186", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "PTEN loss of function may confer sensitivity to selective PI3K inhibition", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.", "url": "https://doi.org/10.1021/jm501629p", "doi": "10.1021/jm501629p", "pmid": "25514658", "nct": NaN, "last_updated": "3/16/17", "feature_display": "PTEN (Splice Site)"}, "417": {"gene": "PTEN", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Uterine Leiomyoma", "context": NaN, "oncotree_term": "Uterine Leiomyoma", "oncotree_code": "ULM", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "PTEN loss may predict resistance to immune checkpoint blockade", "preferred_assertion": NaN, "source_type": "Journal", "citation": "George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.", "url": "https://doi.org/10.1016/j.immuni.2017.02.001", "doi": "10.1016/j.immuni.2017.02.001", "pmid": "28228279", "nct": NaN, "last_updated": "3/7/19", "feature_display": "PTEN (Nonsense)"}, "418": {"gene": "PTEN", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Uterine Leiomyoma", "context": NaN, "oncotree_term": "Uterine Leiomyoma", "oncotree_code": "ULM", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "PTEN loss may predict resistance to immune checkpoint blockade", "preferred_assertion": NaN, "source_type": "Journal", "citation": "George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.", "url": "https://doi.org/10.1016/j.immuni.2017.02.001", "doi": "10.1016/j.immuni.2017.02.001", "pmid": "28228279", "nct": NaN, "last_updated": "3/7/19", "feature_display": "PTEN (Frameshift)"}, "419": {"gene": "PTEN", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Splice Site", "exon": "", "rsid": NaN, "disease": "Uterine Leiomyoma", "context": NaN, "oncotree_term": "Uterine Leiomyoma", "oncotree_code": "ULM", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "PTEN loss may predict resistance to immune checkpoint blockade", "preferred_assertion": NaN, "source_type": "Journal", "citation": "George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.", "url": "https://doi.org/10.1016/j.immuni.2017.02.001", "doi": "10.1016/j.immuni.2017.02.001", "pmid": "28228279", "nct": NaN, "last_updated": "3/7/19", "feature_display": "PTEN (Splice Site)"}, "420": {"gene": "PTEN", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Prostate Cancer", "context": NaN, "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical trial", "description": "Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.", "url": "https://doi.org/10.1200/JCO.2017.75.7310", "doi": "10.1200/JCO.2017.75.7310", "pmid": "29261439", "nct": "NCT01576172", "last_updated": "1/29/19", "feature_display": "PTEN"}, "421": {"gene": "PTEN", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Uterine Leiomyoma", "context": NaN, "oncotree_term": "Uterine Leiomyoma", "oncotree_code": "ULM", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "PTEN loss may predict resistance to immune checkpoint blockade", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Peng W, Chen JQ, Liu C, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016;6(2):202-16.", "url": "https://doi.org/10.1158/2159-8290.CD-15-0283", "doi": "10.1158/2159-8290.CD-15-0283", "pmid": "26645196", "nct": NaN, "last_updated": "9/14/18", "feature_display": "PTEN (Nonsense)"}, "422": {"gene": "PTEN", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Uterine Leiomyoma", "context": NaN, "oncotree_term": "Uterine Leiomyoma", "oncotree_code": "ULM", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "PTEN loss may predict resistance to immune checkpoint blockade", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Peng W, Chen JQ, Liu C, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016;6(2):202-16.", "url": "https://doi.org/10.1158/2159-8290.CD-15-0283", "doi": "10.1158/2159-8290.CD-15-0283", "pmid": "26645196", "nct": NaN, "last_updated": "9/14/18", "feature_display": "PTEN (Frameshift)"}, "423": {"gene": "PTEN", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Splice Site", "exon": "", "rsid": NaN, "disease": "Uterine Leiomyoma", "context": NaN, "oncotree_term": "Uterine Leiomyoma", "oncotree_code": "ULM", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "PTEN loss may predict resistance to immune checkpoint blockade", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Peng W, Chen JQ, Liu C, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016;6(2):202-16.", "url": "https://doi.org/10.1158/2159-8290.CD-15-0283", "doi": "10.1158/2159-8290.CD-15-0283", "pmid": "26645196", "nct": NaN, "last_updated": "9/14/18", "feature_display": "PTEN (Splice Site)"}, "424": {"gene": "PTEN", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "PTEN loss may predict resistance to immune checkpoint blockade", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Peng W, Chen JQ, Liu C, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016;6(2):202-16.", "url": "https://doi.org/10.1158/2159-8290.CD-15-0283", "doi": "10.1158/2159-8290.CD-15-0283", "pmid": "26645196", "nct": NaN, "last_updated": "9/14/18", "feature_display": "PTEN (Nonsense)"}, "425": {"gene": "PTPN11", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "4/30/19", "feature_display": "PTPN11"}, "426": {"gene": "RAD51B", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Prostate Cancer", "context": "Metastatic castration resistant prostate cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/22/20", "feature_display": "RAD51B"}, "427": {"gene": "RAD51C", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51C"}, "428": {"gene": "RAD51C", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51C"}, "429": {"gene": "RAD51C", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51C"}, "430": {"gene": "RAD51C", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51C"}, "431": {"gene": "RAD51C", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51C"}, "432": {"gene": "RAD51C", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51C"}, "433": {"gene": "RAD51C", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Prostate Cancer", "context": "Metastatic castration resistant prostate cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/22/20", "feature_display": "RAD51C"}, "434": {"gene": "RAD51D", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51D"}, "435": {"gene": "RAD51D", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51D"}, "436": {"gene": "RAD51D", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51D"}, "437": {"gene": "RAD51D", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51D"}, "438": {"gene": "RAD51D", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51D"}, "439": {"gene": "RAD51D", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51D"}, "440": {"gene": "RAD51D", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Prostate Cancer", "context": "Metastatic castration resistant prostate cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/22/20", "feature_display": "RAD51D"}, "441": {"gene": "RAD54L", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Prostate Cancer", "context": "Metastatic castration resistant prostate cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/22/20", "feature_display": "RAD54L"}, "442": {"gene": "RBM10", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Pancreatic Cancer", "context": NaN, "oncotree_term": "Pancreatic Adenocarcinoma", "oncotree_code": "PAAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Clinical evidence", "description": "RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.", "url": "https://doi.org/10.1038/ncomms7744", "doi": "10.1038/ncomms7744", "pmid": "25855536", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RBM10"}, "443": {"gene": "RET", "chromosome": "10", "start_position": "43614996", "end_position": "43614996", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.2410G>A", "protein_change": "p.V804M", "variant_annotation": "Missense", "exon": "14", "rsid": "rs79658334", "disease": "Medullary Thyroid Cancer", "context": NaN, "oncotree_term": "Medullary Thyroid Cancer", "oncotree_code": "THME", "therapy_name": "LOXO-292", "therapy_strategy": "RET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Certain missesnse mutations may predict resistance to RET inhibitors", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.", "url": "https://doi.org/10.1093/annonc/mdy137", "doi": "10.1093/annonc/mdy137", "pmid": "29912274", "nct": NaN, "last_updated": "6/13/19", "feature_display": "RET p.V804M (Missense)"}, "444": {"gene": "RET", "chromosome": "10", "start_position": "43617416", "end_position": "43617416", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.2753T>C", "protein_change": "p.M918T", "variant_annotation": "Missense", "exon": "16", "rsid": "rs74799832", "disease": "Medullary Thyroid Cancer", "context": NaN, "oncotree_term": "Medullary Thyroid Cancer", "oncotree_code": "THME", "therapy_name": "LOXO-292", "therapy_strategy": "RET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Certain missesnse mutations may predict sensitivity to RET inhibitors", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.", "url": "https://doi.org/10.1093/annonc/mdy137", "doi": "10.1093/annonc/mdy137", "pmid": "29912274", "nct": NaN, "last_updated": "6/13/19", "feature_display": "RET p.M918T (Missense)"}, "445": {"gene": "RET", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Medullary Thyroid Cancer", "context": "Advanced or metastatic", "oncotree_term": "Medullary Thyroid Cancer", "oncotree_code": "THME", "therapy_name": "Selpercatinib", "therapy_strategy": "RET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf. Revised May 2020. Accessed October 22, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/22/20", "feature_display": "RET"}, "446": {"gene": "RET", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Medullary Thyroid Cancer", "context": "Advanced or metastatic", "oncotree_term": "Medullary Thyroid Cancer", "oncotree_code": "THME", "therapy_name": "Pralsetinib", "therapy_strategy": "RET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who required systemic therapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214701s000lbl.pdf. Revised 12/2020. Accessed December 3, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214701s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "12/3/20", "feature_display": "RET"}, "447": {"gene": "RUNX1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "May be familial in rare cases.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "RUNX1 (Nonsense)"}, "448": {"gene": "RUNX1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "May be familial in rare cases.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "RUNX1 (Frameshift)"}, "449": {"gene": "SETBP1", "chromosome": "18", "start_position": "42531877", "end_position": "42531877", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.2572G>A", "protein_change": "p.E858K", "variant_annotation": "Missense", "exon": "4", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SETBP1 p.E858K (Missense)"}, "450": {"gene": "SETBP1", "chromosome": "18", "start_position": "42531896", "end_position": "42531896", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2591C>T", "protein_change": "p.T864M", "variant_annotation": "Missense", "exon": "4", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SETBP1 p.T864M (Missense)"}, "451": {"gene": "SETBP1", "chromosome": "18", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Missense", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "SETBP1 (Missense)"}, "452": {"gene": "SETBP1", "chromosome": "18", "start_position": "42531907", "end_position": "42531907", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.2602G>A", "protein_change": "p.D868N", "variant_annotation": "Missense", "exon": "4", "rsid": "rs267607042", "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SETBP1 p.D868N (Missense)"}, "453": {"gene": "SETBP1", "chromosome": "18", "start_position": "42531907", "end_position": "42531907", "reference_allele": "G", "alternate_allele": "T", "cdna_change": "c.2602G>T", "protein_change": "p.D868Y", "variant_annotation": "Missense", "exon": "4", "rsid": "rs267607042", "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SETBP1 p.D868Y (Missense)"}, "454": {"gene": "SETBP1", "chromosome": "18", "start_position": "42531910", "end_position": "42531910", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.2605A>T", "protein_change": "p.S869C", "variant_annotation": "Missense", "exon": "4", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SETBP1 p.S869C (Missense)"}, "455": {"gene": "SETBP1", "chromosome": "18", "start_position": "42531913", "end_position": "42531913", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.2608G>A", "protein_change": "p.G870S", "variant_annotation": "Missense", "exon": "4", "rsid": "rs267607040", "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SETBP1 p.G870S (Missense)"}, "456": {"gene": "SETBP1", "chromosome": "18", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "SETBP1"}, "457": {"gene": "SF3B1", "chromosome": "2", "start_position": "198267493", "end_position": "198267493", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.1864G>C", "protein_change": "p.E622Q", "variant_annotation": "Missense", "exon": "14", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SF3B1 p.E622Q (Missense)"}, "458": {"gene": "SF3B1", "chromosome": "2", "start_position": "198267491", "end_position": "198267491", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.1866G>C", "protein_change": "p.E622D", "variant_annotation": "Missense", "exon": "14", "rsid": "rs763149798", "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SF3B1 p.E622D (Missense)"}, "459": {"gene": "SF3B1", "chromosome": "2", "start_position": "198267489", "end_position": "198267489", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.1868A>G", "protein_change": "p.Y623C", "variant_annotation": "Missense", "exon": "14", "rsid": "rs1039242157", "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SF3B1 p.Y623C (Missense)"}, "460": {"gene": "SF3B1", "chromosome": "2", "start_position": "198267484", "end_position": "198267484", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.1873C>T", "protein_change": "p.R625C", "variant_annotation": "Missense", "exon": "14", "rsid": "rs775623976", "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SF3B1 p.R625C (Missense)"}, "461": {"gene": "SF3B1", "chromosome": "2", "start_position": "198267483", "end_position": "198267483", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.1874G>A", "protein_change": "p.R625H", "variant_annotation": "Missense", "exon": "14", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SF3B1 p.R625H (Missense)"}, "462": {"gene": "SF3B1", "chromosome": "2", "start_position": "198267481", "end_position": "198267481", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1876A>C", "protein_change": "p.N626H", "variant_annotation": "Missense", "exon": "14", "rsid": "rs769888451", "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SF3B1 p.N626H (Missense)"}, "463": {"gene": "SF3B1", "chromosome": "2", "start_position": "198267481", "end_position": "198267481", "reference_allele": "T", "alternate_allele": "A", "cdna_change": "c.1876A>T", "protein_change": "p.N626Y", "variant_annotation": "Missense", "exon": "14", "rsid": "rs769888451", "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SF3B1 p.N626Y (Missense)"}, "464": {"gene": "SF3B1", "chromosome": "2", "start_position": "198267481", "end_position": "198267481", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.1876A>G", "protein_change": "p.N626D", "variant_annotation": "Missense", "exon": "14", "rsid": "rs769888451", "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SF3B1 p.N626D (Missense)"}, "465": {"gene": "SF3B1", "chromosome": "2", "start_position": "198267372", "end_position": "198267372", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.1985A>G", "protein_change": "p.H662R", "variant_annotation": "Missense", "exon": "14", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SF3B1 p.H662R (Missense)"}, "466": {"gene": "SF3B1", "chromosome": "2", "start_position": "198267370", "end_position": "198267370", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1987A>C", "protein_change": "p.T663P", "variant_annotation": "Missense", "exon": "14", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SF3B1 p.T663P (Missense)"}, "467": {"gene": "SF3B1", "chromosome": "2", "start_position": "198267359", "end_position": "198267359", "reference_allele": "C", "alternate_allele": "G", "cdna_change": "c.1998G>C", "protein_change": "p.K666N", "variant_annotation": "Missense", "exon": "14", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SF3B1 p.K666N (Missense)"}, "468": {"gene": "SF3B1", "chromosome": "2", "start_position": "198267360", "end_position": "198267360", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.1997A>C", "protein_change": "p.K666T", "variant_annotation": "Missense", "exon": "14", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SF3B1 p.K666T (Missense)"}, "469": {"gene": "SF3B1", "chromosome": "2", "start_position": "198267361", "end_position": "198267361", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.1996A>G", "protein_change": "p.K666E", "variant_annotation": "Missense", "exon": "14", "rsid": "rs754688962", "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SF3B1 p.K666E (Missense)"}, "470": {"gene": "SF3B1", "chromosome": "2", "start_position": "198266834", "end_position": "198266834", "reference_allele": "T", "alternate_allele": "C", "cdna_change": "c.2098A>G", "protein_change": "p.K700E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs559063155", "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SF3B1 p.K700E (Missense)"}, "471": {"gene": "SF3B1", "chromosome": "2", "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Missense", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "SF3B1 (Missense)"}, "472": {"gene": "SF3B1", "chromosome": "2", "start_position": "198266713", "end_position": "198266713", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2219G>A", "protein_change": "p.G740E", "variant_annotation": "Missense", "exon": "15", "rsid": "rs776846119", "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SF3B1 p.G740E (Missense)"}, "473": {"gene": "SF3B1", "chromosome": "2", "start_position": "198266713", "end_position": "198266713", "reference_allele": "C", "alternate_allele": "A", "cdna_change": "c.2219G>T", "protein_change": "p.G740V", "variant_annotation": "Missense", "exon": "15", "rsid": "rs776846119", "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SF3B1 p.G740V (Missense)"}, "474": {"gene": "SF3B1", "chromosome": "2", "start_position": "198266611", "end_position": "198266611", "reference_allele": "C", "alternate_allele": "T", "cdna_change": "c.2225G>A", "protein_change": "p.G742D", "variant_annotation": "Missense", "exon": "16", "rsid": "rs755415626", "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SF3B1 p.G742D (Missense)"}, "475": {"gene": "SF3B1", "chromosome": "2", "start_position": "198266493", "end_position": "198266493", "reference_allele": "A", "alternate_allele": "T", "cdna_change": "c.2343T>A", "protein_change": "p.D781E", "variant_annotation": "Missense", "exon": "16", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": NaN, "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "6/13/19", "feature_display": "SF3B1 p.D781E (Missense)"}, "476": {"gene": "SMARCA4", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "VX-680", "therapy_strategy": "Aurora kinase inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.", "url": "https://doi.org/10.1038/ncomms14098", "doi": "10.1038/ncomms14098", "pmid": "28102363", "nct": NaN, "last_updated": "11/3/17", "feature_display": "SMARCA4 (Nonsense)"}, "477": {"gene": "SMARCA4", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "VX-680", "therapy_strategy": "Aurora kinase inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.", "url": "https://doi.org/10.1038/ncomms14098", "doi": "10.1038/ncomms14098", "pmid": "28102363", "nct": NaN, "last_updated": "11/3/17", "feature_display": "SMARCA4 (Frameshift)"}, "478": {"gene": "SMARCA4", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Splice Site", "exon": "", "rsid": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "VX-680", "therapy_strategy": "Aurora kinase inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.", "url": "https://doi.org/10.1038/ncomms14098", "doi": "10.1038/ncomms14098", "pmid": "28102363", "nct": NaN, "last_updated": "11/3/17", "feature_display": "SMARCA4 (Splice Site)"}, "479": {"gene": "STAG2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "NCCN guideline for Myelodysplastic Syndromes.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "STAG2 (Nonsense)"}, "480": {"gene": "STAG2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "NCCN guideline for Myelodysplastic Syndromes.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "STAG2 (Frameshift)"}, "481": {"gene": "STAG2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Splice Site", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "NCCN guideline for Myelodysplastic Syndromes.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "STAG2 (Splice Site)"}, "482": {"gene": "TET2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": "Azacitidine", "therapy_strategy": "Hypomethylating agent chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "TET2"}, "483": {"gene": "TP53", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "4/30/19", "feature_display": "TP53"}, "484": {"gene": "TP53", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": "Lenalidomide", "therapy_strategy": "Immunomodulation", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "More frequent with complex karyotypes and del(5q).", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "TP53 (Nonsense)"}, "485": {"gene": "TP53", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": "Lenalidomide", "therapy_strategy": "Immunomodulation", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "More frequent with complex karyotypes and del(5q).", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "TP53 (Frameshift)"}, "486": {"gene": "TP53", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Splice Site", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": "Lenalidomide", "therapy_strategy": "Immunomodulation", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "More frequent with complex karyotypes and del(5q).", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "TP53 (Splice Site)"}, "487": {"gene": "TP53", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Missense", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "TP53 (Missense)"}, "488": {"gene": "TP53", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Gastric Cancer", "context": "Metastatic", "oncotree_term": "Gastric Remnant Adenocarcinoma", "oncotree_code": "GRC", "therapy_name": "nutlin-3", "therapy_strategy": "MDM2-p53 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Presence of mutant TP53 may suggest resistance to nutlin-3.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Endo S, Yamato K, Hirai S, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci. 2011;102(3):605-13.", "url": "https://doi.org/10.1111/j.1349-7006.2010.01821.x", "doi": "10.1111/j.1349-7006.2010.01821.x", "pmid": "21205074", "nct": NaN, "last_updated": "11/3/17", "feature_display": "TP53"}, "489": {"gene": "TP53", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Prostate Cancer", "context": NaN, "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical trial", "description": "Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.", "url": "https://doi.org/10.1200/JCO.2017.75.7310", "doi": "10.1200/JCO.2017.75.7310", "pmid": "29261439", "nct": "NCT01576172", "last_updated": "1/29/19", "feature_display": "TP53"}, "490": {"gene": "TP53", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Rectal Adenocarcinoma", "context": NaN, "oncotree_term": "Rectal Adenocarcinoma", "oncotree_code": "READ", "therapy_name": "Neoadjuvant chemoradiation", "therapy_strategy": "Chemotherapy + Radiation", "therapy_type": "Combination therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "In 17 rectal adenocarcinomas molecularly profiled pre- and post- chemoradiation, concurrent KRAS/TP53 mutations predicted non-responder status and worse PFS.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Kamran SC, Lennerz JK, Margolis CA, et al. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer Clin Cancer Res. 2019;", "url": "https://doi.org/10.1158/1078-0432.CCR-19-0908", "doi": "10.1158/1078-0432.CCR-19-0908", "pmid": "31253631", "nct": NaN, "last_updated": "8/8/19", "feature_display": "TP53"}, "491": {"gene": "TSC1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Oncogenic Mutations", "exon": "", "rsid": NaN, "disease": "Subependymal giant cell astrocytoma", "context": NaN, "oncotree_term": NaN, "oncotree_code": NaN, "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "TSC1 (Oncogenic Mutations)"}, "492": {"gene": "TSC1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Bladder Cancer", "context": "Metastatic", "oncotree_term": "Bladder Urothelial Carcinoma", "oncotree_code": "BLCA", "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.", "url": "https://doi.org/10.1126/science.1226344", "doi": "10.1126/science.1226344", "pmid": "22923433", "nct": NaN, "last_updated": "9/19/18", "feature_display": "TSC1 (Nonsense)"}, "493": {"gene": "TSC1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Bladder Cancer", "context": "Metastatic", "oncotree_term": "Bladder Urothelial Carcinoma", "oncotree_code": "BLCA", "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.", "url": "https://doi.org/10.1126/science.1226344", "doi": "10.1126/science.1226344", "pmid": "22923433", "nct": NaN, "last_updated": "9/19/18", "feature_display": "TSC1 (Frameshift)"}, "494": {"gene": "TSC1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Anaplastic Thyroid Cancer", "context": NaN, "oncotree_term": "Anaplastic Thyroid Cancer", "oncotree_code": "THAP", "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wagle N, Grabiner BC, Van allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371(15):1426-33.", "url": "https://doi.org/10.1056/NEJMoa1403352", "doi": "10.1056/NEJMoa1403352", "pmid": "25295501", "nct": NaN, "last_updated": "9/19/18", "feature_display": "TSC1 (Nonsense)"}, "495": {"gene": "TSC1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Anaplastic Thyroid Cancer", "context": NaN, "oncotree_term": "Anaplastic Thyroid Cancer", "oncotree_code": "THAP", "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wagle N, Grabiner BC, Van allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371(15):1426-33.", "url": "https://doi.org/10.1056/NEJMoa1403352", "doi": "10.1056/NEJMoa1403352", "pmid": "25295501", "nct": NaN, "last_updated": "9/19/18", "feature_display": "TSC1 (Frameshift)"}, "496": {"gene": "TSC1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Renal clear cell carcinoma", "context": "Advanced", "oncotree_term": "Renal Clear Cell Carcinoma", "oncotree_code": "RCC", "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "0", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "In a study of 184 everolimus-treated patients with RCC from a phase 2 randomized trial,  PFS neither differed on univariate analysis nor on multivariate testing based on variant status in TSC1, TSC2, or MTOR.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Voss MH, Chen D, Reising A, et al. PTEN Expression, Not Mutation Status in, or, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial. Clin Cancer Res. 2019;25(2):506-514.", "url": "https://doi.org/10.1158/1078-0432.CCR-18-1833", "doi": "10.1158/1078-0432.CCR-18-1833", "pmid": "30327302", "nct": "NCT00903175 ", "last_updated": "8/12/19", "feature_display": "TSC1"}, "497": {"gene": "TSC2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "disease": "Renal clear cell carcinoma", "context": "Advanced", "oncotree_term": "Renal Clear Cell Carcinoma", "oncotree_code": "RCC", "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "0", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "In a study of 184 everolimus-treated patients with RCC from a phase 2 randomized trial,  PFS neither differed on univariate analysis nor on multivariate testing based on variant status in TSC1, TSC2, or MTOR.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Voss MH, Chen D, Reising A, et al. PTEN Expression, Not Mutation Status in, or, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial. Clin Cancer Res. 2019;25(2):506-514.", "url": "https://doi.org/10.1158/1078-0432.CCR-18-1833", "doi": "10.1158/1078-0432.CCR-18-1833", "pmid": "30327302", "nct": "NCT00903175 ", "last_updated": "8/12/19", "feature_display": "TSC2"}, "498": {"gene": "TSC2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Oncogenic Mutations", "exon": "", "rsid": NaN, "disease": "Subependymal giant cell astrocytoma", "context": NaN, "oncotree_term": NaN, "oncotree_code": NaN, "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "TSC2 (Oncogenic Mutations)"}, "499": {"gene": "TSC2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Bladder Cancer", "context": "Metastatic", "oncotree_term": "Bladder Urothelial Carcinoma", "oncotree_code": "BLCA", "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.", "url": "https://doi.org/10.1126/science.1226344", "doi": "10.1126/science.1226344", "pmid": "22923433", "nct": NaN, "last_updated": "9/19/18", "feature_display": "TSC2 (Nonsense)"}, "500": {"gene": "TSC2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Bladder Cancer", "context": "Metastatic", "oncotree_term": "Bladder Urothelial Carcinoma", "oncotree_code": "BLCA", "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.", "url": "https://doi.org/10.1126/science.1226344", "doi": "10.1126/science.1226344", "pmid": "22923433", "nct": NaN, "last_updated": "9/19/18", "feature_display": "TSC2 (Frameshift)"}, "501": {"gene": "TSC2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Anaplastic Thyroid Cancer", "context": NaN, "oncotree_term": "Anaplastic Thyroid Cancer", "oncotree_code": "THAP", "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wagle N, Grabiner BC, Van allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371(15):1426-33.", "url": "https://doi.org/10.1056/NEJMoa1403352", "doi": "10.1056/NEJMoa1403352", "pmid": "25295501", "nct": NaN, "last_updated": "9/19/18", "feature_display": "TSC2 (Nonsense)"}, "502": {"gene": "TSC2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Anaplastic Thyroid Cancer", "context": NaN, "oncotree_term": "Anaplastic Thyroid Cancer", "oncotree_code": "THAP", "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wagle N, Grabiner BC, Van allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014;371(15):1426-33.", "url": "https://doi.org/10.1056/NEJMoa1403352", "doi": "10.1056/NEJMoa1403352", "pmid": "25295501", "nct": NaN, "last_updated": "9/19/18", "feature_display": "TSC2 (Frameshift)"}, "503": {"gene": "ZRSR2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Nonsense", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "NCCN guideline for Myelodysplastic Syndromes.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "ZRSR2 (Nonsense)"}, "504": {"gene": "ZRSR2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "Frameshift", "exon": "", "rsid": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "NCCN guideline for Myelodysplastic Syndromes.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "ZRSR2 (Frameshift)"}}, "Germline Variant": {"1": {"gene": "ATM", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Any solid tumor", "context": NaN, "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Radiation therapy", "therapy_strategy": "Radiation", "therapy_type": "Radiation therapy", "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Germline variants in ATM and other DNA repair genes have been described in patients experiencing extreme normal tissue toxicity from radiation.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pollard JM, Gatti RA. Clinical Radiation Sensitivity With DNA Repair Disorders: An Overview International Journal of Radiation Oncology*Biology*Physics. 2009; 74(5):1323-1331.", "url": "https://doi.org/10.1016/j.ijrobp.2009.02.057", "doi": "10.1016/j.ijrobp.2009.02.057", "pmid": "19616740", "nct": NaN, "last_updated": "9/12/19", "feature_display": "ATM"}, "2": {"gene": "ATM", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "Pathogenic germline variants in ATM may increase risk of acquiring CRC. Germline pathogenic variants in ATM were enriched in several large cohorts of CRC patients when the frequency of multiple DNA-repair genes was compared to that of ancestry-matched healthy patients.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "AlDubayan SH, Giannakis M, Moore ND, et al. Inherited DNA-Repair Defects in Colorectal Cancer The American Journal of Human Genetics. 2018; 102(3):401-414.", "url": "https://doi.org/10.1016/j.ajhg.2018.01.018", "doi": "10.1016/j.ajhg.2018.01.018", "pmid": "29478780", "nct": NaN, "last_updated": "4/16/19", "feature_display": "ATM"}, "3": {"gene": "ATM", "chromosome": "11", "start_position": "108128198", "end_position": "108128198", "reference_allele": "T", "alternate_allele": "G", "cdna_change": "c.2251-10T>G", "protein_change": "", "variant_annotation": "", "exon": "", "rsid": "rs730881346", "pathogenic": "1", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "SK-CO-1 cells are homozygous for ATM c.2251-10>T, lack ATM protein expression, and are sensitive to the PARP inhibitor olaparib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.", "url": "https://doi.org/10.1016/j.tranon.2017.01.007", "doi": "10.1016/j.tranon.2017.01.007", "pmid": "28182994", "nct": NaN, "last_updated": "8/15/19", "feature_display": "ATM"}, "4": {"gene": "BARD1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BARD1"}, "5": {"gene": "BARD1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BARD1"}, "6": {"gene": "BARD1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BARD1"}, "7": {"gene": "BARD1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BARD1"}, "8": {"gene": "BARD1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BARD1"}, "9": {"gene": "BARD1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BARD1"}, "10": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Ovarian Cancer", "context": "Advanced, treated with three or more prior lines of chemotherapy", "oncotree_term": "Ovarian Epithelial Tumor", "oncotree_code": "OVT", "therapy_name": "Niraparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "BRCA1"}, "11": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Fallopian tube cancer", "context": "Treated with three or more prior lines of chemotherapy", "oncotree_term": "High-Grade Serous Fallopian Tube Cancer", "oncotree_code": "HGSFT", "therapy_name": "Niraparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "BRCA1"}, "12": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Peritoneal cancer", "context": "Primary, treated with three or more prior lines of chemotherapy", "oncotree_term": "Peritoneal Serous Carcinoma", "oncotree_code": "PSEC", "therapy_name": "Niraparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "BRCA1"}, "13": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Breast Cancer", "context": "HER2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRCA1"}, "14": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Epithelial ovarian cancer", "context": "Advanced, treated with three or more prior lines of chemotherapy", "oncotree_term": "Ovarian Epithelial Tumor", "oncotree_code": "OVT", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT01844986", "last_updated": "11/12/20", "feature_display": "BRCA1"}, "15": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Fallopian tube cancer", "context": "Advanced, treated with three or more prior lines of chemotherapy", "oncotree_term": "High-Grade Serous Fallopian Tube Cancer", "oncotree_code": "HGSFT", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT01844986", "last_updated": "11/12/20", "feature_display": "BRCA1"}, "16": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Peritoneal cancer", "context": "Primary", "oncotree_term": "Peritoneal Serous Carcinoma", "oncotree_code": "PSEC", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT01844986", "last_updated": "11/12/20", "feature_display": "BRCA1"}, "17": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Ovarian Cancer", "context": NaN, "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Patients with chemotherapy-refractory ovarian cancer have higher response rates to PARP inhibitor therapy in the presence of BRCA1 and BRCA2 mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Ovarian Cancer NCCN Evidence Blocks (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT01844986", "last_updated": "3/7/19", "feature_display": "BRCA1"}, "18": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Ovarian Cancer", "context": NaN, "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Pazopanib", "therapy_strategy": "FGFR inhibition + KIT inhibition + PDGFR inhibition + VEGF/VEGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Pazopanib may increase PFS in patients whose disease does not progress following first-line treatment.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Ovarian Cancer NCCN Evidence Blocks (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf", "doi": NaN, "pmid": "26740259", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BRCA1"}, "19": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Pancreatic Cancer", "context": NaN, "oncotree_term": "Pancreatic Adenocarcinoma", "oncotree_code": "PAAD", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "When present alongside genomic instability, defined by a large number of structural variation events, the inactivation of DNA maintenance genes (BRCA1, BRCA2, PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients. ", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495-501.", "url": "https://doi.org/10.1038/nature14169", "doi": "10.1038/nature14169", "pmid": "25719666", "nct": NaN, "last_updated": "3/7/19", "feature_display": "BRCA1"}, "20": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Invasive Breast Cancer", "context": "HER2-negative, recurrent or metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "PARP inhibitors are recommended for patients with recurrent or stage IV disease with HER2-negative tumors with germline BRCA1/2 variants.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Invasive Breast Cancer NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf. Accessed August 10, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/10/19", "feature_display": "BRCA1"}, "21": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Invasive Breast Cancer", "context": "HER2-negative, recurrent or metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Talazoparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "PARP inhibitors are recommended for patients with recurrent or stage IV disease with HER2-negative tumors with germline BRCA1/2 variants.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Invasive Breast Cancer NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf. Accessed August 10, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/10/19", "feature_display": "BRCA1"}, "22": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Invasive Breast Cancer", "context": "Triple-negative, recurrent or metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Carboplatin", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Platinum chemotherapies are recommended for patients with recurrent or stage IV disease with triple-negative tumors and germline BRCA 1/2 variants.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Invasive Breast Cancer NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf. Accessed August 10, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/10/19", "feature_display": "BRCA1"}, "23": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Invasive Breast Cancer", "context": "Triple-negative, recurrent or metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Cisplatin", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Platinum chemotherapies are recommended for patients with recurrent or stage IV disease with triple-negative tumors and germline BRCA 1/2 variants.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Invasive Breast Cancer NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf. Accessed August 10, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/10/19", "feature_display": "BRCA1"}, "24": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Breast Cancer", "context": "HER2-negative locally advanced or metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Talazoparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative localy advanced or metastatic breast cancer. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Talzenna [package insert]. New York, NY: Pfizer Inc.; 2018.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT01945775", "last_updated": "3/23/20", "feature_display": "BRCA1"}, "25": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Ovarian Cancer", "context": "Advanced, treated with three or more prior lines of chemotherapy", "oncotree_term": "Ovarian Epithelial Tumor", "oncotree_code": "OVT", "therapy_name": "Niraparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "BRCA1"}, "26": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Fallopian tube cancer", "context": "Treated with three or more prior lines of chemotherapy", "oncotree_term": "High-Grade Serous Fallopian Tube Cancer", "oncotree_code": "HGSFT", "therapy_name": "Niraparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "BRCA1"}, "27": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Peritoneal cancer", "context": "Primary, treated with three or more prior lines of chemotherapy", "oncotree_term": "Peritoneal Serous Carcinoma", "oncotree_code": "PSEC", "therapy_name": "Niraparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "BRCA1"}, "28": {"gene": "BRCA1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Prostate Cancer", "context": "Metastatic castration resistant prostate cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/22/20", "feature_display": "BRCA1"}, "29": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Invasive Breast Cancer", "context": "HER2-negative, recurrent or metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "PARP inhibitors are recommended for patients with recurrent or stage IV disease that are also HER2-negative tumors with germline BRCA1/2 variants.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Invasive Breast Cancer NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf. Accessed August 10, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/10/19", "feature_display": "BRCA2"}, "30": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Invasive Breast Cancer", "context": "HER2-negative, recurrent or metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Talazoparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "PARP inhibitors are recommended for patients with recurrent or stage IV disease that are also HER2-negative tumors with germline BRCA1/2 variants.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Invasive Breast Cancer NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf. Accessed August 10, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/10/19", "feature_display": "BRCA2"}, "31": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Invasive Breast Cancer", "context": "Triple-negative, recurrent or metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Carboplatin", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Platinum chemotherapies are recommended for patients with recurrent or stage IV disease with triple-negative tumors and germline BRCA 1/2 variants.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Invasive Breast Cancer NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf. Accessed August 10, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/10/19", "feature_display": "BRCA2"}, "32": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Invasive Breast Cancer", "context": "Triple-negative, recurrent or metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Cisplatin", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Platinum chemotherapies are recommended for patients with recurrent or stage IV disease with triple-negative tumors and germline BRCA 1/2 variants.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Invasive Breast Cancer NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf. Accessed August 10, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/10/19", "feature_display": "BRCA2"}, "33": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Breast Cancer", "context": "HER2-negative locally advanced or metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Talazoparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative localy advanced or metastatic breast cancer. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211651s006lbl.pdf. Revised October 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211651s006lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT01945775", "last_updated": "11/12/20", "feature_display": "BRCA2"}, "34": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Breast Cancer", "context": "HER2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BRCA2"}, "35": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Ovarian Cancer", "context": "Advanced, treated with three or more prior lines of chemotherapy", "oncotree_term": "Ovarian Epithelial Tumor", "oncotree_code": "OVT", "therapy_name": "Niraparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "BRCA2"}, "36": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Fallopian tube cancer", "context": "Treated with three or more prior lines of chemotherapy", "oncotree_term": "High-Grade Serous Fallopian Tube Cancer", "oncotree_code": "HGSFT", "therapy_name": "Niraparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "BRCA2"}, "37": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Peritoneal cancer", "context": "Primary, treated with three or more prior lines of chemotherapy", "oncotree_term": "Peritoneal Serous Carcinoma", "oncotree_code": "PSEC", "therapy_name": "Niraparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "BRCA2"}, "38": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Epithelial ovarian cancer", "context": "Advanced, treated with three or more prior lines of chemotherapy", "oncotree_term": "Ovarian Epithelial Tumor", "oncotree_code": "OVT", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT01844986", "last_updated": "11/12/20", "feature_display": "BRCA2"}, "39": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Fallopian tube cancer", "context": "Advanced, treated with three or more prior lines of chemotherapy", "oncotree_term": "High-Grade Serous Fallopian Tube Cancer", "oncotree_code": "HGSFT", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT01844986", "last_updated": "11/12/20", "feature_display": "BRCA2"}, "40": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Peritoneal cancer", "context": "Primary", "oncotree_term": "Peritoneal Serous Carcinoma", "oncotree_code": "PSEC", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT01844986", "last_updated": "11/12/20", "feature_display": "BRCA2"}, "41": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Ovarian Cancer", "context": NaN, "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Patients with chemotherapy-refractory ovarian cancer have higher response rates to PARP inhibitor therapy in the presence of BRCA1 and BRCA2 mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Ovarian Cancer NCCN Evidence Blocks (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "BRCA2"}, "42": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Ovarian Cancer", "context": NaN, "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Patients with chemotherapy-refractory ovarian cancer have higher response rates to PARP inhibitor therapy in the presence of BRCA1 and BRCA2 mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Ovarian Cancer NCCN Evidence Blocks (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "BRCA2"}, "43": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Ovarian Cancer", "context": NaN, "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Pazopanib", "therapy_strategy": "FGFR inhibition + KIT inhibition + PDGFR inhibition + VEGF/VEGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Pazopanib may increase PFS in patients whose disease does not progress following first-line treatment.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Ovarian Cancer NCCN Evidence Blocks (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf", "doi": NaN, "pmid": "26740259", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BRCA2"}, "44": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Prostate Cancer", "context": NaN, "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "Patients with chemotherapy-refractory prostate cancer have higher response rates to PARP inhibitor therapy in the presence of DNA repair mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Mateo J, Carreira S, Sandhu S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373(18):1697-708.", "url": "https://doi.org/10.1056/NEJMoa1506859", "doi": "10.1056/NEJMoa1506859", "pmid": "26510020", "nct": "NCT01682772", "last_updated": "11/3/17", "feature_display": "BRCA2"}, "45": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Pancreatic Cancer", "context": NaN, "oncotree_term": "Pancreatic Adenocarcinoma", "oncotree_code": "PAAD", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "When present alongside genomic instability, defined by a large number of structural variation events, the inactivation of DNA maintenance genes (BRCA1, BRCA2, PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients. ", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495-501.", "url": "https://doi.org/10.1038/nature14169", "doi": "10.1038/nature14169", "pmid": "25719666", "nct": NaN, "last_updated": "3/7/19", "feature_display": "BRCA2"}, "46": {"gene": "BRCA2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Prostate Cancer", "context": "Metastatic castration resistant prostate cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/22/20", "feature_display": "BRCA2"}, "47": {"gene": "CHEK1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK1"}, "48": {"gene": "CHEK1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK1"}, "49": {"gene": "CHEK1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK1"}, "50": {"gene": "CHEK1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK1"}, "51": {"gene": "CHEK1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK1"}, "52": {"gene": "CHEK1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK1"}, "53": {"gene": "CHEK2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK2"}, "54": {"gene": "CHEK2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK2"}, "55": {"gene": "CHEK2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK2"}, "56": {"gene": "CHEK2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK2"}, "57": {"gene": "CHEK2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK2"}, "58": {"gene": "CHEK2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CHEK2"}, "59": {"gene": "CHEK2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Testicular Germ Cell Tumors", "context": NaN, "oncotree_term": "Testicular Germ Cell Tumors", "oncotree_code": "TGCT", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "CHEK2 variants may increase risk of acquiring testicular germ cells tumors. Germline pathogenic mutations in CHEK2 were enriched in both discovery and validation cohorts of European men with TGCTs, compared to the ExAC Non-Finnish Europeans cohort of healthy patients.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "AlDubayan SH, Pyle LC, Gamulin M, et al. Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 ( ) With Susceptibility to Testicular Germ Cell Tumors JAMA Oncol. 2019; 5(4):514-.", "url": "https://doi.org/10.1001/jamaoncol.2018.6477", "doi": "10.1001/jamaoncol.2018.6477", "pmid": "30676620", "nct": NaN, "last_updated": "4/16/19", "feature_display": "CHEK2"}, "60": {"gene": "EPCAM", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": "Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf", "doi": NaN, "pmid": "20498393", "nct": NaN, "last_updated": "11/3/17", "feature_display": "EPCAM"}, "61": {"gene": "IL12RB1", "chromosome": "19", "start_position": "18194272", "end_position": "18194272", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.94C>T", "protein_change": "p.Q32*", "variant_annotation": "Nonsense", "exon": "2", "rsid": "rs121434492", "pathogenic": "", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883.", "url": "https://doi.org/10.1038/ncomms11883", "doi": "10.1038/ncomms11883", "pmid": "27329137", "nct": NaN, "last_updated": "6/13/19", "feature_display": "IL12RB1 p.Q32* (Nonsense)"}, "62": {"gene": "IL12RB1", "chromosome": "19", "start_position": "18173082", "end_position": "18173082", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.1624C>T", "protein_change": "p.Q542*", "variant_annotation": "Nonsense", "exon": "15", "rsid": "rs372833507", "pathogenic": "", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883.", "url": "https://doi.org/10.1038/ncomms11883", "doi": "10.1038/ncomms11883", "pmid": "27329137", "nct": NaN, "last_updated": "6/13/19", "feature_display": "IL12RB1 p.Q542* (Nonsense)"}, "63": {"gene": "LIMK2", "chromosome": "22", "start_position": "31672776", "end_position": "31672776", "reference_allele": "-", "alternate_allele": "C", "cdna_change": "c.1719dup", "protein_change": "p.G574Rfs*12", "variant_annotation": "Frameshift", "exon": "15", "rsid": "rs540206607", "pathogenic": "", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883.", "url": "https://doi.org/10.1038/ncomms11883", "doi": "10.1038/ncomms11883", "pmid": "27329137", "nct": NaN, "last_updated": "6/13/19", "feature_display": "LIMK2 p.G574Rfs*12 (Frameshift)"}, "64": {"gene": "LIMK2", "chromosome": "22", "start_position": "31672807", "end_position": "31672807", "reference_allele": "-", "alternate_allele": "G", "cdna_change": "c.1742dup", "protein_change": "p.C582Lfs*4", "variant_annotation": "Frameshift", "exon": "15", "rsid": NaN, "pathogenic": "", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883.", "url": "https://doi.org/10.1038/ncomms11883", "doi": "10.1038/ncomms11883", "pmid": "27329137", "nct": NaN, "last_updated": "6/13/19", "feature_display": "LIMK2 p.C582Lfs*4 (Frameshift)"}, "65": {"gene": "LIMK2", "chromosome": "22", "start_position": "31673114", "end_position": "31673114", "reference_allele": "-", "alternate_allele": "A", "cdna_change": "c.2049_2050insA", "protein_change": "p.G684Tfs*16", "variant_annotation": "Frameshift", "exon": "15", "rsid": NaN, "pathogenic": "", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883.", "url": "https://doi.org/10.1038/ncomms11883", "doi": "10.1038/ncomms11883", "pmid": "27329137", "nct": NaN, "last_updated": "6/13/19", "feature_display": "LIMK2 p.G684Tfs*16 (Frameshift)"}, "66": {"gene": "MLH1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": "Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf", "doi": NaN, "pmid": "20498393", "nct": NaN, "last_updated": "11/3/17", "feature_display": "MLH1"}, "67": {"gene": "MLH3", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.", "url": "https://doi.org/10.1056/NEJMoa1500596", "doi": "10.1056/NEJMoa1500596", "pmid": "26028255", "nct": "NCT01876511", "last_updated": "2/4/19", "feature_display": "MLH3"}, "68": {"gene": "MRE11", "chromosome": "11", "start_position": "94180442", "end_position": "94180442", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.1726C>T", "protein_change": "p.R576*", "variant_annotation": "Nonsense", "exon": "15", "rsid": "rs774277300", "pathogenic": "", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883.", "url": "https://doi.org/10.1038/ncomms11883", "doi": "10.1038/ncomms11883", "pmid": "27329137", "nct": NaN, "last_updated": "6/13/19", "feature_display": "MRE11 p.R576* (Nonsense)"}, "69": {"gene": "MRE11", "chromosome": "11", "start_position": "94201010", "end_position": "94201011", "reference_allele": "C", "alternate_allele": "-", "cdna_change": "c.1066del", "protein_change": "p.H356Tfs*34", "variant_annotation": "Frameshift", "exon": "10", "rsid": NaN, "pathogenic": "", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883.", "url": "https://doi.org/10.1038/ncomms11883", "doi": "10.1038/ncomms11883", "pmid": "27329137", "nct": NaN, "last_updated": "6/13/19", "feature_display": "MRE11 p.H356Tfs*34 (Frameshift)"}, "70": {"gene": "MRE11", "chromosome": "11", "start_position": "94224125", "end_position": "94224137", "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": "c.21-6_26del", "protein_change": "p.L7fs*18", "variant_annotation": "Frameshift", "exon": "3", "rsid": "rs587780138", "pathogenic": "", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883.", "url": "https://doi.org/10.1038/ncomms11883", "doi": "10.1038/ncomms11883", "pmid": "27329137", "nct": NaN, "last_updated": "6/13/19", "feature_display": "MRE11 p.L7fs*18 (Frameshift)"}, "71": {"gene": "MSH2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": "Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf", "doi": NaN, "pmid": "20498393", "nct": NaN, "last_updated": "11/3/17", "feature_display": "MSH2"}, "72": {"gene": "MSH2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.", "url": "https://doi.org/10.1056/NEJMoa1500596", "doi": "10.1056/NEJMoa1500596", "pmid": "26028255", "nct": "NCT01876511", "last_updated": "2/4/19", "feature_display": "MSH2"}, "73": {"gene": "MSH6", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": "Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf", "doi": NaN, "pmid": "20498393", "nct": NaN, "last_updated": "11/3/17", "feature_display": "MSH6"}, "74": {"gene": "MSH6", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.", "url": "https://doi.org/10.1056/NEJMoa1500596", "doi": "10.1056/NEJMoa1500596", "pmid": "26028255", "nct": "NCT01876511", "last_updated": "2/4/19", "feature_display": "MSH6"}, "75": {"gene": "NF1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Any solid tumor", "context": NaN, "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Radiation therapy", "therapy_strategy": "Radiation", "therapy_type": "Radiation therapy", "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Germline variants in genes known to cause cancer syndromes, such as TP53, RB1, and NF1, can increase the risk of radiation-induced secondary malignancies.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Kleinerman RA. Radiation-sensitive genetically susceptible pediatric sub-populations Pediatr Radiol. 2008; 39(S1):27-31.", "url": "https://doi.org/10.1007/s00247-008-1015-6", "doi": "10.1007/s00247-008-1015-6", "pmid": "19083227", "nct": NaN, "last_updated": "9/12/19", "feature_display": "NF1"}, "76": {"gene": "PALB2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "PALB2"}, "77": {"gene": "PALB2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "PALB2"}, "78": {"gene": "PALB2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "PALB2"}, "79": {"gene": "PALB2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "PALB2"}, "80": {"gene": "PALB2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "PALB2"}, "81": {"gene": "PALB2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "PALB2"}, "82": {"gene": "PALB2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Pancreatic Cancer", "context": NaN, "oncotree_term": "Pancreatic Adenocarcinoma", "oncotree_code": "PAAD", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "When present alongside genomic instability, defined by a large number of structural variation events, the inactivation of DNA maintenance genes (BRCA1, BRCA2, PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients. ", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495-501.", "url": "https://doi.org/10.1038/nature14169", "doi": "10.1038/nature14169", "pmid": "25719666", "nct": NaN, "last_updated": "3/7/19", "feature_display": "PALB2"}, "83": {"gene": "PALB2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "1", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "Pathogenic germline variants in PALB2 may increase risk of acquiring CRC. Germline pathogenic variants in PALB2 were enriched in several large cohorts of CRC patients when the frequency of multiple DNA-repair genes was compared to that of ancestry-matched healthy patients.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "AlDubayan SH, Giannakis M, Moore ND, et al. Inherited DNA-Repair Defects in Colorectal Cancer The American Journal of Human Genetics. 2018; 102(3):401-414.", "url": "https://doi.org/10.1016/j.ajhg.2018.01.018", "doi": "10.1016/j.ajhg.2018.01.018", "pmid": "29478780", "nct": NaN, "last_updated": "4/16/19", "feature_display": "PALB2"}, "84": {"gene": "PMS2", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": "Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf", "doi": NaN, "pmid": "20498393", "nct": NaN, "last_updated": "11/3/17", "feature_display": "PMS2"}, "85": {"gene": "POLE2", "chromosome": "14", "start_position": "50117073", "end_position": "50117073", "reference_allele": "-", "alternate_allele": "A", "cdna_change": "c.1406dup", "protein_change": "p.L469Ffs*17", "variant_annotation": "Frameshift", "exon": "17", "rsid": "rs776517397", "pathogenic": "", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883.", "url": "https://doi.org/10.1038/ncomms11883", "doi": "10.1038/ncomms11883", "pmid": "27329137", "nct": NaN, "last_updated": "6/13/19", "feature_display": "POLE2 p.L469Ffs*17 (Frameshift)"}, "86": {"gene": "POT1", "chromosome": "7", "start_position": "124464068", "end_position": "124464070", "reference_allele": "TTA", "alternate_allele": "T", "cdna_change": "c.1851_1852del", "protein_change": "p.D617Efs*9", "variant_annotation": "Frameshift", "exon": "19", "rsid": "rs758673417", "pathogenic": "", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883.", "url": "https://doi.org/10.1038/ncomms11883", "doi": "10.1038/ncomms11883", "pmid": "27329137", "nct": NaN, "last_updated": "6/13/19", "feature_display": "POT1 p.D617Efs*9 (Frameshift)"}, "87": {"gene": "POT1", "chromosome": "7", "start_position": "124482937", "end_position": "124482937", "reference_allele": "G", "alternate_allele": "A", "cdna_change": "c.1087C>T", "protein_change": "p.R363*", "variant_annotation": "Nonsense", "exon": "13", "rsid": "rs756198077", "pathogenic": "", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883.", "url": "https://doi.org/10.1038/ncomms11883", "doi": "10.1038/ncomms11883", "pmid": "27329137", "nct": NaN, "last_updated": "6/13/19", "feature_display": "POT1 p.R363* (Nonsense)"}, "88": {"gene": "POT1", "chromosome": "7", "start_position": "124511000", "end_position": "124511000", "reference_allele": "-", "alternate_allele": "A", "cdna_change": "c.224dup", "protein_change": "p.N75Kfs*16", "variant_annotation": "Frameshift", "exon": "7", "rsid": NaN, "pathogenic": "", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "Mutation may indicate increased susceptibility to early-onset colorectal cancer.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883.", "url": "https://doi.org/10.1038/ncomms11883", "doi": "10.1038/ncomms11883", "pmid": "27329137", "nct": NaN, "last_updated": "6/13/19", "feature_display": "POT1 p.N75Kfs*16 (Frameshift)"}, "89": {"gene": "RAD51C", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51C"}, "90": {"gene": "RAD51C", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51C"}, "91": {"gene": "RAD51C", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51C"}, "92": {"gene": "RAD51C", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51C"}, "93": {"gene": "RAD51C", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51C"}, "94": {"gene": "RAD51C", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51C"}, "95": {"gene": "RAD51D", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51D"}, "96": {"gene": "RAD51D", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Ovarian Cancer", "context": "Primary", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51D"}, "97": {"gene": "RAD51D", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51D"}, "98": {"gene": "RAD51D", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Peritoneal Carcinoma", "context": "Primary", "oncotree_term": "Peritoneal Mesothelioma", "oncotree_code": "PEMESO", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51D"}, "99": {"gene": "RAD51D", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51D"}, "100": {"gene": "RAD51D", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Fallopian Tube Carcinoma", "context": "Primary", "oncotree_term": "Serous Ovarian Cancer", "oncotree_code": "SOC", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Inferential", "description": "Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.", "url": "https://doi.org/10.1158/1078-0432.CCR-13-2287", "doi": "10.1158/1078-0432.CCR-13-2287", "pmid": "24240112", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RAD51D"}, "101": {"gene": "RB1", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Any solid tumor", "context": NaN, "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Radiation therapy", "therapy_strategy": "Radiation", "therapy_type": "Radiation therapy", "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Germline variants in genes known to cause cancer syndromes, such as TP53, RB1, and NF1, can increase the risk of radiation-induced secondary malignancies.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Kleinerman RA. Radiation-sensitive genetically susceptible pediatric sub-populations Pediatr Radiol. 2008; 39(S1):27-31.", "url": "https://doi.org/10.1007/s00247-008-1015-6", "doi": "10.1007/s00247-008-1015-6", "pmid": "19083227", "nct": NaN, "last_updated": "9/12/19", "feature_display": "RB1"}, "102": {"gene": "TP53", "chromosome": NaN, "start_position": NaN, "end_position": NaN, "reference_allele": NaN, "alternate_allele": NaN, "cdna_change": NaN, "protein_change": "", "variant_annotation": "", "exon": "", "rsid": NaN, "pathogenic": "", "disease": "Any solid tumor", "context": NaN, "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Radiation therapy", "therapy_strategy": "Radiation", "therapy_type": "Radiation therapy", "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Germline variants in genes known to cause cancer syndromes, such as TP53, RB1, and NF1, can increase the risk of radiation-induced secondary malignancies.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Kleinerman RA. Radiation-sensitive genetically susceptible pediatric sub-populations Pediatr Radiol. 2008; 39(S1):27-31.", "url": "https://doi.org/10.1007/s00247-008-1015-6", "doi": "10.1007/s00247-008-1015-6", "pmid": "19083227", "nct": NaN, "last_updated": "9/12/19", "feature_display": "TP53"}}, "Copy Number": {"1": {"gene": "AR", "direction": "Amplification", "cytoband": NaN, "disease": "Prostate Cancer", "context": "Castration Resistant Prostate Cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Abiraterone", "therapy_strategy": "Antiandrogen", "therapy_type": "Hormone therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Androgen receptor activation is a potential mechanism of recurrence of prostate cancer during androgen deprivation therapy.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "AR Amplification"}, "2": {"gene": "AR", "direction": "Amplification", "cytoband": NaN, "disease": "Prostate Cancer", "context": "Castration Resistant Prostate Cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Abiraterone", "therapy_strategy": "Antiandrogen", "therapy_type": "Hormone therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "AR Amplification"}, "3": {"gene": "AR", "direction": "Amplification", "cytoband": NaN, "disease": "Prostate Cancer", "context": "Castration Resistant Prostate Cancer", "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Enzalutamide", "therapy_strategy": "Antiandrogen", "therapy_type": "Hormone therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Androgen receptor activation may predict sensitivity to second generation androgen deprivation or direct androgen inhibitors.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Prostate Cancer NCCN Evidence Blocks (Version 3.2016). Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "AR Amplification"}, "4": {"gene": "AR", "direction": "Amplification", "cytoband": NaN, "disease": "Breast Cancer", "context": "Triple-negative", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Radiation therapy", "therapy_strategy": "Radiation", "therapy_type": "Radiation therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "In analysis of triple-negative breast cancer samples and cell lines, increased expression of androgen receptor was associated with increased risk of locoregional recurrence after RT. Radiation resistance in androgen receptor-postive, TNBC cell lines was reversed with enzalutamide.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Speers C, Zhao SG, Chandler B, et al. Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer npj Breast Cancer. 2017; 3(1).", "url": "https://doi.org/10.1038/s41523-017-0038-2", "doi": "10.1038/s41523-017-0038-2", "pmid": "28840192", "nct": NaN, "last_updated": "8/9/19", "feature_display": "AR Amplification"}, "5": {"gene": "ARID1A", "direction": "Deletion", "cytoband": NaN, "disease": "Ovarian Cancer", "context": "Metastatic", "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Durvalumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.", "url": "https://doi.org/10.1038/s41591-018-0012-z", "doi": "10.1038/s41591-018-0012-z", "pmid": "29736026", "nct": NaN, "last_updated": "2/4/19", "feature_display": "ARID1A Deletion"}, "6": {"gene": "AURKA", "direction": "Amplification", "cytoband": "20q13.2", "disease": "Prostate Cancer", "context": "Castration Resistant Prostate Cancer", "oncotree_term": "Prostate Neuroendocrine Cancer", "oncotree_code": "PRNE", "therapy_name": "Danusertib", "therapy_strategy": "Aurora kinase inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Neuroendocrine prostate cancer (NEPC) cell lines shows enhanced sensitivity to pan-Aurora kinase inhibitor therapy, specifically to PHA-739358 (Danusertib).", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487-95.", "url": "https://doi.org/10.1158/2159-8290.CD-11-0130", "doi": "10.1158/2159-8290.CD-11-0130", "pmid": "22389870", "nct": NaN, "last_updated": "11/3/17", "feature_display": "AURKA Amplification"}, "7": {"gene": "AURKA", "direction": "Amplification", "cytoband": "20q13.2", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Preclinical", "description": "Downmodulation of TPX2 and AURKA in the presence of 20q copy gain was shown to tumor growth", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Sillars-Hardebol, Anke H., et al. \"TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression.\" Gut 61.11 (2012): 1568-1575.", "url": "https://doi.org/10.1136/gutjnl-2011-301153", "doi": "10.1136/gutjnl-2011-301153", "pmid": "22207630", "nct": NaN, "last_updated": "11/3/17", "feature_display": "AURKA Amplification"}, "8": {"gene": "AURKB", "direction": "Amplification", "cytoband": NaN, "disease": "Small-Cell Lung Cancer", "context": "Advanced", "oncotree_term": "Small Cell Lung Cancer", "oncotree_code": "SCLC", "therapy_name": "Barasertib", "therapy_strategy": "Aurora-B kinase inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "MYC amplified small cell lung cancer", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Helfrich BA, Kim J, Gao D, et al. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther. 2016;15(10):2314-2322.", "url": "https://doi.org/10.1158/1535-7163.MCT-16-0298", "doi": "10.1158/1535-7163.MCT-16-0298", "pmid": "27496133", "nct": NaN, "last_updated": "11/3/17", "feature_display": "AURKB Amplification"}, "9": {"gene": "BRAF", "direction": "Amplification", "cytoband": NaN, "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Selumetinib", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "BRAF V600E mutant colorectal cancer cell lines were cultured in increasing concentrations of the MEK inhibitor AZD6244 (Selumetinib). FISH analysis marked increase in BRAF gene copies in resistant cells.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Corcoran, Ryan B., et al. \"BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.\" Science signaling 3.149 (2010): ra84.", "url": "https://doi.org/10.1126/scisignal.2001148", "doi": "10.1126/scisignal.2001148", "pmid": "21098728", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BRAF Amplification"}, "10": {"gene": "BRAF", "direction": "Amplification", "cytoband": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Vemurafenib", "therapy_strategy": "B-RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Amplification of BRAF may predict resistance to RAF inhibition.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Wagle, Nikhil, et al. \"MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.\" Cancer discovery 4.1 (2014): 61-68.", "url": "https://doi.org/10.1158/2159-8290.CD-13-0631", "doi": "10.1158/2159-8290.CD-13-0631", "pmid": "24265153", "nct": NaN, "last_updated": "11/3/17", "feature_display": "BRAF Amplification"}, "11": {"gene": "BRCA2", "direction": "Deletion", "cytoband": NaN, "disease": "Prostate Cancer", "context": NaN, "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "Patients with chemotherapy-refractory prostate cancer have higher response rates to PARP inhibitor therapy in the presence of DNA repair mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Mateo J, Carreira S, Sandhu S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373(18):1697-708.", "url": "https://doi.org/10.1056/NEJMoa1506859", "doi": "10.1056/NEJMoa1506859", "pmid": "26510020", "nct": "NCT01682772", "last_updated": "11/3/17", "feature_display": "BRCA2 Deletion"}, "12": {"gene": "CCND1", "direction": "Amplification", "cytoband": "11p13", "disease": "Invasive Breast Carcinoma", "context": NaN, "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "CCND1 amplification showed reduced recurrence-free survival in a randomized control trial of postmenopausal breast cancer patients.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Bostner, Josefine, et al. \"Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.\" Oncogene 26.49 (2007): 6997-7005.", "url": "https://doi.org/10.1038/sj.onc.1210506", "doi": "10.1038/sj.onc.1210506", "pmid": "7486065", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CCND1 Amplification"}, "13": {"gene": "CCND1", "direction": "Amplification", "cytoband": NaN, "disease": "Pancreatic Cancer", "context": NaN, "oncotree_term": "Pancreatic Adenocarcinoma", "oncotree_code": "PAAD", "therapy_name": "Palbociclib", "therapy_strategy": "CDK4/6 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "CCND1 amplification was observed in a study of 109 microdissected pancreatic adenocarcinoma tumors, and is predicted to have antitumor effects in response to palbociclib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.", "url": "https://doi.org/10.1038/ncomms7744", "doi": "10.1038/ncomms7744", "pmid": "25855536", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CCND1 Amplification"}, "14": {"gene": "CCNE1", "direction": "Amplification", "cytoband": "19q12", "disease": "Ovarian Cancer", "context": NaN, "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Bortezomib", "therapy_strategy": "Proteasome inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Sensitivity to Bortezomib was observed in ovarian cancer cell lines.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Etemadmoghadam, Dariush, et al. \"Synthetic lethality between CCNE1 amplification and loss of BRCA1.\" Proceedings of the National Academy of Sciences 110.48 (2013): 19489-19494.", "url": "https://doi.org/10.1073/pnas.1314302110", "doi": "10.1073/pnas.1314302110", "pmid": "24218601", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CCNE1 Amplification"}, "15": {"gene": "CD274", "direction": "Amplification", "cytoband": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab in a trial of 495 patients with non-small cell lung cancer. ", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28.", "url": "https://doi.org/10.1056/NEJMoa1501824", "doi": "10.1056/NEJMoa1501824", "pmid": "25891174", "nct": "NCT01295827", "last_updated": "11/4/19", "feature_display": "CD274 Amplification"}, "16": {"gene": "CD274", "direction": "Amplification", "cytoband": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Atezolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "The U.S. Food and Drug Administration (FDA) approved atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 staining >= 50% of tumor cells) or PD-L1 stained tumor-infiltrating immune cells covering >= 10% of the tumor area, with no EGFR or ALK genomic tumor aberrations.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Genentech, Inc. Tecentriq (atezolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761034s029lbl.pdf. Revised September 2020. Accessed October 22, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761034s029lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "CD274 Amplification"}, "17": {"gene": "CD274", "direction": "Amplification", "cytoband": NaN, "disease": "Triple Negative Breast Cancer", "context": "Locally recurrent or metastatic triple-negative", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Chemotherapy + Pembrolizumab", "therapy_strategy": "Chemotherapy + PD-1/PD-L1 inhibition", "therapy_type": "Combination therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS>=10) as determined by an FDA approved test. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf. Revised October 2020. Accessed November 4, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s088lbl.pdf?utm_source=Salesforce%20Marketing%20Cloud&utm_medium=Email&utm_campaign=", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/19/20", "feature_display": "CD274 Amplification"}, "18": {"gene": "CDK4", "direction": "Amplification", "cytoband": NaN, "disease": "Well-differentiated liposarcoma", "context": NaN, "oncotree_term": "Well-Differentiated Liposarcoma", "oncotree_code": "WDLS", "therapy_name": "Palbociclib", "therapy_strategy": "CDK4/6 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "CDK4 amplification is characteristic of well-differentiated and dedifferentiated liposarcomas. Palbociclib shows activity in this context.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Soft Tissue Sarcoma NCCN Evidence Blocks (Version 1.2021). Accessed November 19th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/19/20", "feature_display": "CDK4 Amplification"}, "19": {"gene": "CDK4", "direction": "Amplification", "cytoband": NaN, "disease": "Dedifferentiated lipsarcoma", "context": NaN, "oncotree_term": "Dedifferentiated Lipsarcoma", "oncotree_code": "DDLS", "therapy_name": "Palbociclib", "therapy_strategy": "CDK4/6 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "CDK4 amplification is characteristic of well-differentiated and dedifferentiated liposarcomas. Palbociclib shows activity in this context.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Soft Tissue Sarcoma NCCN Evidence Blocks (Version 1.2021). Accessed November 19th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/19/20", "feature_display": "CDK4 Amplification"}, "20": {"gene": "CDK4", "direction": "Amplification", "cytoband": NaN, "disease": "Liposarcoma", "context": NaN, "oncotree_term": "Liposarcoma", "oncotree_code": "LIPO", "therapy_name": "Palbociclib", "therapy_strategy": "CDK4/6 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "Treatment with CDK4 inhibitor PD033299 showed favorable progression free survival for patients with CDK4 amplification.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Dickson, Mark A., et al. \"Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.\" Journal of clinical oncology 31.16 (2013): 2024-2028.", "url": "https://doi.org/10.1200/JCO.2012.46.5476", "doi": "10.1200/JCO.2012.46.5476", "pmid": "23569312", "nct": "NCT01209598", "last_updated": "1/29/19", "feature_display": "CDK4 Amplification"}, "21": {"gene": "CDK4", "direction": "Amplification", "cytoband": NaN, "disease": "Pancreatic Cancer", "context": NaN, "oncotree_term": "Pancreatic Adenocarcinoma", "oncotree_code": "PAAD", "therapy_name": "Palbociclib", "therapy_strategy": "CDK4/6 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "CDK4 amplification was observed in a study of 109 microdissected pancreatic adenocarcinoma tumors, and is predicted to have antitumor effects in response to palbociclib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.", "url": "https://doi.org/10.1038/ncomms7744", "doi": "10.1038/ncomms7744", "pmid": "25855536", "nct": NaN, "last_updated": "9/14/18", "feature_display": "CDK4 Amplification"}, "22": {"gene": "CDKN2A", "direction": "Deletion", "cytoband": NaN, "disease": NaN, "context": NaN, "oncotree_term": NaN, "oncotree_code": NaN, "therapy_name": "EPZ015666", "therapy_strategy": "PRMT5 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.", "url": "https://doi.org/10.1126/science.aad5214", "doi": "10.1126/science.aad5214", "pmid": "26912360", "nct": NaN, "last_updated": "2/4/19", "feature_display": "CDKN2A Deletion"}, "23": {"gene": "CDKN2A", "direction": "Deletion", "cytoband": NaN, "disease": "Pancreatic Cancer", "context": NaN, "oncotree_term": "Pancreatic Adenocarcinoma", "oncotree_code": "PAAD", "therapy_name": "Palbociclib", "therapy_strategy": "CDK4/6 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "CDKN2A loss was observed in a study of 109 microdissected pancreatic adenocarcinoma tumors, and is predicted to have antitumor effects in response to palbociclib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.", "url": "https://doi.org/10.1038/ncomms7744", "doi": "10.1038/ncomms7744", "pmid": "25855536", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CDKN2A Deletion"}, "24": {"gene": "CDKN2C", "direction": "Deletion", "cytoband": "1p32.3", "disease": "Multiple Myeloma", "context": NaN, "oncotree_term": "Multiple Myeloma", "oncotree_code": "MM", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "Either hemizygous or homozygous CDKN2C loss, identified by FISH, resulted in worse overall survival relative to wild type in a study of 515 multiple myeloma patients.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Leone, Paola E., et al. \"Deletions of CDKN2C in multiple myeloma: biological and clinical implications.\" Clinical Cancer Research 14.19 (2008): 6033-6041.", "url": "https://doi.org/10.1158/1078-0432.CCR-08-0347", "doi": "10.1158/1078-0432.CCR-08-0347", "pmid": "18829482", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CDKN2C Deletion"}, "25": {"gene": "CDKN2C", "direction": "Deletion", "cytoband": "1p", "disease": "Multiple Myeloma", "context": NaN, "oncotree_term": "Multiple Myeloma", "oncotree_code": "MM", "therapy_name": "Palbociclib", "therapy_strategy": "CDK4/6 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Palbociclib is predicted to have antitumor effects in multiple myeloma patients with del(1p) resulting in loss of CDKN2C.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100-113.", "url": "https://doi.org/10.1038/nrclinonc.2016.122", "doi": "10.1038/nrclinonc.2016.122", "pmid": "27531699", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CDKN2C Deletion"}, "26": {"gene": "CRKL", "direction": "Amplification", "cytoband": "22q11.21", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Gefitinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "CRKL amplification was observed in an EGFR inhibitor resistant tumor after researchers observed that cells from gefitinib-sensitive cell line (HCC827) overexpressing CRKL became resistant to gefitinib relative to controls.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Cheung HW, Du J, Boehm JS, et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011;1(7):608-25.", "url": "https://doi.org/10.1158/2159-8290.CD-11-0046", "doi": "10.1158/2159-8290.CD-11-0046", "pmid": "22586683", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CRKL Amplification"}, "27": {"gene": "EGFR", "direction": "Amplification", "cytoband": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Gefitinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Amplification and mutation of EGFR was associated with better clinical outcomes in a trial of 66 non-small cell lung cancer patients who had experienced relapse after surgery.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23(28):6829-37.", "url": "https://doi.org/10.1200/JCO.2005.01.0793", "doi": "10.1200/JCO.2005.01.0793", "pmid": "15998907", "nct": NaN, "last_updated": "11/3/17", "feature_display": "EGFR Amplification"}, "28": {"gene": "ERBB2", "direction": "Amplification", "cytoband": NaN, "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Lapatinib + Trastuzumab", "therapy_strategy": "ER signaling inhibition + EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "The combination of lapatinib with trastuzumab provided a statistically significant improvement in PFS compared with single-agent lapatinib when tested for erbb2 positive breast cancer patients, both primary and metastatic.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Blackwell, Kimberly L., et al. \"Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.\" Journal of Clinical Oncology 28.7 (2010): 1124-1130.", "url": "https://doi.org/10.1200/JCO.2008.21.4437", "doi": "10.1200/JCO.2008.21.4437", "pmid": "20124187", "nct": "NCT00320385", "last_updated": "11/3/17", "feature_display": "ERBB2 Amplification"}, "29": {"gene": "ERBB2", "direction": "Amplification", "cytoband": NaN, "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Ado-Trastuzumab Emtansine", "therapy_strategy": "ER signaling inhibition", "therapy_type": "Hormone therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "ERBB2 Amplification"}, "30": {"gene": "ERBB2", "direction": "Amplification", "cytoband": NaN, "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Lapatinib", "therapy_strategy": "ER signaling inhibition + EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "ERBB2 Amplification"}, "31": {"gene": "ERBB2", "direction": "Amplification", "cytoband": NaN, "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Lapatinib + Trastuzumab", "therapy_strategy": "ER signaling inhibition + EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "ERBB2 Amplification"}, "32": {"gene": "ERBB2", "direction": "Amplification", "cytoband": NaN, "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Neratinib", "therapy_strategy": "ER signaling inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Neratinib is indicated for extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "ERBB2 Amplification"}, "33": {"gene": "ERBB2", "direction": "Amplification", "cytoband": NaN, "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Pertuzumab + Trastuzumab", "therapy_strategy": "ER signaling inhibition", "therapy_type": "Combination therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "ERBB2 Amplification"}, "34": {"gene": "ERBB2", "direction": "Amplification", "cytoband": NaN, "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Trastuzumab", "therapy_strategy": "ER signaling inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Indicated for the adjuvant treatment of HER2-overexpressing breast cancer", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "ERBB2 Amplification"}, "35": {"gene": "ERBB2", "direction": "Amplification", "cytoband": NaN, "disease": "Esophagogastric Cancer", "context": "Metastatic, in combintation with cisplatin and capecitabine or 5-FU", "oncotree_term": "Gastric Adenocarcinoma", "oncotree_code": "STAD", "therapy_name": "Trastuzumab", "therapy_strategy": "ER signaling inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Trastuzumab, in combination with cisplatin and capecitabine or 5-fluorouracil, is indicated for the initial treatment of human epidermal growth factor receptor 2 (HER2) overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "ERBB2 Amplification"}, "36": {"gene": "ERBB2", "direction": "Amplification", "cytoband": NaN, "disease": "Esophagogastric Cancer", "context": "Metastatic", "oncotree_term": "GEJ Adenocarcinoma", "oncotree_code": "GEJ", "therapy_name": "Trastuzumab", "therapy_strategy": "ER signaling inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Trastuzumab, in combination with cisplatin and capecitabine or 5-fluorouracil, is indicated for the initial treatment of human epidermal growth factor receptor 2 (HER2) overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "ERBB2 Amplification"}, "37": {"gene": "ERBB2", "direction": "Amplification", "cytoband": NaN, "disease": "Gastric Cancer", "context": "Metastatic", "oncotree_term": "Gastric Remnant Adenocarcinoma", "oncotree_code": "GRC", "therapy_name": "Chemotherapy + Trastuzumab", "therapy_strategy": "Chemotherapy + ER signaling inhibition", "therapy_type": "Combination therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Patients with HER2 overexpression or amplification showed significant improvement in median overall survival with the addition of trastuzumab to chemotherapy compared to chemotherapy alone. This benefit is limited to patients with a tumor score of IHC 3 + or IHC 2 + and FISH positive.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Gastric Cancer NCCN Evidence Blocks (Version 3.2016). https://www.nccn.org/professionals/physician_gls/pdf/gastric_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/gastric_blocks.pdf", "doi": NaN, "pmid": "20728210", "nct": "NCT01041404", "last_updated": "11/3/17", "feature_display": "ERBB2 Amplification"}, "38": {"gene": "ERBB2", "direction": "Amplification", "cytoband": NaN, "disease": "Breast Cancer", "context": "Advanced unresectable or metastatic", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Capecitabine + Trastuzumab + Tucatinib", "therapy_strategy": "Thymidylate synthase inhibition + ER signaling inhibition", "therapy_type": "Combination therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Seattle Genetics, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf. Revised April 2020. Accessed October 15, 2020. ", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "ERBB2 Amplification"}, "39": {"gene": "ERBB2", "direction": "Amplification", "cytoband": NaN, "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Inferential", "description": "Overexpression and gene amplification of ErbB2 (HER2/neu) is an adverse prognostic indicator associated with aggressive histopathologic parameters and correlated with decreased disease-free survival and overall survival (OS) in breast cancer (BC).", "preferred_assertion": NaN, "source_type": "Journal", "citation": "F Revillion, J Bonneterre, JP Peyrat: ERBB2 oncogene in human breast cancer and its clinical significance Eur J Cancer 34: 791", "url": "https://doi.org/10.1016/S0959-8049(97)10157-5", "doi": "10.1016/S0959-8049(97)10157-5", "pmid": "9797688", "nct": NaN, "last_updated": "11/3/17", "feature_display": "ERBB2 Amplification"}, "40": {"gene": "ERBB2", "direction": "Amplification", "cytoband": NaN, "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Radiation therapy", "therapy_strategy": "Radiation", "therapy_type": "Radiation therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Breast cancer cells with HER2 amplification demonstrate radiation resistance, which can be reversed with trastuzumab.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Molecular cancer therapeutics. 2003; 2(11):1113-20. ", "url": "https://mct.aacrjournals.org/content/2/11/1113.long", "doi": NaN, "pmid": "14617784", "nct": NaN, "last_updated": "8/9/19", "feature_display": "ERBB2 Amplification"}, "41": {"gene": "ERBB2", "direction": "Amplification", "cytoband": NaN, "disease": "Breast Cancer", "context": "Locally advanced, inflammatory, or early stage", "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab", "therapy_strategy": "Chemotherapy + ER signaling inhibition", "therapy_type": "Combination therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "ERBB2 Amplification"}, "42": {"gene": "ERBB2", "direction": "Amplification", "cytoband": NaN, "disease": "Breast Cancer", "context": "Metastatic", "oncotree_term": "Metastatic Breast Cancer", "oncotree_code": "MBC", "therapy_name": "Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab", "therapy_strategy": "Taxane-based chemotherapy + ER signaling inhibition", "therapy_type": "Combination therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "ERBB2 Amplification"}, "43": {"gene": "ERBB2", "direction": "Amplification", "cytoband": NaN, "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Metastatic Breast Cancer", "oncotree_code": "MBC", "therapy_name": "Margetuximab-cmkb + Chemotherapy", "therapy_strategy": "ER signaling inhibition + Chemotherapy", "therapy_type": "Combination therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "2/2/21", "feature_display": "ERBB2 Amplification"}, "44": {"gene": "ESR1", "direction": "Amplification", "cytoband": NaN, "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "Ampifications of ESR1 was significantly associated with poor disease-free survival and overall survival in a study of 99 patients with ER-positive breast cancer tumors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Nielsen KV, Ejlertsen B, Muller S, et al. Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer. Breast Cancer Res Treat. 2011;127(2):345-55.", "url": "https://doi.org/10.1007/s10549-010-0984-y", "doi": "10.1007/s10549-010-0984-y", "pmid": "20556506", "nct": NaN, "last_updated": "11/3/17", "feature_display": "ESR1 Amplification"}, "45": {"gene": "FBXW7", "direction": "Deletion", "cytoband": NaN, "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Breast Invasive Ductal Carcinoma", "oncotree_code": "IDC", "therapy_name": "Sirolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.", "url": "https://doi.org/10.1126/science.1162981", "doi": "10.1126/science.1162981", "pmid": "18787170", "nct": NaN, "last_updated": "11/3/17", "feature_display": "FBXW7 Deletion"}, "46": {"gene": "FGFR1", "direction": "Amplification", "cytoband": NaN, "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Infigratinib", "therapy_strategy": "FGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.", "url": "https://doi.org/10.1158/2159-8290.CD-12-0210", "doi": "10.1158/2159-8290.CD-12-0210", "pmid": "23002168", "nct": NaN, "last_updated": "4/30/19", "feature_display": "FGFR1 Amplification"}, "47": {"gene": "FGFR1", "direction": "Amplification", "cytoband": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Infigratinib", "therapy_strategy": "FGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.", "url": "https://doi.org/10.1158/2159-8290.CD-12-0210", "doi": "10.1158/2159-8290.CD-12-0210", "pmid": "23002168", "nct": NaN, "last_updated": "4/30/19", "feature_display": "FGFR1 Amplification"}, "48": {"gene": "FGFR1", "direction": "Amplification", "cytoband": NaN, "disease": "Osteosarcoma", "context": NaN, "oncotree_term": "Osteosarcoma", "oncotree_code": "OS", "therapy_name": "Infigratinib", "therapy_strategy": "FGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.", "url": "https://doi.org/10.1158/2159-8290.CD-12-0210", "doi": "10.1158/2159-8290.CD-12-0210", "pmid": "23002168", "nct": NaN, "last_updated": "4/30/19", "feature_display": "FGFR1 Amplification"}, "49": {"gene": "FGFR1", "direction": "Amplification", "cytoband": NaN, "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Infigratinib", "therapy_strategy": "FGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.", "url": "https://doi.org/10.1158/2159-8290.CD-12-0210", "doi": "10.1158/2159-8290.CD-12-0210", "pmid": "23002168", "nct": NaN, "last_updated": "4/30/19", "feature_display": "FGFR1 Amplification"}, "50": {"gene": "FGFR2", "direction": "Amplification", "cytoband": NaN, "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Infigratinib", "therapy_strategy": "FGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.", "url": "https://doi.org/10.1158/2159-8290.CD-12-0210", "doi": "10.1158/2159-8290.CD-12-0210", "pmid": "23002168", "nct": NaN, "last_updated": "4/30/19", "feature_display": "FGFR2 Amplification"}, "51": {"gene": "FGFR2", "direction": "Amplification", "cytoband": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Infigratinib", "therapy_strategy": "FGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.", "url": "https://doi.org/10.1158/2159-8290.CD-12-0210", "doi": "10.1158/2159-8290.CD-12-0210", "pmid": "23002168", "nct": NaN, "last_updated": "4/30/19", "feature_display": "FGFR2 Amplification"}, "52": {"gene": "FGFR2", "direction": "Amplification", "cytoband": NaN, "disease": "Osteosarcoma", "context": NaN, "oncotree_term": "Osteosarcoma", "oncotree_code": "OS", "therapy_name": "Infigratinib", "therapy_strategy": "FGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.", "url": "https://doi.org/10.1158/2159-8290.CD-12-0210", "doi": "10.1158/2159-8290.CD-12-0210", "pmid": "23002168", "nct": NaN, "last_updated": "4/30/19", "feature_display": "FGFR2 Amplification"}, "53": {"gene": "FGFR2", "direction": "Amplification", "cytoband": NaN, "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Infigratinib", "therapy_strategy": "FGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.", "url": "https://doi.org/10.1158/2159-8290.CD-12-0210", "doi": "10.1158/2159-8290.CD-12-0210", "pmid": "23002168", "nct": NaN, "last_updated": "4/30/19", "feature_display": "FGFR2 Amplification"}, "54": {"gene": "HIF1a", "direction": "Amplification", "cytoband": NaN, "disease": "Bladder Cancer", "context": "Muscle-Invasive", "oncotree_term": "Bladder Urothelial Carcinoma", "oncotree_code": "BLCA", "therapy_name": "Carbogen and nicotinamide  + radiotherapy", "therapy_strategy": "Radiation", "therapy_type": "Radiation therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "In a retrospective study of 137 patients with high-grade invasive bladder cancer, patients with high HIF-1a expression had improved local relapse-free survival when receiving RT+CON compared with RT alone.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Hunter BA, Eustace A, Irlam JJ, et al. Expression of hypoxia-inducible factor-1_ predicts benefit from hypoxia modification in invasive bladder cancer Br J Cancer. 2014; 111(3):437-443.", "url": "https://10.1038/bjc.2014.315", "doi": "10.1038/bjc.2014.315", "pmid": "24937673", "nct": NaN, "last_updated": "8/9/19", "feature_display": "HIF1a Amplification"}, "55": {"gene": "KEAP1", "direction": "Deletion", "cytoband": NaN, "disease": "Squamous Cell Lung Cancer", "context": NaN, "oncotree_term": "Lung Squamous Cell Carcinoma", "oncotree_code": "LUSC", "therapy_name": "Radiation therapy", "therapy_strategy": "Radiation", "therapy_type": "Radiation therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "In a mouse model of lung scamous cell carcinoma, deletion of KEAP1 promoted tumor aggressiveness, metastasis, and resistance to oxidative stress and radiotherapy (RT). KEAP1 / NRF2 mutation status predicted risk of local recurrence after RT in patients with non-small lung cancer (NSCLC).", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Jeong Y, Hoang NT, Lovejoy A, et al. Role of / and Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance Cancer Discov. 2017; 7(1):86-101.", "url": "https://doi.org/10.1158/2159-8290.cd-16-0127", "doi": "10.1158/2159-8290.cd-16-0127", "pmid": "27663899", "nct": NaN, "last_updated": "4/30/19", "feature_display": "KEAP1 Deletion"}, "56": {"gene": "KIT", "direction": "Amplification", "cytoband": NaN, "disease": "Melanoma", "context": NaN, "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Imatinib", "therapy_strategy": "KIT inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "0", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "KIT amplifications appear to have minimal or no sensitivity to KIT inhibitors.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Cutaneous Melanoma NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf. Accessed August 12, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/12/19", "feature_display": "KIT Amplification"}, "57": {"gene": "MDM2", "direction": "Amplification", "cytoband": NaN, "disease": "Gastric Cancer", "context": "Metastatic", "oncotree_term": "Gastric Remnant Adenocarcinoma", "oncotree_code": "GRC", "therapy_name": "nutlin-3", "therapy_strategy": "MDM2-p53 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Presence of amplified MDM2 may suggest sensitivity to nutlin-3 in the absense of mutant TP53.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Endo S, Yamato K, Hirai S, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci. 2011;102(3):605-13.", "url": "https://doi.org/10.1111/j.1349-7006.2010.01821.x", "doi": "10.1111/j.1349-7006.2010.01821.x", "pmid": "21205074", "nct": NaN, "last_updated": "11/3/17", "feature_display": "MDM2 Amplification"}, "58": {"gene": "MET", "direction": "Amplification", "cytoband": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Crizotinib", "therapy_strategy": "MET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Crizotinib is an available targeted agent with activity against MET amplifications in metastatic, NSCLC.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/12/19", "feature_display": "MET Amplification"}, "59": {"gene": "MET", "direction": "Amplification", "cytoband": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Gefitinib", "therapy_strategy": "EGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Amplification of alternative kinases, such as MET, may suggest resistance to EGFR TKIs.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "MET Amplification"}, "60": {"gene": "MET", "direction": "Amplification", "cytoband": NaN, "disease": "Renal clear cell carcinoma", "context": NaN, "oncotree_term": "Renal Clear Cell Carcinoma", "oncotree_code": "RCC", "therapy_name": "Cabozantinib", "therapy_strategy": "RET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "0", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Results from the METEOR trial (n=658) suggest that the MET expression level might not affect treatment outcomes with cabozantinib in this patient population.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1814-23.", "url": "https://doi.org/10.1056/NEJMoa1510016", "doi": "10.1056/NEJMoa1510016", "pmid": "26406150", "nct": "NCT01865747", "last_updated": "8/12/19", "feature_display": "MET Amplification"}, "61": {"gene": "MET", "direction": "Amplification", "cytoband": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Crizotinib", "therapy_strategy": "MET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "A phase I trial of crizotinib in 40 patients with MET amplified advanced NSCLC showed a 33% response rate.", "preferred_assertion": NaN, "source_type": "Abstract", "citation": "Camidge DR, Otterson GA, Clark JW, et al. Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial. JCO. 2018; 36(15_suppl):9062-9062.", "url": "https://doi.org/10.1200/JCO.2018.36.15_suppl.9062 ", "doi": "10.1200/JCO.2018.36.15_suppl.9062 ", "pmid": NaN, "nct": "NCT00585195", "last_updated": "4/16/19", "feature_display": "MET Amplification"}, "62": {"gene": "MIR17HG", "direction": "Amplification", "cytoband": NaN, "disease": "Rectal Cancer", "context": NaN, "oncotree_term": "Rectal Adenocarcinoma", "oncotree_code": "READ", "therapy_name": "Neoadjuvant chemotherapy + surgery", "therapy_strategy": "Chemotherapy + Surgical removal", "therapy_type": "Combination therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Amplification of the 13q31-34 region, which contains MIR17HG, was associated with increased sensitivity to neoadjuvant chemotherapy and surgery in 41% of participants in a 120-patient study.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Molinari C, Salvi S, Foca F, et al. miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. Onco Targets Ther. 2016;9:2735-42.", "url": "https://doi.org/10.2147/OTT.S105760", "doi": "10.2147/OTT.S105760", "pmid": "27226732", "nct": NaN, "last_updated": "11/3/17", "feature_display": "MIR17HG Amplification"}, "63": {"gene": "MIR17HG", "direction": "Deletion", "cytoband": NaN, "disease": "Rectal Cancer", "context": NaN, "oncotree_term": "Rectal Adenocarcinoma", "oncotree_code": "READ", "therapy_name": "Neoadjuvant chemotherapy + surgery", "therapy_strategy": "Chemotherapy + Surgical removal", "therapy_type": "Combination therapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Deletion of the 13q31-34 region, which contains MIR17HG, was associated with resistance to neoadjuvant chemotherapy and surgery in 41% of participants in a 120-patient study.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Molinari C, Salvi S, Foca F, et al. miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. Onco Targets Ther. 2016;9:2735-42.", "url": "https://doi.org/10.2147/OTT.S105760", "doi": "10.2147/OTT.S105760", "pmid": "27226732", "nct": NaN, "last_updated": "11/3/17", "feature_display": "MIR17HG Deletion"}, "64": {"gene": "MRE11", "direction": "Amplification", "cytoband": NaN, "disease": "Bladder Cancer", "context": "Muscle-Invasive", "oncotree_term": "Bladder Urothelial Carcinoma", "oncotree_code": "BLCA", "therapy_name": "Radical radiotherapy", "therapy_strategy": "Radiation", "therapy_type": "Radiation therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "In a cohort of 86 patients with muscle-invasive bladder cancer, high MRE11 expression as assessed by IHC was associated with improved cancer-specific survival when treated with radical radiotherapy compared to low MRE11 expression as well as high-expression MRE11 treated with cystectomy.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Choudhury A, Nelson LD, Teo MTW, et al. MRE11 Expression Is Predictive of Cause-Specific Survival following Radical Radiotherapy for Muscle-Invasive Bladder Cancer Cancer Research. 2010; 70(18):7017-7026.", "url": "https://doi.org/10.1158/0008-5472.CAN-10-1202", "doi": "10.1158/0008-5472.CAN-10-1202", "pmid": "20843819", "nct": NaN, "last_updated": "8/8/19", "feature_display": "MRE11 Amplification"}, "65": {"gene": "MYC", "direction": "Amplification", "cytoband": NaN, "disease": "Medulloblastoma", "context": "Metastatic", "oncotree_term": "Medulloblastoma", "oncotree_code": "MBL", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13.", "url": "https://doi.org/10.1007/s00401-011-0923-y", "doi": "10.1007/s00401-011-0923-y", "pmid": "22139329", "nct": NaN, "last_updated": "1/29/19", "feature_display": "MYC Amplification"}, "66": {"gene": "MYC", "direction": "Amplification", "cytoband": "8q24", "disease": "Pancreatic Cancer", "context": NaN, "oncotree_term": "Pancreatic Adenocarcinoma", "oncotree_code": "PAAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "Amplification of 8q24 (which includes the MYC oncogene) was associated with poor outcomes in a study of 109 microdissected pancreatic adenocarcinoma tumors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.", "url": "https://doi.org/10.1038/ncomms7744", "doi": "10.1038/ncomms7744", "pmid": "25855536", "nct": NaN, "last_updated": "4/30/19", "feature_display": "MYC Amplification"}, "67": {"gene": "PAK1", "direction": "Amplification", "cytoband": "11p13", "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "PAK1 amplification showed reduced recurrence-free survival and decreased benefit from Tamoxifen in a randomized control trial of postmenopausal breast cancer patients.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Bostner, Josefine, et al. \"Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.\" Oncogene 26.49 (2007): 6997-7005.", "url": "https://doi.org/10.1038/sj.onc.1210506", "doi": "10.1038/sj.onc.1210506", "pmid": "7486065", "nct": NaN, "last_updated": "1/29/19", "feature_display": "PAK1 Amplification"}, "68": {"gene": "PAK1", "direction": "Amplification", "cytoband": "11p13", "disease": "Breast Cancer", "context": NaN, "oncotree_term": "Invasive Breast Carcinoma", "oncotree_code": "BRCA", "therapy_name": "Tamoxifen", "therapy_strategy": "ER signaling inhibition", "therapy_type": "Hormone therapy", "therapy_sensitivity": "0", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "PAK1 amplification showed reduced recurrence-free survival and decreased benefit from Tamoxifen in a randomized control trial of postmenopausal breast cancer patients.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Bostner, Josefine, et al. \"Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.\" Oncogene 26.49 (2007): 6997-7005.", "url": "https://doi.org/10.1038/sj.onc.1210506", "doi": "10.1038/sj.onc.1210506", "pmid": "7486065", "nct": NaN, "last_updated": "1/29/19", "feature_display": "PAK1 Amplification"}, "69": {"gene": "PBRM1", "direction": "Deletion", "cytoband": NaN, "disease": "Renal clear cell carcinoma", "context": "Metastatic", "oncotree_term": "Renal Clear Cell Carcinoma", "oncotree_code": "CCRCC", "therapy_name": "Nivolumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.", "url": "https://doi.org/10.1126/science.aan5951", "doi": "10.1126/science.aan5951", "pmid": "29301960", "nct": NaN, "last_updated": "11/29/18", "feature_display": "PBRM1 Deletion"}, "70": {"gene": "PIK3CA", "direction": "Amplification", "cytoband": NaN, "disease": "Ovarian Cancer", "context": NaN, "oncotree_term": "Ovarian Cancer, Other", "oncotree_code": "OOVC", "therapy_name": "Pictilisib", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "A heavily-pretreated, platinum-refractory ovarian cancer patient with PIK3CA amplification achieved radiologically stable disease for four months in a phase 1 clinical trial of pictisilib in solid tumors (RP2D of 330mg daily).", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Sarker D, Ang JE, Baird R, et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21(1):77-86.", "url": "https://doi.org/10.1158/1078-0432.CCR-14-0947", "doi": "10.1158/1078-0432.CCR-14-0947", "pmid": "25370471", "nct": "NCT00876122", "last_updated": "1/29/19", "feature_display": "PIK3CA Amplification"}, "71": {"gene": "PTEN", "direction": "Deletion", "cytoband": NaN, "disease": NaN, "context": "Metastatic", "oncotree_term": NaN, "oncotree_code": NaN, "therapy_name": "AZD8186", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "PTEN loss of function may confer sensitivity to selective PI3K inhibition", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.", "url": "https://doi.org/10.1021/jm501629p", "doi": "10.1021/jm501629p", "pmid": "25514658", "nct": NaN, "last_updated": "3/16/17", "feature_display": "PTEN Deletion"}, "72": {"gene": "PTEN", "direction": "Deletion", "cytoband": NaN, "disease": "Uterine Leiomyoma", "context": NaN, "oncotree_term": "Uterine Leiomyoma", "oncotree_code": "ULM", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "PTEN loss may predict resistance to immune checkpoint blockade", "preferred_assertion": NaN, "source_type": "Journal", "citation": "George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.", "url": "https://doi.org/10.1016/j.immuni.2017.02.001", "doi": "10.1016/j.immuni.2017.02.001", "pmid": "28228279", "nct": NaN, "last_updated": "3/7/19", "feature_display": "PTEN Deletion"}, "73": {"gene": "PTEN", "direction": "Deletion", "cytoband": NaN, "disease": "Pancreatic Cancer", "context": NaN, "oncotree_term": "Pancreatic Adenocarcinoma", "oncotree_code": "PAAD", "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "PTEN loss in the setting of KRAS G12D mutation was associated with an increased sensitivity to mTOR inhibition in a mouse model.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Morran DC, Wu J, Jamieson NB, et al. Targeting mTOR dependency in pancreatic cancer. Gut. 2014;63(9):1481-9.", "url": "https://doi.org/10.1136/gutjnl-2013-306202", "doi": "10.1136/gutjnl-2013-306202", "pmid": "24717934", "nct": NaN, "last_updated": "3/7/19", "feature_display": "PTEN Deletion"}, "74": {"gene": "PTEN", "direction": "Deletion", "cytoband": NaN, "disease": "Uterine Leiomyoma", "context": NaN, "oncotree_term": "Uterine Leiomyoma", "oncotree_code": "ULM", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "PTEN loss may predict resistance to immune checkpoint blockade", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Peng W, Chen JQ, Liu C, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016;6(2):202-16.", "url": "https://doi.org/10.1158/2159-8290.CD-15-0283", "doi": "10.1158/2159-8290.CD-15-0283", "pmid": "26645196", "nct": NaN, "last_updated": "3/7/19", "feature_display": "PTEN Deletion"}, "75": {"gene": "PTEN", "direction": "Deletion", "cytoband": NaN, "disease": "Uterine Leiomyoma", "context": NaN, "oncotree_term": "Uterine Leiomyoma", "oncotree_code": "ULM", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "PTEN loss may predict resistance to immune checkpoint blockade", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Peng W, Chen JQ, Liu C, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016;6(2):202-16.", "url": "https://doi.org/10.1158/2159-8290.CD-15-0283", "doi": "10.1158/2159-8290.CD-15-0283", "pmid": "26645196", "nct": NaN, "last_updated": "3/7/19", "feature_display": "PTEN Deletion"}, "76": {"gene": "PTEN", "direction": "Deletion", "cytoband": NaN, "disease": "Renal clear cell carcinoma", "context": "Advanced", "oncotree_term": "Renal Clear Cell Carcinoma", "oncotree_code": "RCC", "therapy_name": "Everolimus", "therapy_strategy": "PI3K/AKT/mTOR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "In a study of everolimus-treated patients with RCC from a phase 2 randomized trial, everolimus treated patients with retained (n=50) versus lost (n=50) PTEN IHC expression had median PFS 5.3 months versus 10.5 months (HR, 2.5; P < 0.001). Such differences were not seen with sunitinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Voss MH, Chen D, Reising A, et al. PTEN Expression, Not Mutation Status in, or, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial. Clin Cancer Res. 2019;25(2):506-514.", "url": "https://doi.org/10.1158/1078-0432.CCR-18-1833", "doi": "10.1158/1078-0432.CCR-18-1833", "pmid": "30327302", "nct": "NCT00903175 ", "last_updated": "8/12/19", "feature_display": "PTEN Deletion"}, "77": {"gene": "PTEN", "direction": "Deletion", "cytoband": NaN, "disease": "Renal clear cell carcinoma", "context": "Advanced", "oncotree_term": "Renal Clear Cell Carcinoma", "oncotree_code": "RCC", "therapy_name": "Sunitinib", "therapy_strategy": "VEGF/VEGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "0", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "In a study of everolimus-treated patients with RCC from a phase 2 randomized trial, everolimus treated patients with retained (n=50) versus lost (n=50) PTEN IHC expression had median PFS 5.3 months versus 10.5 months (HR, 2.5; P < 0.001). Such differences were not seen with sunitinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Voss MH, Chen D, Reising A, et al. PTEN Expression, Not Mutation Status in, or, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial. Clin Cancer Res. 2019;25(2):506-514.", "url": "https://doi.org/10.1158/1078-0432.CCR-18-1833", "doi": "10.1158/1078-0432.CCR-18-1833", "pmid": "30327302", "nct": "NCT00903175 ", "last_updated": "8/12/19", "feature_display": "PTEN Deletion"}, "78": {"gene": "RB1", "direction": "Deletion", "cytoband": "13", "disease": "Multiple Myeloma", "context": NaN, "oncotree_term": "Multiple Myeloma", "oncotree_code": "MM", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Deletion of chromosome 13 seems to have an amplifying effect on cell cycle gene expression and is reported to be associated with short event-free survival (EFS) and overall survival (OS). This copy loss event results in haploinsufficiency of RB1 and other genes mapped to chromosome 13.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf", "doi": NaN, "pmid": "12531801", "nct": NaN, "last_updated": "11/3/17", "feature_display": "RB1 Deletion"}, "79": {"gene": "TP53", "direction": "Deletion", "cytoband": "17p13", "disease": "Multiple Myeloma", "context": NaN, "oncotree_term": "Multiple Myeloma", "oncotree_code": "MM", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "Deletion of 17p13 leads to LoH of TP53 and is considered a high-risk feature of multiple myeloma.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "TP53 Deletion"}, "80": {"gene": "TPX2", "direction": "Amplification", "cytoband": "20q11", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Preclinical", "description": "Downmodulation of TPX2 and AURKA in the presence of 20q copy gain was shown to tumor growth", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Sillars-Hardebol, Anke H., et al. \"TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression.\" Gut 61.11 (2012): 1568-1575.", "url": "https://doi.org/10.1136/gutjnl-2011-301153", "doi": "10.1136/gutjnl-2011-301153", "pmid": "22207630", "nct": NaN, "last_updated": "11/3/17", "feature_display": "TPX2 Amplification"}}, "Rearrangement": {"1": {"gene1": "BCR", "gene2": "ABL1", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Chronic Myelogenous Leukemia", "context": "Chronic, accelerated, or blast phase", "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Bosutinib", "therapy_strategy": "targets BCR-ABL", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for adult patients with chronic, accelerated, or blast phase Philidelphia chromosome-positive (Ph+) CML with resistance or intolernace to prior therapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203441s018lbl.pdf. Revised June 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203441s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BCR--ABL1 Fusion"}, "2": {"gene1": "BCR", "gene2": "ABL1", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Chronic Myelogenous Leukemia", "context": "Chronic phase", "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Dasatinib", "therapy_strategy": "targets BCR-ABL", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for dasatinib for newly diagnosed patients with Philidelphia chromosome-positive (Ph+) CML in chronic phase. It is also approved for adults with chronic, accelerated, myeloid, or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf. Revised December 2018. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BCR--ABL1 Fusion"}, "3": {"gene1": "BCR", "gene2": "ABL1", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Acute Lymphoblastic Leukemia", "context": NaN, "oncotree_term": "Acute Lymphoid Leukemia", "oncotree_code": "ALL", "therapy_name": "Dasatinib", "therapy_strategy": "targets BCR-ABL", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for dasatinib for adults with Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf. Revised December 2018. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BCR--ABL1 Fusion"}, "4": {"gene1": "BCR", "gene2": "ABL1", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Chronic Myelogenous Leukemia", "context": "Chronic phase", "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Imatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for imatinib for newly diagnosed adult and pediatric patients with Philidelphia chromosome-positive (Ph+) CML in chronic phase. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BCR--ABL1 Fusion"}, "5": {"gene1": "BCR", "gene2": "ABL1", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Acute Lymphoblastic Leukemia", "context": "Relapsed or refactory", "oncotree_term": "Acute Lymphoid Leukemia", "oncotree_code": "ALL", "therapy_name": "Imatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "BCR--ABL1 Fusion"}, "6": {"gene1": "BCR", "gene2": "ABL1", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Chronic Myeloid Leukemia", "context": "Chronic Phase CML", "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Dasatinib", "therapy_strategy": "targets BCR-ABL", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "SPRYCEL (dasatinib) is indicated for the treatment of adult patients with: newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase; chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib; Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. SPRYCEL (dasatinib) is indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase, newly diagnosed Ph+ ALL in combination with chemotherapy. Translocations predict sensitivity to tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib. Secondary mutations can cause resistance to these agents. Nilotinib or Bosutinib are second-line and subsequent therapies for cytogenetic or hematologic resistance to TKIs.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myelogenous Leukemia (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "1/30/19", "feature_display": "BCR--ABL1 Fusion"}, "7": {"gene1": "BCR", "gene2": "ABL1", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Acute Lymphoblastic Leukemia", "context": "Resistance or intolerance to prior therapy", "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Dasatinib", "therapy_strategy": "targets BCR-ABL", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "SPRYCEL (dasatinib) is indicated for the treatment of adult patients with: newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase; chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib; Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. SPRYCEL (dasatinib) is indicated for the treatment of pediatric patients 1 year of age and older with Ph+ CML in chronic phase, newly diagnosed Ph+ ALL in combination with chemotherapy. Translocations predict sensitivity to tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib. Secondary mutations can cause resistance to these agents. Nilotinib or Bosutinib are second-line and subsequent therapies for cytogenetic or hematologic resistance to TKIs.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myelogenous Leukemia (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "1/30/19", "feature_display": "BCR--ABL1 Fusion"}, "8": {"gene1": "BCR", "gene2": "ABL1", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Chronic Myeloid Leukemia", "context": "Chronic Phase CML", "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Imatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Translocations predict sensitivity to tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib. Secondary mutations can cause resistance to these agents. Dasatinib, Nilotinib, or Bosutinib are second-line and subsequent therapies for cytogenetic or hematologic resistance to TKIs.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myelogenous Leukemia (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "BCR--ABL1 Fusion"}, "9": {"gene1": "BCR", "gene2": "ABL1", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Chronic Myeloid Leukemia", "context": "Chronic Phase CML", "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Nilotinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Translocations predict sensitivity to tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib. Secondary mutations can cause resistance to these agents. Dasatinib or Bosutinib are second-line and subsequent therapies for cytogenetic or hematologic resistance to TKIs.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Chronic Myelogenous Leukemia (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "BCR--ABL1 Fusion"}, "10": {"gene1": "BCR", "gene2": "ABL1", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Chronic Myeloid Leukemia", "context": "Newly diagnosed chronic phase CML", "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Nilotinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "Nilotinib was superior to imatinib in patients (n=846) with newly diagnosed chronic-phase Ph+ CML.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Saglio G, Kim D, Issaragrisil S, et al. Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia N Engl J Med. 2010; 362(24):2251-2259.", "url": "https://doi.org/10.1056/NEJMoa0912614", "doi": "10.1056/NEJMoa0912614", "pmid": "20525993", "nct": "NCT00471497", "last_updated": "8/14/19", "feature_display": "BCR--ABL1 Fusion"}, "11": {"gene1": "ALK", "gene2": NaN, "rearrangement_type": "Fusion", "locus": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Alectinib", "therapy_strategy": "ALK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT02075840", "last_updated": "11/12/20", "feature_display": "ALK Fusion"}, "12": {"gene1": "ALK", "gene2": NaN, "rearrangement_type": "Fusion", "locus": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Crizotinib", "therapy_strategy": "MET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202570s028lbl.pdf. Revised June 2016. Accessed November 12, 2020. ", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202570s028lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "ALK Fusion"}, "13": {"gene1": "ALK", "gene2": NaN, "rearrangement_type": "Fusion", "locus": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Lorlatinib", "therapy_strategy": "ALK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "ALK Fusion"}, "14": {"gene1": "ALK", "gene2": NaN, "rearrangement_type": NaN, "locus": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Ceritinib", "therapy_strategy": "ALK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "ALK"}, "15": {"gene1": "ALK", "gene2": NaN, "rearrangement_type": "Fusion", "locus": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Alectinib", "therapy_strategy": "ALK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "ALK rearrangement may suggest sensitivity to Alectinib as a first or subsequent line of therapy. See NCCN guidelines (NSCL-21) for more details.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 3.2019). Accessed March 7th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "3/7/19", "feature_display": "ALK Fusion"}, "16": {"gene1": "ALK", "gene2": NaN, "rearrangement_type": NaN, "locus": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Advanced", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Ceritinib", "therapy_strategy": "ALK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "Ceritinib was highly active in patients with advanced, ALK-rearranged NSCLC, including those who had had disease progression during crizotinib treatment, regardless of the presence of resistance mutations in ALK. ", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370(13):1189-97.", "url": "https://doi.org/10.1056/NEJMoa1311107", "doi": "10.1056/NEJMoa1311107", "pmid": "24670165", "nct": "NCT01283516", "last_updated": "8/10/19", "feature_display": "ALK"}, "17": {"gene1": "ALK", "gene2": NaN, "rearrangement_type": "Translocation", "locus": NaN, "disease": "Inflammatory Myofibroblastic Tumor (IMT)", "context": NaN, "oncotree_term": "Inflammatory Myofibroblastic Tumor", "oncotree_code": "IMT", "therapy_name": "Crizotinib", "therapy_strategy": "MET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Crizotinib has shown efficacy in inflammatory myofibroblastic tumors (IMT) with ALK translocations.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Soft Tissue Sarcoma NCCN Evidence Blocks (Version 2.2019). Accessed August 10th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/10/19", "feature_display": "ALK Translocation"}, "18": {"gene1": "ALK", "gene2": NaN, "rearrangement_type": "Translocation", "locus": NaN, "disease": "Inflammatory Myofibroblastic Tumor (IMT)", "context": NaN, "oncotree_term": "Inflammatory Myofibroblastic Tumor", "oncotree_code": "IMT", "therapy_name": "Ceritinib", "therapy_strategy": "ALK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Crizotinib has shown efficacy in inflammatory myofibroblastic tumors (IMT) with ALK translocations.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Soft Tissue Sarcoma NCCN Evidence Blocks (Version 2.2019). Accessed August 10th, 2019.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/10/19", "feature_display": "ALK Translocation"}, "19": {"gene1": "ALK", "gene2": NaN, "rearrangement_type": "Translocation", "locus": NaN, "disease": "Inflammatory Myofibroblastic Tumor (IMT)", "context": NaN, "oncotree_term": "Inflammatory Myofibroblastic Tumor", "oncotree_code": "IMT", "therapy_name": "Crizotinib", "therapy_strategy": "MET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "A sustained partial response is observed ot the ALK inhibitor crizotinib in a patient with ALK-translocated IMT, as compared with no observed activity in another patient without the ALK translocation.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Butrynski JE, D'adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010;363(18):1727-33.", "url": "https://doi.org/10.1056/NEJMoa1007056", "doi": "10.1056/NEJMoa1007056", "pmid": "20979472", "nct": "NCT00585195 ", "last_updated": "8/10/19", "feature_display": "ALK Translocation"}, "20": {"gene1": "BRD4", "gene2": NaN, "rearrangement_type": "Translocation", "locus": "t(15;19)", "disease": "Squamous Cell Carcinoma", "context": NaN, "oncotree_term": "Squamous Cell Carcinoma, NOS", "oncotree_code": "SCCNOS", "therapy_name": "JQ1", "therapy_strategy": "BET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "BET inhibition was found to have an antitumor effect in a murine model of squamous cell carcinoma.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067-73.", "url": "https://doi.org/10.1038/nature09504", "doi": "10.1038/nature09504", "pmid": "20871596", "nct": NaN, "last_updated": "9/14/18", "feature_display": "BRD4 Translocation"}, "21": {"gene1": "CCND1", "gene2": NaN, "rearrangement_type": "Translocation", "locus": "t(11;14)", "disease": "Multiple Myeloma", "context": NaN, "oncotree_term": "Multiple Myeloma", "oncotree_code": "MM", "therapy_name": "Palbociclib", "therapy_strategy": "CDK4/6 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Palbociclib is predicted to have antitumor effects in multiple myeloma patients with t(11;14) resulting in CCND1 overexpression.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100-113.", "url": "https://doi.org/10.1038/nrclinonc.2016.122", "doi": "10.1038/nrclinonc.2016.122", "pmid": "27531699", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CCND1 Translocation"}, "22": {"gene1": "CCND1", "gene2": NaN, "rearrangement_type": "Translocation", "locus": "t(11;14)", "disease": "Multiple Myeloma", "context": NaN, "oncotree_term": "Multiple Myeloma", "oncotree_code": "MM", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "In a meta-analysis of 1,661 patients, the t(11;14) translocation accompanied by CCND1 mutation was found to be associated with poor prognosis.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Weinhold N, Johnson DC, Chubb D, et al. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet. 2013;45(5):522-5.", "url": "https://doi.org/10.1038/ng.2583", "doi": "10.1038/ng.2583", "pmid": "23502783", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CCND1 Translocation"}, "23": {"gene1": "CCND3", "gene2": NaN, "rearrangement_type": "Translocation", "locus": "t(6;14)", "disease": "Multiple Myeloma", "context": NaN, "oncotree_term": "Multiple Myeloma", "oncotree_code": "MM", "therapy_name": "Palbociclib", "therapy_strategy": "CDK4/6 inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Palbociclib is predicted to have antitumor effects in multiple myeloma patients with t(6;14) resulting in CCND3 overexpression.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100-113.", "url": "https://doi.org/10.1038/nrclinonc.2016.122", "doi": "10.1038/nrclinonc.2016.122", "pmid": "27531699", "nct": NaN, "last_updated": "11/3/17", "feature_display": "CCND3 Translocation"}, "24": {"gene1": "COL1A1", "gene2": "PDGFB", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Dermatofibrosarcoma", "context": NaN, "oncotree_term": "Dermatofibrosarcoma Protuberans", "oncotree_code": "DFSP", "therapy_name": "Imatinib", "therapy_strategy": "PDGF-R inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Imatinib has shown clinical activity against localized and metastatic DFSP tumors containing t(17;22)(q22;q13).", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Dermatofibrosarcoma NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "COL1A1--PDGFB Fusion"}, "25": {"gene1": "EML4", "gene2": "ALK", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Intracranial metastases", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Gamma knife", "therapy_strategy": "Radiation", "therapy_type": "Radiation therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "In a retrospective study of patients with NSCLC, tumors with EGFR mutations or EML4-ALK locations had improved in-field local control of brain metastases treated with gamma knife.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Johung, Kimberly L. A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non-small cell lung cancer. Clin Cancer Res. 2013 Oct 1;19(19):5523-32.", "url": "https://clincancerres.aacrjournals.org/content/19/19/5523.long", "doi": "10.1158/1078-0432.CCR-13-0836", "pmid": "23897899", "nct": NaN, "last_updated": "8/9/19", "feature_display": "EML4--ALK Fusion"}, "26": {"gene1": "EML4", "gene2": "ALK", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Crizotinib", "therapy_strategy": "MET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "ALK rearrangement, notably with EML4, may suggest sensitivity to Crizotinib as a first or subsequent line of therapy. See NCCN guidelines for more details in the case of resistance to Crizotinib in the presence of ALK rearrangement.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "EML4--ALK Fusion"}, "27": {"gene1": "ESRP1", "gene2": "RAF1", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Prostate Cancer", "context": NaN, "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Sorafenib", "therapy_strategy": "RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Rearrangements in BRAF are rare but may result in dependencies that can be targeted with RAF and MAP2K1 inhibitors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Palanisamy N, Ateeq B, Kalyana-sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010;16(7):793-8.", "url": "https://doi.org/10.1038/nm.2166", "doi": "10.1038/nm.2166", "pmid": "20526349", "nct": NaN, "last_updated": "3/7/19", "feature_display": "ESRP1--RAF1 Fusion"}, "28": {"gene1": "ESRP1", "gene2": "RAF1", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Prostate Cancer", "context": NaN, "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "U0126", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Rearrangements in BRAF are rare but may result in dependencies that can be targeted with RAF and MAP2K1 inhibitors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Palanisamy N, Ateeq B, Kalyana-sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010;16(7):793-8.", "url": "https://doi.org/10.1038/nm.2166", "doi": "10.1038/nm.2166", "pmid": "20526349", "nct": NaN, "last_updated": "3/7/19", "feature_display": "ESRP1--RAF1 Fusion"}, "29": {"gene1": "EWSR1", "gene2": "FLI1", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Ewing's Sarcoma", "context": NaN, "oncotree_term": "Ewing Sarcoma", "oncotree_code": "ES", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": "EWS-FLI1 translocations may be associated with improved prognosis in Ewing's Sarcoma; however, current treatments result in patient outcomes indistinguishable by EWS-FLI1 status.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Bone Cancer (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf. Accessed November 6, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/bone.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "EWSR1--FLI1 Fusion"}, "30": {"gene1": "FGFR2", "gene2": "TACC3", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Cholangiocarcinoma", "context": NaN, "oncotree_term": "Cholangiocarcinoma", "oncotree_code": "CHOL", "therapy_name": "Ponatinib", "therapy_strategy": "BCR-ABL inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "After progressing on previous treatments, a patient with a FGFR2-TACC3 fusion obtained stable disease after being treated with ponatinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.", "url": "https://doi.org/10.1371/journal.pgen.1004135", "doi": "10.1371/journal.pgen.1004135", "pmid": "24550739", "nct": NaN, "last_updated": "11/3/17", "feature_display": "FGFR2--TACC3 Fusion"}, "31": {"gene1": "FGFR2", "gene2": NaN, "rearrangement_type": "Fusion", "locus": NaN, "disease": "Urothelial carcinoma", "context": "Locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy.", "oncotree_term": "Bladder Urothelial Carcinoma", "oncotree_code": "BLCA", "therapy_name": "Erdafitinib", "therapy_strategy": "FGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "FGFR2 Fusion"}, "32": {"gene1": "FGFR2", "gene2": NaN, "rearrangement_type": "Fusion", "locus": NaN, "disease": "Cholangiocarcinoma", "context": NaN, "oncotree_term": "Cholangiocarcinoma", "oncotree_code": "CHOL", "therapy_name": "Pemigatinib", "therapy_strategy": "FGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresctable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf. Revised April 2020. Accessed October 15, 2020. ", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "FGFR2 Fusion"}, "33": {"gene1": "FGFR2", "gene2": NaN, "rearrangement_type": NaN, "locus": NaN, "disease": "Cholangiocarcinoma", "context": NaN, "oncotree_term": "Cholangiocarcinoma", "oncotree_code": "CHOL", "therapy_name": "Pemigatinib", "therapy_strategy": "FGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresctable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf. Revised April 2020. Accessed October 15, 2020. ", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/15/20", "feature_display": "FGFR2"}, "34": {"gene1": "FGFR3", "gene2": NaN, "rearrangement_type": "Fusion", "locus": NaN, "disease": "Urothelial carcinoma", "context": "Locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy.", "oncotree_term": "Bladder Urothelial Carcinoma", "oncotree_code": "BLCA", "therapy_name": "Erdafitinib", "therapy_strategy": "FGFR inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "FGFR3 Fusion"}, "35": {"gene1": "FGFR3", "gene2": "NSD2", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Multiple Myeloma", "context": NaN, "oncotree_term": "Multiple Myeloma", "oncotree_code": "MM", "therapy_name": "Bortezomib", "therapy_strategy": "Proteasome inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "The combination of bortezomib with tandem transplant therapy was associated with increased event-free survival and complete remission duration in multiple myeloma patients.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Pineda-roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol. 2008;140(6):625-34.", "url": "https://doi.org/10.1111/j.1365-2141.2007.06921.x", "doi": "10.1111/j.1365-2141.2007.06921.x", "pmid": "18302711", "nct": NaN, "last_updated": "11/3/17", "feature_display": "FGFR3--NSD2 Fusion"}, "36": {"gene1": "IGH", "gene2": NaN, "rearrangement_type": "Translocation", "locus": "t(11;14)(q13;q32)", "disease": "Multiple Myeloma", "context": NaN, "oncotree_term": "Multiple Myeloma", "oncotree_code": "MM", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": "A translocation between 11 and 14 [t(11;14)] has been reported to be associated with improved survival.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "IGH Translocation"}, "37": {"gene1": "IGH", "gene2": NaN, "rearrangement_type": "Translocation", "locus": "t(4;14)(q16;q32)", "disease": "Multiple Myeloma", "context": NaN, "oncotree_term": "Multiple Myeloma", "oncotree_code": "MM", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Guideline", "description": "A translocation between 4 and 14 [t(4;14)] has been reported in several studies to be associated with poor prognosis.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "IGH Translocation"}, "38": {"gene1": "NTRK1", "gene2": NaN, "rearrangement_type": "Translocation", "locus": NaN, "disease": "Any solid tumor", "context": NaN, "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Larotrectinib", "therapy_strategy": "TRK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT02122913", "last_updated": "11/12/20", "feature_display": "NTRK1 Translocation"}, "39": {"gene1": "NTRK1", "gene2": NaN, "rearrangement_type": "Translocation", "locus": NaN, "disease": "Any solid tumor", "context": NaN, "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Entrectinib", "therapy_strategy": "TRK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "NTRK fusions may respond to NTRK inhibitors", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2).", "url": "https://doi.org/10.1136/esmoopen-2015-000023", "doi": "10.1136/esmoopen-2015-000023", "pmid": "27843590", "nct": NaN, "last_updated": "3/16/17", "feature_display": "NTRK1 Translocation"}, "40": {"gene1": "NTRK2", "gene2": NaN, "rearrangement_type": "Fusion", "locus": NaN, "disease": "Any solid tumor", "context": NaN, "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Entrectinib", "therapy_strategy": "TRK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for entrectinib for adult and pediatric patients 12 years or old with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212726s000lbl.pdf. Revised August 2019. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212726s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "NTRK2 Fusion"}, "41": {"gene1": "NTRK2", "gene2": NaN, "rearrangement_type": "Translocation", "locus": NaN, "disease": "Any solid tumor", "context": NaN, "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Larotrectinib", "therapy_strategy": "TRK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT02122913", "last_updated": "11/12/20", "feature_display": "NTRK2 Translocation"}, "42": {"gene1": "NTRK2", "gene2": NaN, "rearrangement_type": "Translocation", "locus": NaN, "disease": "Any solid tumor", "context": NaN, "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Entrectinib", "therapy_strategy": "TRK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "NTRK fusions may respond to NTRK inhibitors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2).", "url": "https://doi.org/10.1136/esmoopen-2015-000023", "doi": "10.1136/esmoopen-2015-000023", "pmid": "27843590", "nct": NaN, "last_updated": "3/16/17", "feature_display": "NTRK2 Translocation"}, "43": {"gene1": "NTRK2", "gene2": NaN, "rearrangement_type": "Fusion", "locus": NaN, "disease": "Any solid tumor", "context": NaN, "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Entrectinib", "therapy_strategy": "TRK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for entrectinib for adult and pediatric patients 12 years or old with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212726s000lbl.pdf. Revised August 2019. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212726s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "NTRK2 Fusion"}, "44": {"gene1": "NTRK3", "gene2": NaN, "rearrangement_type": "Translocation", "locus": NaN, "disease": "Any solid tumor", "context": NaN, "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Larotrectinib", "therapy_strategy": "TRK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": "NCT02122913", "last_updated": "11/12/20", "feature_display": "NTRK3 Translocation"}, "45": {"gene1": "NTRK3", "gene2": NaN, "rearrangement_type": "Translocation", "locus": NaN, "disease": "Any solid tumor", "context": NaN, "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Entrectinib", "therapy_strategy": "TRK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "NTRK fusions may respond to NTRK inhibitors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2).", "url": "https://doi.org/10.1136/esmoopen-2015-000023", "doi": "10.1136/esmoopen-2015-000023", "pmid": "27843590", "nct": NaN, "last_updated": "3/16/17", "feature_display": "NTRK3 Translocation"}, "46": {"gene1": "NTRK3", "gene2": NaN, "rearrangement_type": "Fusion", "locus": NaN, "disease": "Any solid tumor", "context": NaN, "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Entrectinib", "therapy_strategy": "TRK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for entrectinib for adult and pediatric patients 12 years or old with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212726s000lbl.pdf. Revised August 2019. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212726s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "NTRK3 Fusion"}, "47": {"gene1": "PDGFRA", "gene2": NaN, "rearrangement_type": NaN, "locus": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": "Imatinib", "therapy_strategy": "PDGF-R inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "PDGFRA"}, "48": {"gene1": "FIP1L1", "gene2": "PDGFRA", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Chronic Eosinophilic Leukemia", "context": NaN, "oncotree_term": "Chronic Eosinophilic Leukemia, NOS", "oncotree_code": "CELNOS", "therapy_name": "Imatinib", "therapy_strategy": "PDGF-R inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with chronic eosinophilic leukemia (CEL) who have FIP1L1-PDGFRA fusions.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "FIP1L1--PDGFRA Fusion"}, "49": {"gene1": "BCR", "gene2": "PDGFRA", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Chronic Myeloid Leukemia", "context": NaN, "oncotree_term": "Chronic Myelogenous Leukemia", "oncotree_code": "CML", "therapy_name": "Imatinib", "therapy_strategy": "BCR-ABL inhibition + PDGF-R inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "A patient with a BCR--PDGFRA fusion observed rapid clinical and molecular response to imatinib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Trempat P, Villalva C, Laurent G, et al. Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor  alpha receptor: a new clinical target for STI571/Glivec Oncogene. 2003; 22(36):5702-5706.", "url": "https://doi.org/10.1038/sj.onc.1206543", "doi": "10.1038/sj.onc.1206543", "pmid": "12944919", "nct": NaN, "last_updated": "3/19/19", "feature_display": "BCR--PDGFRA Fusion"}, "50": {"gene1": "PDGFRB", "gene2": NaN, "rearrangement_type": NaN, "locus": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": "Imatinib", "therapy_strategy": "PDGF-R inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "PDGFRB"}, "51": {"gene1": "PDGFRB", "gene2": NaN, "rearrangement_type": "Translocation", "locus": "5q31-33", "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": "Imatinib", "therapy_strategy": "PDGF-R inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "PDGFRB translocations are associated with sensitivity to imatinib in Chronic Myelomonocytic Leuekmia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "PDGFRB Translocation"}, "52": {"gene1": "PDGFRB", "gene2": NaN, "rearrangement_type": "Translocation", "locus": "4p12", "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": "Imatinib", "therapy_strategy": "PDGF-R inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "PDGFRB translocations are associated with sensitivity to imatinib in Chronic Myelomonocytic Leuekmia.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/3/17", "feature_display": "PDGFRB Translocation"}, "53": {"gene1": "RET", "gene2": NaN, "rearrangement_type": NaN, "locus": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Cabozantinib", "therapy_strategy": "RET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Cabozantinib is an available targeted agent with activity against RET rearrangements in metastatic, NSCLC.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/12/19", "feature_display": "RET"}, "54": {"gene1": "RET", "gene2": NaN, "rearrangement_type": NaN, "locus": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Vandetanib", "therapy_strategy": "RET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Vandetanib is an available targeted agent with activity against RET rearrangements in metastatic, NSCLC.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/12/19", "feature_display": "RET"}, "55": {"gene1": "RET", "gene2": NaN, "rearrangement_type": "Fusion", "locus": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Cabozantinib", "therapy_strategy": "RET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "Cabozantinib (a dual MET-VEGF inhibitor) is being evaluated for efficacy in patients with RET fusion-positive tumors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Drilon A, Wang L, Hasanovic A, et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013;3(6):630-5.", "url": "https://doi.org/10.1158/2159-8290.CD-13-0035", "doi": "10.1158/2159-8290.CD-13-0035", "pmid": "23533264", "nct": "NCT01639508", "last_updated": "1/29/19", "feature_display": "RET Fusion"}, "56": {"gene1": "RET", "gene2": NaN, "rearrangement_type": "Fusion", "locus": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Selpercatinib", "therapy_strategy": "RET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf. Revised May 2020. Accessed October 22, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/22/20", "feature_display": "RET Fusion"}, "57": {"gene1": "RET", "gene2": NaN, "rearrangement_type": "Fusion", "locus": NaN, "disease": "Thyroid Cancer", "context": "Advanced or metastatic", "oncotree_term": "Anaplastic Thyroid Cancer", "oncotree_code": "THAP", "therapy_name": "Selpercatinib", "therapy_strategy": "RET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf. Revised May 2020. Accessed October 22, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "10/22/20", "feature_display": "RET Fusion"}, "58": {"gene1": "RET", "gene2": NaN, "rearrangement_type": "Fusion", "locus": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Pralsetinib", "therapy_strategy": "RET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for pralsetinib for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf. Revised May 2020. Accessed October 22, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/4/20", "feature_display": "RET Fusion"}, "59": {"gene1": "RET", "gene2": NaN, "rearrangement_type": "Fusion", "locus": NaN, "disease": "Thyroid Cancer", "context": "Advanced or metastatic", "oncotree_term": "Anaplastic Thyroid Cancer", "oncotree_code": "THAP", "therapy_name": "Pralsetinib", "therapy_strategy": "RET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate).", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214701s000lbl.pdf. Revised 12/2020. Accessed December 3, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214701s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "12/3/20", "feature_display": "RET Fusion"}, "60": {"gene1": "ROS1", "gene2": NaN, "rearrangement_type": "Fusion", "locus": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Crizotinib", "therapy_strategy": "MET inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for patients with ROS positive metastatic non-small cell lung cancer (NSCLC).", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202570s028lbl.pdf. Revised June 2016. Accessed November 12, 2020. ", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202570s028lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "ROS1 Fusion"}, "61": {"gene1": "ROS1", "gene2": NaN, "rearrangement_type": "Fusion", "locus": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Entrectinib", "therapy_strategy": "ROS inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted approval for entrectinib for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. ", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212726s000lbl.pdf. Revised August 2019. Accessed November 12, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212726s000lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "ROS1 Fusion"}, "62": {"gene1": "RUNX1", "gene2": "RUNX1T1", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Myelodysplastic Syndromes", "context": NaN, "oncotree_term": "Myelodysplasia ", "oncotree_code": "MDS", "therapy_name": "Azacitidine + Panobinostat", "therapy_strategy": "Hypomethylating agent chemotherapy + HDAC inhibition", "therapy_type": "Combination therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "t(8;21)(q22;q22) results in the expression of fusion protein RUNX1-RUNX1T1, which recruits histone deacetylases (HDAC) to silence RUNX1 target genes (such as IL-3). Combined use of HDAC inhibitors and DNMT inhibitors may rescue RUNX1 target genes.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf", "doi": NaN, "pmid": "15735013", "nct": NaN, "last_updated": "2/4/19", "feature_display": "RUNX1--RUNX1T1 Fusion"}, "63": {"gene1": "SLC45A3", "gene2": "BRAF", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Prostate Cancer", "context": NaN, "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Sorafenib", "therapy_strategy": "RAF inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Rearrangements in BRAF are rare but may result in dependencies that can be targeted with RAF and MAP2K1 inhibitors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Palanisamy N, Ateeq B, Kalyana-sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010;16(7):793-8.", "url": "https://doi.org/10.1038/nm.2166", "doi": "10.1038/nm.2166", "pmid": "20526349", "nct": NaN, "last_updated": "3/7/19", "feature_display": "SLC45A3--BRAF Fusion"}, "64": {"gene1": "SLC45A3", "gene2": "BRAF", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Prostate Cancer", "context": NaN, "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "U0126", "therapy_strategy": "MEK inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Rearrangements in BRAF are rare but may result in dependencies that can be targeted with RAF and MAP2K1 inhibitors.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Palanisamy N, Ateeq B, Kalyana-sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med. 2010;16(7):793-8.", "url": "https://doi.org/10.1038/nm.2166", "doi": "10.1038/nm.2166", "pmid": "20526349", "nct": NaN, "last_updated": "3/7/19", "feature_display": "SLC45A3--BRAF Fusion"}, "65": {"gene1": "TMPRSS2", "gene2": "ERG", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Prostate Cancer", "context": NaN, "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Rucaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Preclinical", "description": "Cells which harbored the TMPRSS2-ERG fusion became radiosensitive following radiation and PARP inhibitor, specifically Rucaparib.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Chatterjee P, Choudhary GS, Sharma A, et al. PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS ONE. 2013;8(4):e60408.", "url": "https://doi.org/10.1371/journal.pone.0060408", "doi": "10.1371/journal.pone.0060408", "pmid": "23565244", "nct": NaN, "last_updated": "11/3/17", "feature_display": "TMPRSS2--ERG Fusion"}, "66": {"gene1": "TMPRSS2", "gene2": "ERG", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Prostate Cancer", "context": NaN, "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Clinical evidence", "description": "A cohort of men with localized prostate cancer was followed and a statistically significant association between the presense of the TMPRSS2-ERG fusion and prostate cancer specific death was observed. Prostate cancer with this fusion may be of a more aggressive phenotype.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26(31):4596-9.", "url": "https://doi.org/10.1038/sj.onc.1210237", "doi": "10.1038/sj.onc.1210237", "pmid": "17237811", "nct": NaN, "last_updated": "11/3/17", "feature_display": "TMPRSS2--ERG Fusion"}, "67": {"gene1": "TMPRSS2", "gene2": "ERG", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Prostate Cancer", "context": NaN, "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Abiraterone", "therapy_strategy": "Antiandrogen", "therapy_type": "Hormone therapy", "therapy_sensitivity": "0", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "ETS fusions did not have a better response to AR suppression and PARP inhibition.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.", "url": "https://doi.org/10.1200/JCO.2017.75.7310", "doi": "10.1200/JCO.2017.75.7310", "pmid": "29261439", "nct": "NCT01576172", "last_updated": "1/29/19", "feature_display": "TMPRSS2--ERG Fusion"}, "68": {"gene1": "TMPRSS2", "gene2": "ERG", "rearrangement_type": "Fusion", "locus": NaN, "disease": "Prostate Cancer", "context": NaN, "oncotree_term": "Prostate Adenocarcinoma", "oncotree_code": "PRAD", "therapy_name": "Veliparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "0", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "ETS fusions did not have a better response to AR suppression and PARP inhibition.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.", "url": "https://doi.org/10.1200/JCO.2017.75.7310", "doi": "10.1200/JCO.2017.75.7310", "pmid": "29261439", "nct": "NCT01576172", "last_updated": "1/29/19", "feature_display": "TMPRSS2--ERG Fusion"}}, "Aneuploidy": {"1": {"event": "Whole genome doubling", "disease": NaN, "context": NaN, "oncotree_term": NaN, "oncotree_code": NaN, "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "0", "predictive_implication": "Inferential", "description": "WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.", "url": "https://doi.org/10.1038/s41588-018-0165-1", "doi": "10.1038/s41588-018-0165-1", "pmid": "30013179", "nct": NaN, "last_updated": "9/1/18", "feature_display": "Whole genome doubling"}}, "Microsatellite Stability": {"1": {"status": "MSI-High", "disease": "Any solid tumor", "context": "Unresectable or metastatic", "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf. Revised October 2020. Accessed November 4, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "MSI-High"}, "2": {"status": "MSI-High", "disease": "Colorectal Cancer", "context": "Unresectable or metastatic", "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf. Revised October 2020. Accessed November 4, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "MSI-High"}, "3": {"status": "MSI-High", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "5-Fluorouracil", "therapy_strategy": "Thymidylate synthase inhibition", "therapy_type": "Chemotherapy", "therapy_sensitivity": NaN, "therapy_resistance": "1", "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Patients with MSI-High colorectal cancer appear not to benefit from, and may be resistant to, 5-fluorouracil therapy.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf", "doi": NaN, "pmid": "20498393", "nct": NaN, "last_updated": "11/3/17", "feature_display": "MSI-High"}, "4": {"status": "MSI-High", "disease": "Colorectal Cancer", "context": NaN, "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": NaN, "therapy_strategy": NaN, "therapy_type": NaN, "therapy_sensitivity": NaN, "therapy_resistance": NaN, "favorable_prognosis": "1", "predictive_implication": "Guideline", "description": "Patients with MSI-High colorectal cancer often have a favorable prognosis.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf", "doi": NaN, "pmid": "20498393", "nct": NaN, "last_updated": "11/3/17", "feature_display": "MSI-High"}, "5": {"status": "MSI-High", "disease": "Colorectal Cancer", "context": "Metastatic", "oncotree_term": "Colorectal Adenocarcinoma", "oncotree_code": "COADREAD", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical trial", "description": "A phase II study of 32 colorectal cancer patients (and 9 noncolorectal cancer patients) found an association between mismatch repair deficiency (measured by MSI status) and both immune-related objective response rate (40% of patients with MSI-High vs. 0% in MSI-Low) and immune-related progression-free survival rate (78% of MSI-High patients at 20 weeks vs. 11% in MSI-Low). Post-hoc cohort comparison showed hazard ratio for disease progression or death of 0.10 and for death of 0.22.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.", "url": "https://doi.org/10.1056/NEJMoa1500596", "doi": "10.1056/NEJMoa1500596", "pmid": "26028255", "nct": "NCT01876511", "last_updated": "2/4/19", "feature_display": "MSI-High"}}, "Mutational Burden": {"1": {"classification": "High", "minimum_mutations": NaN, "mutations_per_mb": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Ipilimumab + Nivolumab", "therapy_strategy": "CTLA-4 inhibition + PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Nivolumab + ipilimumab is an available immunotherapy agent with activity in metastatic, NSCLC patients with high TMB.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/12/19", "feature_display": "High mutational burden"}, "2": {"classification": "High", "minimum_mutations": NaN, "mutations_per_mb": NaN, "disease": "Non-Small Cell Lung Cancer", "context": "Metastatic", "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Nivolumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Guideline", "description": "Nivolumab is an available immunotherapy agent with activity in metastatic, NSCLC patients with high TMB.", "preferred_assertion": NaN, "source_type": "Guideline", "citation": "National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.", "url": "https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "8/12/19", "feature_display": "High mutational burden"}, "3": {"classification": "High", "minimum_mutations": "178", "mutations_per_mb": NaN, "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "In a validation set of 18 non-small cell lung cancer patients treated with pembrolizumab, a nonsynonymous mutational burden >= 178 was associated with durable clinical response in some patients (75% of patients with burden >= 178 showed a response, compared to 14% patients with burden < 178 that showed a response; sensitivity of 86%, specificity of 75%).", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-8.", "url": "https://doi.org/10.1126/science.aaa1348", "doi": "10.1126/science.aaa1348", "pmid": "25765070", "nct": NaN, "last_updated": "3/12/17", "feature_display": "High mutational burden"}, "4": {"classification": "High", "minimum_mutations": "100", "mutations_per_mb": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Ipilimumab", "therapy_strategy": "CTLA-4 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.", "url": "https://doi.org/10.1056/NEJMoa1406498", "doi": "10.1056/NEJMoa1406498", "pmid": "25409260", "nct": NaN, "last_updated": "3/12/17", "feature_display": "High mutational burden"}, "5": {"classification": "High", "minimum_mutations": "100", "mutations_per_mb": NaN, "disease": "Melanoma", "context": "Metastatic", "oncotree_term": "Melanoma", "oncotree_code": "MEL", "therapy_name": "Ipilimumab", "therapy_strategy": "CTLA-4 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Clinical evidence", "description": "A study of pretreatment biopsies of tumors from 110 patients showed that patients with a mutational load of >= 100 were significantly more likely to have a clinical benefit to ipilimumab.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207-11.", "url": "https://doi.org/10.1126/science.aad0095", "doi": "10.1126/science.aad0095", "pmid": "26359337", "nct": NaN, "last_updated": "3/12/17", "feature_display": "High mutational burden"}, "6": {"classification": "High", "minimum_mutations": NaN, "mutations_per_mb": 10.0, "disease": "Any solid tumor", "context": "Unresectable or metastatic", "oncotree_term": "Any solid tumor", "oncotree_code": NaN, "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "FDA-Approved", "description": "The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative traetment options.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf. Revised October 2020. Accessed November 4, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/4/20", "feature_display": "High mutational burden"}}, "Mutational Signature": {"1": {"cosmic_signature_number": "10", "disease": NaN, "context": NaN, "oncotree_term": NaN, "oncotree_code": NaN, "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Signature 10 is related to mutant pole, which may suggest sensitivity to immunotherapy. ", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.", "url": "https://doi.org/10.1056/NEJMoa1500596", "doi": "10.1056/NEJMoa1500596", "pmid": "26028255", "nct": "NCT01876511", "last_updated": "2/4/19", "feature_display": "Cosmic signature 10"}, "2": {"cosmic_signature_number": "10", "disease": NaN, "context": NaN, "oncotree_term": NaN, "oncotree_code": NaN, "therapy_name": "Durvalumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "COSMIC Signature 10 is observed in some of the most hypermutant samples and recurrent POLE mutations. POLE mutant tumors are being included along with MMR-deficient tumors in several ongoing trials for sensitivity to immunotherapy.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. DNA Damage and Repair Biomarkers of Immunotherapy Response Cancer Discov. 2017; 7(7):675-693.", "url": "https://doi.org/10.1038/nature12477", "doi": "10.1038/nature12477", "pmid": "28630051", "nct": NaN, "last_updated": "9/19/18", "feature_display": "Cosmic signature 10"}, "3": {"cosmic_signature_number": "10", "disease": NaN, "context": NaN, "oncotree_term": NaN, "oncotree_code": NaN, "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "COSMIC Signature 10 is observed in some of the most hypermutant samples and recurrent POLE mutations. POLE mutant tumors are being included along with MMR-deficient tumors in several ongoing trials for sensitivity to immunotherapy.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. DNA Damage and Repair Biomarkers of Immunotherapy Response Cancer Discov. 2017; 7(7):675-693.", "url": "https://doi.org/10.1038/nature12477", "doi": "10.1038/nature12477", "pmid": "28630051", "nct": NaN, "last_updated": "9/19/18", "feature_display": "Cosmic signature 10"}, "4": {"cosmic_signature_number": "2", "disease": "Bladder Cancer", "context": NaN, "oncotree_term": "Urethral Urothelial Carcinoma", "oncotree_code": "UCU", "therapy_name": "Durvalumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "APOBEC signature (COSMIC 2) suggests sensitivity to immunotherapy in bladder cancer.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Mullane SA, Werner L, Rosenberg J, et al. Correlation of Apobec Mrna Expression with overall Survival and PD-L1 expression in urothelial carcinoma. Sci Rep. 2016; 6:27702. ", "url": "https://doi.org/10.1038/srep27702", "doi": "10.1038/srep27702", "pmid": "27283319", "nct": NaN, "last_updated": "3/7/19", "feature_display": "Cosmic signature 2"}, "5": {"cosmic_signature_number": "2", "disease": "Bladder Cancer", "context": NaN, "oncotree_term": "Bladder Urothelial Carcinoma", "oncotree_code": "BLCA", "therapy_name": "Durvalumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "APOBEC signature (COSMIC 2) suggests sensitivity to immunotherapy in bladder cancer.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Mullane SA, Werner L, Rosenberg J, et al. Correlation of Apobec Mrna Expression with overall Survival and PD-L1 expression in urothelial carcinoma. Sci Rep. 2016; 6:27702. ", "url": "https://doi.org/10.1038/srep27702", "doi": "10.1038/srep27702", "pmid": "27283319", "nct": NaN, "last_updated": "3/7/19", "feature_display": "Cosmic signature 2"}, "6": {"cosmic_signature_number": "3", "disease": "Gastric Cancer", "context": NaN, "oncotree_term": "Gastric Remnant Adenocarcinoma", "oncotree_code": "GRC", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Responders to platinum based chemotherapy exhibit COSMIC signature 3 (HR signature) mutations in pancreatic cancer.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683.", "url": "https://doi.org/10.1038/ncomms9683", "doi": "10.1038/ncomms9683", "pmid": "26511885", "nct": NaN, "last_updated": "1/14/18", "feature_display": "Cosmic signature 3"}, "7": {"cosmic_signature_number": "3", "disease": "Gastric Cancer", "context": NaN, "oncotree_term": "Gastric Remnant Adenocarcinoma", "oncotree_code": "GRC", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Responders to platinum based chemotherapy usually exhibited COSMIC signature 3 (HR signature), which may suggest sensitivity to PARP inhibition.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683.", "url": "https://doi.org/10.1038/ncomms9683", "doi": "10.1038/ncomms9683", "pmid": "26511885", "nct": NaN, "last_updated": "3/7/19", "feature_display": "Cosmic signature 3"}, "8": {"cosmic_signature_number": "3", "disease": "Gastric Cancer", "context": NaN, "oncotree_term": "Gastric Remnant Adenocarcinoma", "oncotree_code": "GRC", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Responders to platinum based chemotherapy usually exhibited COSMIC signature 3 (HR signature), which may suggest sensitivity to PARP inhibition.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683.", "url": "https://doi.org/10.1038/ncomms9683", "doi": "10.1038/ncomms9683", "pmid": "26511885", "nct": NaN, "last_updated": "3/7/19", "feature_display": "Cosmic signature 3"}, "9": {"cosmic_signature_number": "3", "disease": "Pancreatic Cancer", "context": NaN, "oncotree_term": "Pancreatic Adenocarcinoma", "oncotree_code": "PAAD", "therapy_name": "Olaparib", "therapy_strategy": "PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Responders to platinum based chemotherapy usually exhibited COSMIC signature 3 (HR signature), which may suggest sensitivity to PARP inhibition.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683.", "url": "https://doi.org/10.1038/ncomms9683", "doi": "10.1038/ncomms9683", "pmid": "26511885", "nct": NaN, "last_updated": "3/7/19", "feature_display": "Cosmic signature 3"}, "10": {"cosmic_signature_number": "3", "disease": "Pancreatic Cancer", "context": NaN, "oncotree_term": "Pancreatic Adenocarcinoma", "oncotree_code": "PAAD", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Responders to platinum based chemotherapy usually exhibited COSMIC signature 3 (HR signature), which may suggest sensitivity to PARP inhibition.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683.", "url": "https://doi.org/10.1038/ncomms9683", "doi": "10.1038/ncomms9683", "pmid": "26511885", "nct": NaN, "last_updated": "3/7/19", "feature_display": "Cosmic signature 3"}, "11": {"cosmic_signature_number": "3", "disease": "Pancreatic Cancer", "context": NaN, "oncotree_term": "Pancreatic Adenocarcinoma", "oncotree_code": "PAAD", "therapy_name": "Platinum", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Responders to platinum based chemotherapy exhibit COSMIC signature 3 (HR signature) mutations in pancreatic cancer.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495-501.", "url": "https://doi.org/10.1038/nature14169", "doi": "10.1038/nature14169", "pmid": "25719666", "nct": NaN, "last_updated": "1/14/18", "feature_display": "Cosmic signature 3"}, "12": {"cosmic_signature_number": "4", "disease": "Non-Small Cell Lung Cancer", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "In a cohort of 34 non-small cell lung cancer patients with pembrolizumab, the presence of a smoking signature (\"transversion-high\" tumors) was associated with a higher overall response rate (56% in transversion-high tumors, vs. 17% in \"transversion-low\" [never-smoker] tumors), a higher rate of DCB (77% vs. 22%), and a longer PFS.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-8.", "url": "https://doi.org/10.1126/science.aaa1348", "doi": "10.1126/science.aaa1348", "pmid": "25765070", "nct": NaN, "last_updated": "3/12/17", "feature_display": "Cosmic signature 4"}, "13": {"cosmic_signature_number": "4", "disease": "Lung", "context": NaN, "oncotree_term": "Non-Small Cell Lung Cancer", "oncotree_code": "NSCLC", "therapy_name": "Pembrolizumab", "therapy_strategy": "PD-1/PD-L1 inhibition", "therapy_type": "Immunotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "Smoking signature (COSMIC 4) suggests sensitivity to immunotherapy in lung cancer.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-8.", "url": "https://doi.org/10.1126/science.aaa1348", "doi": "10.1126/science.aaa1348", "pmid": "25765070", "nct": NaN, "last_updated": "8/23/17", "feature_display": "Cosmic signature 4"}, "14": {"cosmic_signature_number": "5", "disease": "Bladder Cancer", "context": NaN, "oncotree_term": "Bladder Urothelial Carcinoma", "oncotree_code": "BLCA", "therapy_name": "Cisplatin", "therapy_strategy": "Platinum-based chemotherapy", "therapy_type": "Chemotherapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "COSMIC Signature 5 is associated with somatic ERCC2 mutations, which may suggest sensitivity to cisplatin based chemotherapy.", "preferred_assertion": NaN, "source_type": "Journal", "citation": "Kim J, Mouw KW, Polak P, et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet. 2016;48(6):600-606.", "url": "https://doi.org/10.1038/ng.3557", "doi": "10.1038/ng.3557", "pmid": "27111033", "nct": NaN, "last_updated": "1/14/18", "feature_display": "Cosmic signature 5"}, "15": {"cosmic_signature_number": "3", "disease": "Epithelial ovarian cancer", "context": "HRD-positive advanced", "oncotree_term": "Ovarian Epithelial Tumor", "oncotree_code": "OVT", "therapy_name": "Bevacizumab + Olaparib", "therapy_strategy": "VEGF/VEGFR inhibition + PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12th, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "Cosmic signature 3"}, "16": {"cosmic_signature_number": "3", "disease": "Fallopian tube cancer", "context": "HRD-positive advanced", "oncotree_term": "High-Grade Serous Fallopian Tube Cancer", "oncotree_code": "HGSFT", "therapy_name": "Bevacizumab + Olaparib", "therapy_strategy": "VEGF/VEGFR inhibition + PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12th, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "Cosmic signature 3"}, "17": {"cosmic_signature_number": "3", "disease": "Peritoneal cancer", "context": "HRD-positive advanced", "oncotree_term": "Peritoneal Serous Carcinoma", "oncotree_code": "PSEC", "therapy_name": "Bevacizumab + Olaparib", "therapy_strategy": "VEGF/VEGFR inhibition + PARP inhibition", "therapy_type": "Targeted therapy", "therapy_sensitivity": "1", "therapy_resistance": NaN, "favorable_prognosis": NaN, "predictive_implication": "Inferential", "description": "The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability.", "preferred_assertion": NaN, "source_type": "FDA", "citation": "AstraZeneca Pharmaceuticals LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12th, 2020.", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf", "doi": NaN, "pmid": NaN, "nct": NaN, "last_updated": "11/12/20", "feature_display": "Cosmic signature 3"}}, "genes": {"1": {"genes": ["ABL1", "AKT1", "AKT2", "AKT3", "ALK", "AR", "ARAF", "ARID1A", "ASXL1", "ATM", "AURKA", "AURKB", "BARD1", "BCOR", "BCR", "BLM", "BRAF", "BRCA1", "BRCA2", "BRD4", "BRIP1", "CCND1", "CCND3", "CCNE1", "CD274", "CDK12", "CDK4", "CDKN2A", "CDKN2C", "CHEK1", "CHEK2", "COL1A1", "CRKL", "CTNNB1", "DNMT3A", "EGFR", "EML4", "EPCAM", "ERBB2", "ERBB3", "ERCC2", "ERG", "ERRFI1", "ESR1", "ESRP1", "ETV6", "EWSR1", "EZH2", "FANCL", "FBXW7", "FGFR1", "FGFR2", "FGFR3", "FIP1L1", "FLCN", "FLI1", "FLT3", "GATA3", "HIF1a", "IDH1", "IDH2", "IGH", "IL12RB1", "JAK1", "JAK2", "JAK3", "KEAP1", "KIT", "KRAS", "LIMK2", "MAP2K1", "MAP2K2", "MAPK1", "MC1R", "MDM2", "MET", "MIR17HG", "MLH1", "MLH3", "MPL", "MRE11", "MSH2", "MSH6", "MTOR", "MYC", "MYH", "NF1", "NFE2L2", "NRAS", "NSD2", "NTRK1", "NTRK2", "NTRK3", "PAK1", "PALB2", "PBRM1", "PDGFB", "PDGFRA", "PDGFRB", "PIK3CA", "PIK3CB", "PMS2", "POLD1", "POLE", "POLE2", "POT1", "PRPF8", "PTEN", "PTPN11", "RAD51B", "RAD51C", "RAD51D", "RAD54L", "RAF1", "RB1", "RBM10", "RET", "ROS1", "RUNX1", "RUNX1T1", "SETBP1", "SF3B1", "SLC45A3", "SMARCA4", "STAG2", "TACC3", "TET2", "TMPRSS2", "TP53", "TPX2", "TSC1", "TSC2", "ZRSR2"]}}, "Release": {"1": {"release": "v.2021-02-04"}}}